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Abstract
The majority of diabetics develop neuropathy, which can be debilitating, but the
underlying pathophysiological mechanisms are poorly understood. Diabetic
neuropathy progresses in a distal to proximal manner. Previous studies have shown
that glutamate, the most common excitatory neurotransmitter, plays a role in the
pathogenesis of neuropathy. The reason why the role of glutamate in nociception
becomes a problem in diabetes and the mechanisms that are involved are unknown.
Based on the preliminary data, the hypothesis was that glutamate pathways are
likely to be involved in diabetic neuropathy particularly neuropathic pain. Pathways
were investigated to look for changes that might reflect neuropathic pain and fit with
previously established pharmacological evidence. The aim of this project was to
identify changes in expression of genes and their protein products that are involved
in glutamate signalling in diabetes. This will help to further the understanding of the
mechanisms of diabetic neuropathy. In diabetic rats, there were consistent changes
in expression, particularly in the lumbar and sacral dorsal root ganglia of the spinal
cord and in the sympathetic ganglia. The changes were consistent between the
different groups of animals as well as between adjacent groups of ganglia. The most
prominent changes in both the GK groups included marked upregulation of Gria4
(ionotropic AMPA receptor), downregulation of Grik3 and Grik4 (both ionotropic,
kainite receptors) and Grin1 and Grin2A (both ionotropic, NMDA receptors),
activation of all of which has been shown to induce hyperalgesia; downregulation of
Slc1a6 (excitatory amino acid transporter 4) and upregulation of Slc1a1 (excitatory
amino acid transporter 3), both of which mediate neural reuptake of glutamate from
the synaptic cleft; and upregulation of Gclc (glutathione synthase), which reflects a
response to protect against oxidative damage.

vii
Despite many theories existing about the pathogenesis of diabetic neuropathy, there
is no unifying hypothesis. It is possible that changes in glutamate signalling can
contribute to these other mechanisms and possibly unify these different theories. A
better understanding of the role that glutamate plays in development of diabetic
neuropathy may pave the way for future therapeutic intervention.
Keywords: Diabetes, Diabetic Neuropathy, Glutamate Signalling, Dorsal Root
Ganglia, Sympathetic Ganglia.
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)Title and Abstract (in Arabic

دور إشارات الجلوتاميت في االعتالل العصبي لمرض السكري
الملخص
أغلبية مرضى السكري يعانون من اإلعتالالت العصبية اللتي تسبب الوهن  .ولكن بالرغم من ذلك  ,فإن اليات
الفسيولوجية المرضية لهذه اإلعتالالت غير مفهومة  .اإلعتالل العصبي لمرض السكري يتطور في المرضى
من الأطراف باتجاه الجذع  .الدراسات السابقة أظهرت أن الجلوتاميت وهو الناقل العصبي المحفز األكثر
شيوعا  ,يلعب دورا بنشوء هذا اإلعتالل  .السبب وراء دور الجلوتاميت باالحساس باأللم عند مرضى السكري
واليات ارتباطه غير معروفة  .الهدف من هذه الدراسة هو تحديد التغيرات بالتعابير الجينية والمنتوج
البروتيني وارتباطه باإلشارات العصبية للجلوتاميت بمرض السكري  .هذه الدراسة ستساهم في تأييد فهمنا
الليات اإلعتالل العصبي لمرض السكري  .لقد وجدنا في الجرذان المصابة بالسكري تغييرات ثابتة بالتعابير
الجينية بالعقد الجذرية العصبية القطنية والعجزية للحبل الشوكي باإلضافة إلى العقد الجذرية العصبية للجهاز
الودي السمبثاوي  .هذه التغيرات كانت ثابتة بين مجموعات الحيوانات باإلضافة إلى المجموعات العقدية
المتجاورة  .أبرز هذه التغيرات في مجموعات حيوانات "جي كيه" ( )GKتضمنت ارتفاع ملحوظ في
مستقبالت " "Gria4من نوع مستقبالت " , "ionotropic AMPAوانخفاض في مستقبالت " "Grik3و
" "Grik4كليهما من نوع مستقبالت " , "ionotropic kainiteو انخفاض في مستقبالت " "Grin1و
" "Grin2Aكليهما من نوع مستقبالت " . "ionotropic NMDAتفعيل جميع هذه المستقبالت أظهرت
حثها لفرط التألم  .باإلضافة لذلك أظهرت الدرساة انخفاض التعبير الجيني ل " "Slca6وهو ناقل األحماض
األمينية من نوع  , 4وارتفاع التعبير الجيني ل " "Slc1a1وهو ناقل األحماض األمينية من نوع  , 3وكليهما
تتواسط إلعاده امتصاص الجلوتاميت في المشابك العصبية ( . )synaptic cleftوأظهرت الدراسة أيضا
ارتفاع التعبير الجيني ل " "Gclcوهو انزيم سنثاز جلوتاثايون ( )glutathione synthaseوالذي يعكس
االستجابة للحمايه من التلف التأكسدي .
بالرغم من النظريات الحالية عن التطور المرضي لالعتالل العصي لمرض السكري  ,فإنه ال يوجد إلى االن أي
نظرية مجمع عليها  .من المحتمل أن التغيرات لإلشارات العصبية للجلوتاميت تسهم في هذه االليات ومن
المحتمل أن توحد هذه النظريات المختلفة  .الفهم األفضل للدور الذي تلعبه الغلوتاميت في تطور اعتالل
األعصاب السكري قد يمهد الطريق لتدخل عالجي في المستقبل.
الكلمات المفتاحية  :مرض السكري  ,االعتالل العصبي لمرض السكري  ,اإلشارات العصبية للجلوتاميت ,
العقد الجذرية العصبية  ,العقد الجذرية للجهاز الودي السيمبثاوي .
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Chapter 1: Introduction
1.1 Diabetes Mellitus
The term Diabetes mellitus comprises a group of metabolic disorders
characterized by the presence of excess blood glucose; hyperglycaemia (A. D.
Association, 2014). The defect in diabetes is characterized by defects in insulin
secretion or action, or a combination of both. This disturbs the carbohydrate, fat and
protein metabolism. The resulting hyperglycaemia leads to long-term damage,
dysfunction and consequent failure of several organs. These complications are
debilitating enough that affect the quality of life and mortality (Alberti, Zimmet, &
Consultation, 1998). Complications and their consequences occur such as
retinopathy lead to blindness, nephropathy to renal failure, neuropathy to foot ulcers
or amputation, autonomic dysfunction and its variety of manifestations. Diabetics
are prone to cardiovascular, peripheral vascular and cerebrovascular disease.
Patients with diabetes often present with characteristic symptoms such as
excessive thirst, the passing of excessive urine (polyuria), blurred vision and loss of
weight. Some patients present in the ketoacidosis or non-ketotic hyperosmolar state
that can lead to stupor, coma and in extreme cases death. Unless dramatic, the
absence of symptoms or unalarming symptoms can go unchecked and lead to the
development of complications before diabetes is diagnosed. These symptoms are
usually because of the presence of hyperglycemia (Alberti, 1998).
1.2 Statistics and Diabetes
Diabetes and other forms of glucose intolerance; impaired glucose tolerance
(IGT) and impaired fasting glucose (IFG), are now found in every population and
there is epidemiological evidence suggesting the burden of diabetes is increasing
globally and continuing to do so. Diabetes places a heavy toll on the socioeconomic
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fabric of society due to the large number of people affected (Wild, Roglic, Green,
Sicree, & King, 2004). From 175 million diabetics in 2000 (Yach, Stuckler, &
Brownell, 2006) to 371 million currently affected (IDF 2014), diabetes is a pandemic
of epic proportions.
Worldwide rank wise, Kuwait 3rd, Qatar 6th, Saudi Arabia 7th, Bahrain 8th and
United Arab Emirates 10th all have places in the top 10 countries with prevalence of
diabetes at 20-79 years of age in 2011. These positions are expected to ascend by
2030 considering the current prevalence rate (D. Chen & Wang).
In the United Arab Emirates the ENDCAD study in 2000, 19.6% of the total
population was found to be diabetic; 24% locals and 17.4% expatriates (ENCAD
UAE, 2009). Diabetes is one of the major causes of mortality in UAE, causing 2 –
3% of deaths (Ministry of Health strategic plan till 2010, 2000).
1.3 Classification of Diabetes Mellitus:
This often depends on how the patient presents at the time of diagnosis and
although some do not easily fit into a single category, the classification is important
from a therapeutic point of view. This allows better understanding of the
pathogenesis of the hyperglycemia and leads towards better treatment options.
Although the majority of the diabetic individuals fall into two broad
etiopathogenetic categories, as discussed below, assigning a type of diabetes to an
individual depends on the circumstances present at the time of diagnosis. Many
diabetic individuals do not easily fit into any single class. For example, a female
patient who has gestational diabetes mellitus may continue to be hyperglycaemic
after delivery and in fact have type 2 diabetes. An individual who acquires diabetes
because of large doses of steroids may become normoglycaemic when the steroids
are discontinued but later on develop diabetes after instances of pancreatitis.
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Another example is a person treated with thiazides who develops diabetes years
later and it could be because the person had type 2 diabetes exacerbated by the
drug. For the clinician and the patient, having the correct label for the type of
diabetes leads to better understanding of the pathogenesis of the hyperglycaemia
and effective treatment strategies.
One of the earliest formal attempts to classify diabetes uniformly was by the
1964 World Health Organization Expert Committee. It was recognized that clear
classification would aid epidemiological approaches and advance clinical research in
developing of evidence based therapies. A symptomatic classification was adopted
and the age of onset was an additional criteria. The age characterization was as
follows (Mellitus & Organization, 1965):
1. Infantile or childhood diabetes (0-14 years of age)
2. Young diabetes (15-24 years of age)
3. Adult diabetes (25-64 years of age)
4. Elderly diabetes (65 and above years of age)
However, the terms type 1 diabetes and type 2 diabetes emerged following
the National Diabetes Data Group (NDDG) in the USA and the second report of the
WHO Expert Committee on Diabetes Mellitus.
Two main classes of diabetes were suggested: insulin-dependent diabetes
mellitus (IDDM/type 1) and non-insulin dependent diabetes mellitus (NIDDM/type 2).
‘Other types’ and gestational diabetes mellitus were also added to the list. The
condition of impaired glucose tolerance (IGT) also appeared, replacing ‘borderline’
diabetes ("WHO Expert Committee on Diabetes Mellitus: second report," 1980).
The 1999 classification retained the main groups of type 1, type 2, other
specific types, and gestational diabetes, but the terms ‘insulin dependent’ and ‘noninsulin dependent’ were presumed to be confusing and so dropped (Alberti, 1998)
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Currently ("WHO, Diabetes report" 2013) diabetes is generally classified into
Type 1, Type 2 and other types of diabetes. Type 1 results from the destruction of
beta cells of pancreas leading to total insulin deficiency. Type 2 is a combination of
progressive secretory defect combined with insulin resistance. Other types include
gestational diabetes and diabetes occurring due to genetic defects of beta cell
function or insulin action or diseases of the pancreas itself or due to chemicals or
drugs (Gabir, 2000).
1.4 Physiology of Insulin and Glucose control
Insulin's name is derived from the Latin insula for "island". Insulin is
produced by the beta cells that lie in the middle of the pancreatic islets. These islets,
which range from one million to three million, form the 2% endocrine part of the
pancreas – a predominantly exocrine gland.

Within the islets, the beta cells

constitute 65–80% of all the cells. The beta cells also secrete amylin (Hall, 2011).
The pancreatic islets are also where the alpha, delta and PP cells reside.
The alpha cells secrete glucagon, the delta cells secrete somatostatin and the PP
cells secrete pancreatic polypeptide. These cells are closely related and the
proximity allows direct control of hormone secretion by the other hormones. Such as
insulin inhibiting the secretion of glucagon, amylin inhibiting insulin and somatostatin
inhibiting insulin and glucagon (Hall, 2011).
Insulin is the main hormone for food derived energy storage and is coded for
on chromosome 11. Insulin is a protein and in humans has a molecular weight of
5808. It consists of two amino acid chains bound by disulfide bonds. Insulin is first
made by the endoplasmic reticulum as preproinsulin which is cleaved to form
proinsulin and cleaved into the A and B chain that are bound together and the C
chain that is separated in the Golgi apparatus. The insulin and C peptide are packed
into secretory granules. When insulin is released into the blood it is an unbound
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form and has a plasma half-life of six minutes. Within fifteen minutes it is cleared
from the circulation. The portion of insulin that is not bound to receptors is degraded
by insulinase. In the liver, 50% of it is degraded, the rest is cleared by the kidneys
(Hall, 2011).
The liver achieves a constant level of glucose despite variations of food
intake and energy usage by processes such as glucose storage and
gluconeogenesis. Tissue specific glucose utilization requires glucose transporters
which ordinarily depend on insulin. The brain however does not need insulin
although it is the main consumer of the body’s glucose. Muscle and fat tissues are
facultative glucose consumers (Barrett E K, 2012; Cahill, Rossini, & Aoki, 1974;
Rodney A. Rhoades, 2014; Rossini, Like, Chick, Appel, & Cahill, 1977).
The insulin receptor is a combination of four subunits that are linked with
each other by disulfide bonds. The two alpha subunits are extracellular and the two
beta subunits are transmembrane. Insulin binds to the alpha subunits and
consequently the beta subunits are activated and become autophosphorylated. This
activates a local tyrosine kinase which causes phosphorylates other enzymes
including a group called insulin-receptor substrates. Different types of these
substrates are expressed in different tissue. Activating these, in turn, activates some
enzymes while inactivating others. Insulin directs the metabolic machinery in cells to
bring about the desired effects on carbohydrates, fat and proteins.
After insulin binds, the cells increase their uptake of glucose. This is of
particular importance for muscle cells and adipose cells. The increase of glucose
levels in the cells leads to phosphorylation and providing a substrate for the
carbohydrate metabolic functions. The glucose is taken up by the increased
availability of intracellular vesicles to the cell surface. Insulin causes cells to become
permeable to amino acids, potassium and phosphate ions. Insulin also affects
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translation of messenger RNAs at the ribosomes for new protein production and
also alters rate of DNA transcription. Insulin thus remolds much of the cellular
enzymes to achieve its metabolic goals (Hall, 2011).
The resting muscle membrane is only slightly glucose permeable but on
insulin stimulation glucose is allowed to enter the muscle. During exercise and when
large amounts glucose is available after a meal, the extra insulin secreted by the
pancreas stimulates the muscle to take up glucose. During much of the day, muscle
depends on fatty acids rather than glucose for its energy requirements.
In muscle, especially during periods of inactivity, the glucose that is taken up
is stored as glycogen or broken into lactate which fuels hepatic gluconeogenesis. In
fat, glucose is a source of energy and a substrate for triglyceride synthesis (Gale
EAM, 2002).
One of the most important effects of insulin is to cause the liver to store
glucose that is available after a meal. Insulin brings about these actions by
enhancing the activity of enzymes such as glucokinase and glycogen synthase. This
helps form glycogen. Insulin suppresses activity of enzymes such as phosphorylase
and glucose phosphatase. The net effect of these actions increases the glycogen
content in the liver. Insulin also prevents gluconeogenesis by suppressing enzymes
and amino acid release from extra hepatic tissues such as the liver. However, hours
after a meal the levels of insulin and glucose fall in the blood and liver glycogen
breaks down to provide the required glucose. If the liver cells cannot store more
glycogen, insulin promotes converting the excess glucose to fatty acids. After the
liver glycogen content reaches approximately five to six percent, further glycogen
synthesis is inhibited and all additional glucose forms fatty acids and triglycerides to
store. Insulin also encourages fat storage into adipose cells by enhancing glucose
transport into cells and inhibiting lipase. The lack of insulin causes lipolysis of stored
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fats and release of fatty acids, increases plasma cholesterol levels and in extreme
cases can lead to ketosis and acidosis. The effect of protein metabolism by insulin
includes stimulating amino acid transport into cells, increasing messenger RNA
translation, increasing the rate of transcription of selected DNA genetic sequences
to allow more RNA and thus protein to form and inhibiting protein catabolism (Hall,
2011).
Glucose transporters are classed as the GLUT family and have distinct
substrate specificities, coding genes kinetic properties, and tissue distributions
determining roles and expression. GLUT-4 is the main insulin responsive glucose
transporter and is mainly located in muscle cells and adipocytes. Insulin binds to the
receptor, activating tyrosine kinase phosphorylation and a series of cellular events
ensue allowing glucose inside the cell (Shepherd & Kahn, 1999). A member of the
glucose transporter (GLUT 2) is found in beta cells and allow a rate of glucose to
enter these cells that is proportional to the blood concentration in the physiological
range. Once inside the beta cells, glucose is converted to glucose-6-phosphate by
glucokinase. This is the rate limiting step for glucose metabolism in the beta cell and
is thought to be the main mechanism for glucose sensing and adjustment of the
amount of secreted insulin to glucose levels (Hall, 2011).
1.5 Type 1 Diabetes
Type 1 Diabetes affects 5-10% of diabetics and arises from the immune
mediated destruction of the beta cells and is commonly associated with other
autoimmune disorders (Amer Diabet, 2011). In some cases there may be an
inherited tendency for beta cell degeneration without the involvement of viral
infections or autoimmune disorders (Hall, 2011).
The commonest form of diabetes is Type 2 with up to 90% of diabetics
having this type, although Type 1 is also on the increase (Patterson, 2002).
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Type 1 diabetes stems from the immune mediated destruction of the beta
cells. Markers of this destruction include autoantibodies such as; islet cell
autoantibodies, insulin autoantibodies, and autoantibodies to GAD and tyrosine
phosphatases IA-2 and IA-2b. Most diabetics have one or more of these
autoantibodies upon diagnosis. These patients are also more prone to other
autoimmune disorder such as Graves’ disease, vitiligo, myasthenia gravis and so
forth.
Type 1 diabetes has strong HLA associations, with linkage to DQA and DQB
genes and is also under the influence of DRB genes. These HLA-DR/DQ alleles can
be either predisposing or protective of diabetes (A. D. Association, 2014).
The term Type 1 diabetes however does not encompass the forms of beta
cell destruction or failure to which specific causes can be attributed such as cystic
fibrosis (Alberti, 1998). There are other forms of Type 1 diabetes that have unknown
etiologies. Some of these diabetics have permanent lack of insulin and are at
increased risk of developing ketoacidosis but have on indication of autoimmunity.
These individuals are rare and more often of African or Asian descent. They
experience ketoacidosis at intervals and have varying degrees of insulin deficiency.
The requirement for insulin to be replaced in their bodies may come and go (A. D.
Association, 2014). This form is often classed as Type 1B – a rarer form of Type 1
diabetes. Type 1A is the commoner form, resulting from the autoimmune destruction
of beta cells (Daneman 2004).
The autoimmunity of type 1 diabetes is a concept that has been backed by
several important research studies and one of the most persuasive evidence was
provided by case reports of diabetes developing in people who received bone
marrow from type 1 diabetics. The recipients first underwent bone marrow ablation
as treatment for conditions such as haematological cancers to remove all immune
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cells. To bring back their immune system they received bone marrow donations from
siblings with type 1 diabetes. However, they themselves developed type 1 diabetes
sever years later. This provides evidence for the theory that immune cells were
transferred in the bone marrow destroyed the beta cells (Wass A.H J, 2011).
Autoreactive T cells against the pancreatic cells are produced and expand.
Due to the deficient regulation of T cell response, clonal expansion of these
particular T cells continues unchecked and triggers a response of beta antigen
specific (T cell) immune and other inflammatory responses that destroy the beta
cells. Ordinarily, T cells the react against self-antigens are checked and halted
during development and eventually eliminated by clonal deletion. However in type 1
diabetes, as in other autoimmune conditions, this censoring process is not effective.
One of the methods to interrupt and reverse the autoimmunity of type 1
diabetes before end organ damage occurs has been the advent of bone marrow
transplant as a treatment option. However, this has its own complications and
difficulties (Domenick & Ildstad, 2001).
Autoimmunity does not exist in all forms of type 1 diabetes. In some patients
this is lacking as is the WHO diabetes classification of the type 1B category. In
Japan, this form of diabetes has been described as affecting 15-20% of type 1
diabetes and marked in the absence of insulitis and diabetes-related antibodies, an
abrupt onset with preceding of common cold like and gastrointestinal symptoms, a
surprisingly near normal level of HbA1c despite the high levels of glucose, and high
levels of serum pancreatic enzyme concentrations (Imagawa, Hanafusa, Miyagawa,
& Matsuzawa, 2000).
The mechanism of beta cell death appears to differ in this particular type of
diabetes compared to the autoimmune category. While the beta cells are destroyed
in autoimmune diabetes over a span of time, often several years – this destruction is
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extremely rapid in the fulminant form of type 1 diabetes. This process is postulated
to be triggered by viral infection (Willcox, 2008).
In the 1980s, Eisenbarth proposed the current model to explain the
development of Type 1A diabetes and today the basic idea of this model persists.
The model hypothesizes that every person has a susceptibility to develop this type
of diabetes but some more so than others. Susceptibility is inherited, residing in the
HLA genotypes DR and DQ and to a lesser extent in other genetic loci termed IDDM
susceptibility genes. 50% of the genetic susceptibility stems from the HLA focus and
15% from two genes; IDDM2 and IDDm12 with minor participation from the other
IDDM genes. The susceptibility genes are thought to be involved in the regulation of
immune response.
Exposure to an environmental trigger that alters immune function leads to
beta cell destruction. Triggers such as viruses; enteroviruses, coxsackie, congenital
rubella), environmental toxins such as nitrosamines or food such as early exposure
to cow milk proteins and gluten have been linked to varying degrees. The over
activation of the T cell mediated immune system in those individuals with increased
susceptibility experience insulitis and a B cell response the produces antibodies to
beta cell antigens. As the beta cells are destroyed, insulin levels drop till below a
critical level a state of absolute insulin deficiency ensues. The so called
‘honeymoon’ period occurs after initiation of insulin therapy begins when some
insulin is secreted by few of the last remaining beta cells but these eventually fail as
well.
The connection to autoimmunity also arises from evidence that these
patients are also more prone to developing other autoimmune diseases such as
Graves’ disease, Addison’s disease, myasthenia gravis and so on. There is one
central theory of cause of type 1 diabetes and occasionally interesting hypotheses

11
have cropped up such as the hygiene hypothesis that postulates early exposure to
infections in children builds immunity and prevents type 1 diabetes. Another
interesting hypothesis is the accelerator hypothesis where the two types of diabetes
are only distinguished by the rate of beta cell loss. Three accelerators are postulated
in the accelerator hypothesis; the high rate of beta cell apoptosis, insulin resistance
that stresses the collapsing beta cells, immunologically vulnerable beta cells in
genetically susceptible individuals. However these hypotheses need more
investigation (Daneman 2004).
Understanding the allelic architecture i.e. identifying disease associated
gene variants, how frequently these occur and the risk attached to each variant, of
type 1 diabetes will help identify new targets for treatment. Individuals are able to
manage with 20% of the beta cell mass and this offers a window of opportunity for
interventions before the diabetes sets in (Wass A.H J, 2011).
Type 1 diabetes is increasing, a recent study by the EURODIAB Study group
that assessed 20 population based registries in 17 European countries, showed that
there has been a 3.9% increase of incidence between 1989 and 2003 in children
aged 5 - 15 and a 5.4% rise per year in the under 5 age group.
Type 1 diabetes results from a complex interaction of several genes and
environmental factors, which can promote the disease and occasionally protect from
it. At least four chromosomal regions are implicated to contribute to the risk of
developing type 1 diabetes, the HLA region on chromosome 6p21 IDDM1, the
insulin gene region at 11p15 IDDM2, the CTLA4 locus at 2q33 IDDM12 and the
PTPN22 locus at 1p13. There is however no standard for defining what is or is not a
risk locus for developing type 1 diabetes but there is consistent evidence that
supports a role for the genes in these regions to implicate them as conferring an

12
increased risk of developing type 1 diabetes in individuals (Concannon, Rich, &
Nepom, 2009).
The pancreatic pathological lesion that is characteristic of type 1 diabetes is
insulitis. This term describes the immune cell infiltration surrounding the islets with
additional immune cells scattered around them. This appears to increase as the
beta cells die off. In later stages, this infiltration subsides. The beta cell proliferative
capacity appeared to be unchanged despite the ongoing destructive processes.
Insulitis is commonly observed in new-onset patients with diabetes of new onset but
it does not affect all insulin containing islets equally. This is perhaps due to the
differences in islet function; factors including sensitivity to glucose, insulin release
and so on could play a role. This also suggest that during periods of physiologic
demand for increased insulin such as during puberty or under the influence of high
sugar intake, there might be a population of islets more vulnerable to dysfunction
and cell death that attract APCs and promote insulitis in certain genetically
susceptible patients. These functional differences between the islets could explain
why autoreactive lymphocytes target some islets more than others (Rowe A. Patrick,
2011).
Analysis of the immune cell infiltrate in T1D islets show that during the initial
period of beta cell death, the most abundant immune cells are the CD8+ cytotoxic T
cells.
Once the decline in beta cells is established, the larger share of population
consists of the CD20+ cells. However, once the beta cells are completely destroyed,
immune cells decrease dramatically in the islets and this suggests that their role is
only while viable beta cells exist. The stimulus for insulitis declines after the death of
beta cells. Glucagon staining is normal in such islets and this shows that alpha cells
are unaffected (Willcox, 2008).
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Type 1 diabetes mellitus develops in stages (Wass A.H J, 2011):
Stage 1 – in this stage, a trigger allows the T lymphocytes to develop the ability to
recognize β cell autoantigens that emerge from the thymus. This lets the peripheral
immune system from birth contain adaptive immune cells with the ability to attack
the beta cells. Immunogenetic studies on type 1 diabetes have backed this
information. HLA genes that increase risk of developing type 1 diabetes could
possibly involve the ineffective functions of the thymus such as reducing the ability
of it to delete beta cell specific T lymphocytes.
Stage 2 – inflammation damages the beta cells. Autoantigens to beta cells are
released and absorbed by dendritic cells which migrate to the pancreatic lymph
nodes and, in combination with defective thymic function, the islet proteins are
presented to naïve beta cell specific T lymphocytes with the relevant T cell
receptors. Viruses have often been thought to be culprits in the initiation.
Stage 3 – the imbalance in immune regulation allows the beta cell specific T
lymphocytes to activate and mature to form the pro-inflammatory phenotype. This
results in a greater propensity to activate the harmful T lymphocytes.
Stage 4 – autoreactive T lymphocytes migrate to the inflamed islets, further adding
to the inflammation and beta cell damage. Autoreactive B lymphocyte recruitment is
also a feature and autoantibodies may help the inflammation by forming immune
complexes. The beta cells are systematically destroyed from islet to islet.
Stage 5 – chronic inflammation settles and in this stage the presence of
autoantibodies are established. Relapses and remissions also occurs in this stage
and these could be influenced by events irrelevant to the initial trigger. The beta cell
destruction spreads till the disease is fully established.
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1.6 Type 2 diabetes
Type 2 diabetes is the result of the complicated interactions of genetic and
environmental factors. Although changes such as an increasingly sedentary lifestyle
and excessive consumption of calories seem to be triggering factors, genetic
elements are involved (Stumvoll, Goldstein, & van Haeften, 2005). One of the
hallmarks of type 2 diabetes is insulin resistance; which is the inability of insulin to
be effective at its normal circulating concentrations (Wass A.H. J, 2011). The
presence of hyperglycaemia, characteristic of diabetes, adds to insulin resistance in
skeletal muscle by glucose toxicity (Rossetti, Giaccari, & DeFronzo, 1990) and
impairs insulin-stimulated glucose utilization and glycogen synthesis in skeletal
muscle (Tomas, 2002).
Insulin and glucagon act for opposing goals. Glucagon increases the glucose
output from the liver to increase circulating glucose by increasing gluconeogenesis
and glycogenolysis. An excessive or imbalanced amount of glucagon contributes to
the post meal hyperglycaemia present in type 2 diabetes since glucagon is not
suppressed normally (Dunning & Gerich, 2007). The incretin effect, observation that
gut derived factors enhance glucose stimulated insulin secretion from the pancreatic
beta cells more than parenteral glucose infusions, is also significantly blunted in type
2 diabetics which could be due to the decrease in sensitivity of islets to the incretin
hormones. Glycaemic control partially compensates for this defect (Drucker &
Nauck).
Type 2 diabetes is the quintessential multifactorial trait, where individual risk
is determined by complicated interactions of genetic and environmental factors.
Although changes such as an increasingly sedentary lifestyle and excessive
consumption of calories seem to be triggering factors, genetic elements are also
involved in the pathogenesis of this disorder. A positive family history increases the
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risk to develop type 2 diabetes by 2.4 fold. 15-25% of first degree relatives of
patients with type 2 diabetes develop diabetes or the state of impaired glucose
tolerance. If one parent has type 2 diabetes, the lifetime risk for the offspring is
calculated to be 38% and this increases to 60% if both parents are afflicted.
Twin studies have also added to this knowledge. Dizygotic twins share 50%
of their genes, unlike monozygotic twins. Concordance rates in the latter twins have
been used to differentiate between genetic and non-genetic contributions. In people
older than 60 years of age, concordance rates for diabetes were 35–58% in
monozygotic twins and 17–20% in dizygotic twins (Stumvoll, 2005).
This is based on the ‘equal environment assumption’ since twins share
similar environments, the increased concordance rates for disease in monozygotic
twins compared with dizygotic twins indicate the importance of genetic factors that
contribute to type 2 diabetes. The understanding of the molecular basis of this
complex disease is hindered at several levels. Several features of this complicated
disease is at root such as the variable age of onset, the varying degrees of severity
that makes phenotyping difficult, locus and allelic heterogeneity which implicates
several genes across multiple biological pathways interact with the environment to
confer risk or offer protection against the disease. Each susceptibility gene and
environmental factor contributes to the disease with varying results in different
populations so replicating these results in other populations is difficult. Also several
minor contributing genes make traditional linkage based approaches difficult and
large studies are needed to find these genes.
Linkage studies in type 2 diabetes have encountered lack of replication of
peaks of lineage and difficulties in identifying the underlying genes. In fact, the only
type 2 diabetes gene identified using linkage and position cloning is calpain 10 and
this too has not been widely accepted. The doubt arises because linkage to
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CAPN10 on chromosome 2q was only detected in Mexican Americans, SNPs
associated with type 2 diabetes were a set of functionally unclear variants, the
original findings with CAPN10 were not replicated in other populations and its actual
function and mechanism in relation to diabetes was unclear. Some loci have been
identified and found to be in different populations as well; however none have strong
evidence in their favour. Study of the intermediate phenotypes of type 2 diabetes,
rather than when the disease is fully established, has uncovered other loci.
Association studies have also been employed, especially of the candidate
gene type, in studying the genetics of type 2 diabetes. These studies have often
focused on genes encoding pathways of glucose induced insulin secretion from beta
cells, peripheral insulin led uptake of glucose by fat and muscle and also the
influence of insulin on the liver’s gluconeogenic pathways. These studies have
revealed certain genes and polymorphisms such as the common Pro12 allele which
has a frequency range 80–90% in different populations of the Pro12Ala
polymorphism in PPARG, the E23K variant of KCNJ11 and lately the involvement of
the HNF4A gene (Barroso, 2005).
Type 2 diabetes has proven to be very heterogeneous and genetic studies
have shown very diverse results. Two of the most popular methods used to study
genetic factors involved in disease include the candidate gene approach and the
genome wide scan approach. The candidate gene approach examines specific
genes with a plausible role in the disease process. This is done by testing the
statistical association of a given allele and a phenotype in unrelated people. The
genome wide scan or linkage basis approach locates genes through their genomic
position and rationales that related individuals sharing a specific phenotype will also
share chromosomal regions surrounding the gene involved (Stumvoll, 2005).
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However, the candidate gene approach has not had very much success.
There are several reasons for this which includes limitations inherent to the method
but also to the era in which this type of research was being widely used. A
fundamental requirement is to have a detailed knowledge of the disease when
candidate genes are being selected and since type 2 diabetes is an incredibly
complex disease, any single candidate gene will have a low chance in affecting
susceptibility to the disease. Also study designs using this technique depend on the
sample size and phenotypic characterization of the studied sample. Thousands of
samples are needed and statistics are often applied to compensate for the lack of
sample sizes. Meta-analysis is often used but this is subject to publication bias
where negative reports often go unpublished and so skew meta-analysis and other
biases and heterogeneity can influence the outcome. Variables such as ethnicity,
age, gender also contribute to heterogeneity (Wass & Stewart, 2011).
One major goal for elucidating the genetic backdrop of type 2 diabetes is to
improve treatment by identifying patients more likely than others to benefit from
specific therapeutic agents. Neonatal diabetic patients with the KCJN11 mutation,
when switched from insulin to sulfonylurea showed improved symptoms especially
their neurological manifestations that are often severe (Ridderstråle & Groop, 2009).
Type 2 diabetes is generally characterized by four major metabolic
abnormalities. These are obesity, the impaired action of insulin, dysfunction of
insulin secretion and the increased output of glucose. The first three are present in
most patients before onset of the disease, the sequence of development and the
contributions to the progress from normal to impaired glucose tolerance to full blown
diabetes has been difficult to ascertain. People who develop diabetes may manifest
primary defects in both insulin action and secretion which predispose them to
diabetes. These defects occur early during development towards established
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diabetes and worsen as glucose tolerance deteriorates. The inability to compensate
for either defective insulin action or secretion distinguishes individuals who develop
diabetes than those who maintain normal glucose tolerance (Weyer, Bogardus,
Mott, & Pratley, 1999).
Insulin resistance is a strong indicator of type 2 diabetes but eventual
development of the disease and hyperglycemia associated with diabetes is
associated with deficient insulin secretion. This defect appears to be determined by
genetics. Insulin resistance is the inability of insulin to be effective at its normal
circulating concentrations. In relation to glucose, it leads to impaired suppression of
endogenous glucose production, in the basal state and after food consumption,
when insulin rises according the glucose absorption from gut and stop further
glucose production by liver.
In muscle and adipocytes, insulin resistance reduces the uptake of glucose
and localized storage of glycogen and triglycerides. For the liver cells, insulin
resistance results in a decrease in the synthesis of glycogen and glycogen storage.
Also glucose production is no longer repressed by the ineffective insulin and more
glucose is present in the blood. The term Insulin resistance usually refers to the
reduced glucose-lowering effects of insulin.
Insulin resistance has tissue specific consequences. Reduced ability of
insulin to suppress VLDL (very low density lipoprotein) production from the liver
increases serum triglycerides, which leads to a decrease in HDL cholesterol and
helps form LDL (low density lipoprotein) that contributes to atherosclerosis. In
adipose tissue, insulin resistance increases the flux of non-esterified fatty acids
(Ishiyama, Taguchi, Yamamoto, & Murakami) to the liver and skeletal muscle and
impairs the action of insulin on the glucose metabolism within these tissues (Wass
A.H. J, 2011).
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The most important site of insulin resistance appears to be the peripheral
tissues (DeFronzo, Ferrannini, Hendler, Felig, & Wahren, 1983). When insulin is
applied as therapy, hepatic insulin sensitivity, as measured directly by insulin’s
ability to suppress production of glucose by the liver, significantly increases. FFA
concentrations and rates of lipid oxidation decrease. Based on the assumption that
insulin inhibits lipolysis, observations that liver fat reduces and hepatic insulin
sensitivity increases could be due to the reduced FFA movement through the liver
(Juurinen, Tiikkainen, Häkkinen, Hakkarainen, & Yki-Järvinen, 2007).
Insulin resistance affects the liver differently during the overnight fast periods
and in the postprandial state. After an overnight fast, normally, insulin inhibits
endogenous glucose production. In type 2 diabetics, the insulin resistance adds to
the increase in basal endogenous production. Excess blood glucose and increased
levels of insulin normally inhibit endogenous glucose production so insulin
resistance is implicated in increasing production of basal endogenous glucose
(Wass A.H. J, 2011).
Once the liver is insulin resistant, the action of insulin is impaired and leads
to hyperglycaemia accompanied by stimulation of insulin secretion. Additionally, the
more the level of resistance at the liver, the higher is the need for endogenous and
exogenous insulin.
It is postulated that one of the reason for individual variation in insulin
requirements in type 2 diabetes is the variation in insulin action. The variation in
hepatic fat content may influence the need for insulin by influencing the sensitivity of
endogenous glucose production to insulin (Ryysy, 2000).
In the postprandial state, under normal conditions, the endogenous glucose
production is suppressed due to the increase in insulin and decrease in glucagon.
The major effect of insulin in liver is the suppression of glucose output. In type 2
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diabetics, the glucose production is not effectively suppressed due to hepatic
resistance, deficiency in insulin and the presence of excess glucose. Continual
production of glucose by the liver adds to the post meal hyperglycaemia. The rate
of glucose usage in type 2 diabetics is normal because the presence of
hyperglyacemia compensates for the impaired action of insulin to increase glucose
uptake into tissues (Wass A.H. J, 2011).
Insulin is an important regulator of several aspects of adipocyte biology since
adipocytes are one of the most insulin responsive cells. Insulin promotes triglyceride
storage in adipocytes by assisting the differentiation of preadipocytes to adipocytes
and, in mature adipocytes, by stimulating the transport of glucose, lipogenesis and
inhibiting lipolysis. Functional defects in type 2 diabetes affects adipocyte regulation
and these defects, in adipocytes, can occur from downregulation of the major insulin
responsive glucose transporter; GLUT4. Also insulin binding to its receptor,
phosphorylation of the receptor and consequent tyrosine kinase activity and IRS
phosphorylation are all reduced. This occurs in muscle and adipose tissue.
Particularly in adipose tissue, type 2 diabetics have adipocytes that have reduced
IRS-1 expression that leads to decreased P13K activity and PI3 turns to depend on
IRS-2 as the main docking protein. In muscle cells, although the levels of IRS 1 and
2 are normal, PI3K activity is impaired (Kahn & Flier, 2000).
Insulin resistance in adipose tissue is important because lipolysis is sensitive
to insulin levels. Adipose tissue is also affected by insulin resistance as is evidenced
by observations that there is increased triglyceride breakdown and higher fatty acid
concentrations in type 2 diabetics compared to normal subjects at similar insulin
levels.

The increased rate of post meal free fatty oxidation could also lead to

impaired glucose output by the liver and defective stimulation of glucose oxidation.
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Excessive lipolysis leading to ketoacidosis does not occur in type 2 diabetes
because the insulin deficiency is not profound enough to do so (Groop C L, 1989).
1.7 Diagnosis of Diabetes
Correct diagnosis and confirmation of the diagnosis is required especially
considering the impact on the individual is considerable and lifelong. The
requirements for diagnostic confirmation differ from individual to individual and are
often based on the presenting symptoms such as severe symptoms and gross
hyperglycemia to patients presenting with blood glucose values just above the cut
off value. Severe glycaemia detected under conditions such as acute traumatic or
infective stress could be transitory and cannot be considered as diagnostic of
diabetes. A single abnormal blood glucose value in patient experiencing no
symptoms is also not enough for a concrete diagnosis of diabetes. In such cases,
one additional blood glucose test with a value in the diabetic range [fasting/random]
or from the oral glucose tolerance test (OGTT) is required for diagnostic
confirmation. In the face of unclear diagnosis, periodic re testing is advisable till the
situation is clarified (Alberti, 1998; Consultation, 1999)
1.7.1 Diagnostic Criteria Values:
A1C ≥ 6.5% OR FPG 126 mg/dl [7.0 mmol/l]. Fasting is defined as no caloric
intake for at least 8 h but plain water is allowed OR 2-h plasma glucose ≥ 200mg/dl
(11.1mmol/l) during an OGTT OR In a patient with classic symptoms of
hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥ 200 mg/dl (11.1
mmol/l) (A. D. Association, 2014)
The OGTT test, for all intents and purposes, should be resorted to only if the
blood glucose values are between levels establishing or excluding the diagnosis of
diabetes and fasting are below diabetic diagnostic values. If this test is performed it
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is enough to measure the blood glucose values while fasting and thereafter 2 hours
after a 75 gm oral glucose load by dissolving anhydrous glucose in water. For
children this is calculated according to body weight: 1.75 gm/kg although the
diagnostic criteria remain the same as for adults. It should be given in the morning
after 3 days of unrestricted eating. The overnight fast is usually for 8 – 14 hours with
water permitted (Alberti, 1998)
Although previously thought to be an unreliable diagnostic tool for diabetes
due to lack of standardization and availability (Alberti, 1998; Consultation, 1999)
glycated haemoglobin (HbA1C) is now considered to be a diagnostic tool that
closely resembles other diagnostic tools currently used for the correct diagnosis of
diabetes. Current recommendations and data show that the A1C cutoff of 6.5% is
highly specific and reasonably sensitive in diagnosing diabetes. Repeating fasting
glucose tests can minimize incorrect diagnosis of diabetes, the high reliability of A1C
suggests a single measurement is enough for diagnosis (Selvin, Steffes, Gregg,
Brancati, & Coresh, 2011).
An International Expert Committee, comprising members from the European
Association for the Study of Diabetes, the International Diabetes Federation and the
American Diabetes Association reported values of HbA1c ≥ 6.5% (48 mmol/mol) as
the cut-off point for diagnosing diabetes. The United Kingdom Department of Health
recommends using algorithms for diabetes screening in high-risk individuals that
include traditional glucose diagnostic criteria or, alternatively, HbA1c measurements
combined or not with glucose measurements. In non-symptomatic patients, a
confirmed HbA1c ± 6.5% (48 mmol/mol) is enough to diagnose Type 2 diabetes. But
patients with HbA1c levels ≥ 6.0% (42 mmol/mol) and < 6.5% (48 mmol/mol) should
undergo the OGTT to determine the diagnosis of diabetes. However, no further
testing is required for patients with HbA1c < 6.0% (42 mmol/mol). Until recently, the
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lack of HbA1c standardization prevented the use of HbA1c as part of a potential
screening and diagnostic program. The introduction of a new reference method
improved HbA1c assay standardization worldwide and its role in the screening and
diagnosis of Type 2 diabetes (Hu, 2010; WHO, 2011).
1.8 Diabetic Complications
Several serious complications are associated with long term diabetes of
either type which increases morbidity and mortality in diabetics, whether acute or
chronic. In terms of the tissues affected, complications can be divided into
microvascular and macrovascular, based on arterial size affected (Hermans, 2007).
The level of hyperglycaemia increases the risk of microvascular damage
such as retinopathy, nephropathy and neuropathy. Incidences of macrovascular
complications such as ischaemic heart disease, stroke and peripheral vascular
disease are also increased.
Although some complications are more specific to the different types of
diabetes, most chronic complications affect both types of diabetes (Gale EAM,
2002).
There are several well studied mechanisms by which hyperglycaemia inflicts
damage such as the polyol pathway, Advanced glycation end product formation,
Protein kinase C activation (PKC), overactive hexosamine pathway and oxidative
stress.
In the polyol pathway, the enzyme aldose reductase shunts the extra
glucose into forming sorbitol that is later oxidized to fructose. This consumes
NADPH which is critical for regenerating intracellular oxidants such as glutathione
which defends against oxidative stress, another critical contributor to cell damage.
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The precursors of AGE products damage cells by modifying intracellular
proteins that regulate gene transcription, modifying nearby extracellular matrix
molecules and proteins leading to cellular dysfunction and activation of inflammatory
pathways. In the protein kinase C pathway, the cellular hyperglycaemia increases
production of diacylglycerol that activates PKC and has varying effects on gene
expression.
Hyperglycaemia also leads to increased flux through the hexosamine
pathway which also has damaging consequences (Brownlee, 2005). The
hexosamine pathway is implicated in glucose toxicity that contributes to insulin
resistance in the muscle, an important pathological mechanism in Type 2 diabetes
(Shepherd & Kahn, 1999).
1.9 Diabetic Neuropathy
Diabetic neuropathy (DN) is one of the most common complications of
diabetes, with up to 50% of patients developing it and altering patients’ quality of life,
mentally and physically (M. J. Young, Boulton, Macleod, Williams, & Sonksen,
1993).
An internationally accepted definition of diabetic polyneuropathy for clinical
practice is the “presence of and/or signs of peripheral nerve dysfunction in people
with diabetes after the exclusion of other causes”.
Factors such as poor control of blood glucose levels, aberrant lipid levels,
hypertension and obesity can be linked to the development of DN (Solomon
Tesfaye, 2010; Thomas, 1997).
Patients experience numbness, tingling, pain, or weakness that often begin
in the feet and spread proximally in a length-dependent manner leading to chronic
pain, ulcer formations, amputations, balance issues and falls. Although DN can
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manifest at any stage of the diabetes, the prevalence increases with age and
duration of diabetes with the highest rates appearing amongst diabetes of twenty
five years (Boulton, 2005b).
Diabetic neuropathy is characterized by diffuse or localized damage to
autonomic or peripheral nerve fibres. Broadly, diabetic neuropathy is classed into
two major groups as shown in Table 1 based on Boulton and Thomas (Boulton,
2005b; Solomon Tesfaye ., 2010).
Generalized symmetric

Focal and multifocal neuropathies

polyneuropathies
Acute sensory

Cranial

Chronic sensorimotor

Truncal

Autonomic

Focal limb
Proximal motor amyotrophy
Coexisting Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP)

Table 1: Classification of diabetic neuropathy

The typical pattern, and the most common, is of a symmetrical and lengthdependent sensorimotor polyneuropathy; distal sensory polyneuropathy (DSPN)
(Thomas, 1997). Focal neuropathies are less common. As the duration and severity
of diabetes progresses, in peripheral neuropathy, there is a ‘stocking-glove’
distribution of sensory deficits ahead of any motor dysfunction observed. The signs
and symptoms depend on the type of fibers involved and their functions. Large fiber
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involvement affects light touch sensation and proprioception (Kleggetveit & Jørum,
2010) while small fiber involvement affects pain and temperature leading to
paresthesias, dysesthesias and neuropathic pain (Aminoff, 2006). With more
advanced neuropathy, complications such as ulceration and diabetic arthropathy
emerge. Diabetic arthropathy, also known as Charcot neuroarthropathy, affects the
bones, joints and soft tissues of the ankle and foot. Charcot first described the
relationship between loss of sensation and arthropathy in 1868 (Kumar, Aslinia,
Yale, & Mazza, 2011). Although it can occur because of various peripheral
neuropathies, diabetes appears to be the commonest cause. The interaction of
diabetes, sensory-motor neuropathy, autonomic and sensory-motor neuropathy,
metabolic derangements of the bones and trauma result in the acute localized
condition that leads to bone destruction, subluxation, dislocation, and deformity
(Rogers, 2011).
Many diabetics develop foot ulcers that are neuropathic in origin, often
accompanied by cellulitis or osteomyelitis. Poor wound healing often provides the
background for severe infections to set in which could complicate to gangrene and
often surgical amputation is required to conserve viable tissue (Ramsey, 1999).
Neuropathy also a contributor to diabetic mortality (Coppini, Bowtell, Weng, Young,
& Sonksen, 2000).
Diabetic autonomic neuropathy (DAN) is a form of diffuse diabetic
neuropathy and can target sympathetic and parasympathetic functions that
encompass genitourinary, cardiovascular and gastrointestinal dysfunctions. DAN
highly prevalent yet poorly understood and has a negative impact on quality of life
and mortality (Coppini, 2000; Freeman, 2005).
In the more focal forms of diabetic neuropathy, the damage can be to single
or multiple peripheral nerves, cranial nerves or regions of plexuses or nerve roots.
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The most common are the single nerve damage, or peripheral nerve
mononeuropathies, affecting the medial and ulnar nerves. Carpal tunnel syndrome
is more common in diabetics (Chammas, 1995) with approximately 30% of diabetics
demonstrating some evidence of this on electrophysiological testing (Dyck, 1993).
Focal diabetic neuropathies often have an acute onset, are self-limiting and
relatively uncommon. The occulomotor nerve is most commonly affected amongst
the cranial neuropathies and manifests as unilateral headache, diplopia, and ptosis
without pupillary involvement.
This is termed as diabetic ophthalmoplegia and often coexistences with other
diabetic complications and cardiovascular risk factors (Greco, Gambina, & Maggio,
2009).
Nerve plexus and nerve root involvement in diabetics often manifests
lumbosacral plexopathy and polyradiculopathy and is termed diabetic amyotrophy. It
is more prevalent in elderly patients with type 2 diabetics and is associated with
unilateral thigh pain innervated by L2 to L4 (L. Smith, Burnet, & McNeil, 2003).
Thoracic radiculopathy often manifests as sharp pains experienced in the thoracic or
abdominal area (Chokroverty, Reyes, Rubino, & Tonaki, 1977).
Overall, diabetic polyneuropathy and diabetic autonomic neuropathy are
common, most often diffuse and often progressive. The focal neuropathies are quite
often rare, appear suddenly and have a self-limiting course (Thomas, 1997; Vinik,
Mehrabyan, Colen, & Boulton, 2004).
The criteria required to diagnose diabetic peripheral neuropathy is based on
the presence of neuropathic symptoms, signs and is reinforced by the presence of
abnormal electrophysiological results – although the latter is more important for
disease progression rather than diagnosis (England, 2005).
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It is apparent that peripheral neuropathy is highly prevalent in diabetics and
appears to increase with the duration of the disease and glycaemic control. Tight
glycaemic control reduces the incidence and progression of neuropathy (Dyck,
1993; S. Tesfaye, 1996; M. J. Young, 1993). While diabetic peripheral neuropathy
affects at least 50% of older type 2 diabetic patients, its pathogenesis is not clearly
understood.
Diabetics can experience a range of symptoms. For some there are
extremely painful symptoms but others, usually those with a more marked deficit,
there may be no symptoms at all. Some of the typical neuropathic symptoms
include; painful symptoms including burning sensations, knife-like pain, electric
sensations of shock, throbbing pain and allodynia. The nonpainful symptoms
including feeling the part of the body is asleep or ‘dead’, numbness, tingling and
prickling sensations (Boulton, 2005).
The biochemical imbalances that underlie diabetic neuropathy are similar to
those of other complications. A few have been mentioned previously and other
mechanisms include activation of mitogen-activated protein kinases and inducible
nitric oxide synthase, elevated cytokines such as tumour necrosis factors, interleukin
16, 18, hypoxia, ischemia and deficiencies of growth factors such as nerve growth
factor (Chan, Terashima, Urabe, Lin, & Kojima, 2011).
The progression of diabetic neuropathy occurs in a ‘stocking glove’ pattern
and has various stages (Table 2) (Thomas, 1997)
There are also various clinical types of peripheral diabetic neuropathy (Table
3) (Boulton, 2005a)
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Stage of neuropathy

Symptoms

Signs

No neuropathy

None

None

Chronic painful

Shooting, stabbing and burning

Absent sensation to

sensations

several modalities

Pin and needle sensations

Reduced/absent
reflexes

Acute painful

Above symptoms including

Minor or absent signs

hyperesthesia
Painless with

Numbness/deadness of feet;

Reduced/absent

complete/partial

painless injury,

sensation

sensory loss

Reduced sensitivity
to heat/cold
Absent reflexes

Late complications

Foot lesions; neuropathic

Various

deformity; amputation

Table 2: Stages of diabetic peripheral neuropathy
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Large

fiber Small

neuropathy

fiber Proximal

neuropathy

motor

Acute

mono Pressure

neuropathies

palsies

neuropathy
Sensory loss

Sensory loss

Sensory loss

Sensory loss

Sensory

0  +++

0+

0+

0  +++

in

(Touch,

(Thermal,

Pain +  +++

Pain +  +++

distribution

vibration)

allodynia)

Tendon reflex Tendon reflex +  +++

Pain +  +++

Pain +  +++

N  ↓↓↓

N

loss
nerve

Pain +  ++

Tendon reflex Tendon reflex

Tendon reflex

N  ↓↓↓

N

N↓

Table 3: Clinical types of peripheral diabetic neuropathy

1.9.1 Impact of Diabetic Neuropathy
The criteria required to diagnose diabetic peripheral neuropathy is based on
the presence of neuropathic symptoms, signs and is reinforced by the presence of
abnormal electrophysiological results – although the latter is more important for
disease progression rather than diagnosis (England, 2005). It is apparent that
peripheral neuropathy is highly prevalent in diabetics and appears to increase with
the duration of the disease and glycaemic control. Tight glycaemic control reduces
the incidence and progression of neuropathy (M. J. Young, 1993), (Dyck, 1993), (S.
Tesfaye, 1996).
Diabetic autonomic neuropathy is poorly understood. All organs receive
innervation from the autonomic nervous system so every organ system can
potentially be affected. Most organs have dual innervation with parasympathetic and
sympathetic input. Most of the parasympathetic activity is mediated by the vagus
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nerve which is the longest autonomic nerve as well (Berthoud & Neuhuber, 2000).
Since the longest nerve fibers are first affected in diabetic neuropathy, early
symptoms usually involve the parasympathetic system and are widespread (Ewing
& Clarke, 1982). Subclinical neuropathy is usually present within a short time of
diagnosing diabetes. The diagnosis of diabetic autonomic neuropathy depends on
clinical and physiological assessments. Although many systems are affected, the
cardiovascular system is the most commonly tested for variations in heart rate in
relation to deep breathing, position changing and breathing out against pressure are
measured by EKG (Pfeifer, 1984).
The risk of autonomic neuropathy increases with poor glycaemic control and
duration of diabetes. The presence of other factors that have been linked to the
development of DN include hypertension, an altered lipid profile and complications
such as retinopathy (Cohen, Jeffers, Faldut, Marcoux, & Schrier, 1998; Gerritsen,
2001; Ziegler, 1993).
The autonomic nervous system practically regulates every bodily function
and when it becomes derailed, the consequences are wide and varied. From
irritating to deadly, diabetic autonomic neuropathy has a significant impact on
patients’ lives. Cardiac manifestations are related to increased mortality. In the early
stages there is resting tachycardia and loss of heart rate variation and as the
sympathetic function is affected later cardiac adrenergic sensitivity increases that
can lead to death. Other complications include exercise intolerance, orthostatic
hypotension, increased intraoperative death and silent myocardial ischaemia
(Freeman, 2005). Gastrointestinal complications of diabetic autonomic neuropathy
can affect any part of the gut. From heartburn and dysphagia in esophageal
involvement (Freeman, 2005) to gastroparesis (Kong, Horowitz, Jones, Wishart, &
Harding, 1999) and diarrhea (P. A. Low, 2004) – the symptoms are myriad.
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The genitourinary involvement of diabetic autonomic neuropathy manifests
as altered urinary frequency (Clarke, Ewing, & Campbell, 1979), bladder disorders
such as urine retention or overflow incontinence (Buck, Reed, Siddiq, Chisholm, &
Russell Fraser, 1976), erectile dysfunction (Kolodny, Kahn, Goldstein, & Barnett,
1974), vaginal dryness and decreased libido (Freeman, 2005).
Sudomotor dysfunction of diabetes often begins as a loss of thermoregulatory
sweating in a glove and stocking distribution and progresses in a length-dependant
manner typical of diabetic neuropathy. It can predispose to heat stroke and
hyperthermia and lead to a compensatory central hyperhidrosis (Fealey, Low, &
Thomas, 1989; Tentolouris, 2009)
1.9.2 Theories on the Pathogenesis of Diabetic Neuropathy
Several

etiologies

have

been

implicated

in

diabetic

neuropathy.

Hyperglycaemia is clearly an important factor for the development and progression
of diabetic neuropathy. Several pathways have been identified and studied; most of
these are glucose metabolic pathways linked to hyperglycaemia that are related to
the cellular metabolic and/or redox status (Norman E Cameron & Cotter, 1997).
These metabolic pathways include glucose flux through the polyol pathway, the
hexosamine pathway, production of the protein kinase C isoforms and accumulation
of advanced glycation endproducts (R. S. Clements, 1979; Toth ., 2008). The
additive imbalance of these pathways leads to an altered state of mitochondrial
redox state of the cell and forms high levels of reactive oxygen species (Phillip A
Low, Nickander, & Tritschler, 1997; Andrea M. Vincent, Brownlee, & Russell, 2002),
(Norman E Cameron & Cotter, 1997). The increased level of reactive oxygen
species within the cells also activates the Poly-ADP ribose polymerase (PARP)
pathway (Irina G Obrosova, 2005; Irina G. Obrosova, 2004). This is involved in
expression of the genes that determine inflammatory reactions that are also involved
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in neuronal dysfunction (Ilnytska, 2006). Other etiologies involved include altered
metabolism of lipids, amino acids, vascular insufficiency, abnormal axon transport
and reduced neurotrophism (Feldman, Stevens, & Greene, 1997). Hyperglycaemia
has been implicated in damaging nerve cells directly and via ischaemia.
1.9.2.1 Polyol Pathway
The polyol pathway was first identified in the seminal vesicles (Hers, 1956)
and demonstrated to convert blood glucose into fructose, an important source of
energy for sperm cells. Sorbitol was later identified to be present in diabetic rat lens
(Hohman, Nishimura, & Robison Jr, 1989) and the link between aldose reductase,
the polyol pathway and the development of diabetic complications was postulated
(Ramana & Srivastava, 2010; Van Heyningen, 1959). Aldose reductase in rat is
highly expressed in the lens, the retina, and sciatic nerve (Hohman, 1989). These
are all major targets for diabetic complications.
Aldose reductase is an enzyme that reduces glucose to sorbitol, which is
converted to fructose by the enzyme sorbitol dehydrogenase (SDH) (Blakley, 1951).
These enzymes are abundant in tissues more sensitive to hyperglycaemic damage.
Aldose reductase is present in most cells (Yabe-Nishimura, 1998) and in the
peripheral nerves it is localized in Schwann cells. This pathway is activated by mass
action of excess glucose and high levels of sorbitol are produced (D. A. Greene,
Lattimer, & Sima, 1988). This resulting cellular hypertonicity causes osmolytes such
as myo-inositol (Finegold, Lattimer, Nolle, Bernstein, & Greene, 1983) and taurine
(Nakamura, 1999) to leave the cell in an effort to compensate the osmotic
imbalance. NADPH, which is essential for regenerating reduced glutathione, is
consumed by the over activity of aldose reductase and the formation of excess
fructose. This contributes to oxidative stress in the cell. Activation of aldose
reductase increases the formation of diacylglycerol which, in turn, activates the
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protein kinase C pathway. The rise in NADH/NAD+ ratio could also facilitate the
formation of diacylglycerol by increasing the availability of dihydroxyacetone
phosphate and favouring its reduction to glycerol 3-phosphate, an intermediate of
diacylglycerol synthesis (Pugliese, Tilton, & Williamson, 1991).
In normoglycemia, most cellular glucose is phosphorylated into glucose 6phosphate by hexokinase as it shunts glucose into the glycolytic pathways (YabeNishimura, 1998). Overactivity of the polyol pathways is associated with a decrease
in energy flux in the diabetic nerve.
1.9.2.2 Hexosamine Pathway
The hexosamine pathway deals with excess fructose-5 phosphate, a
metabolic intermediate from the glycolytic pathway, and converts it to glucosamine-6
phosphate by glutamine fructose-6 phosphate amidotransferase. The result is the
formation of uridine diphosphate-N-acetyl glucosamine - a molecule that attaches to
the serine and threonine residues of transcription factors (Kornfeld, 1967).
Hyperglycaemia allows excess amounts of uridine diphosphate-N-acetyl
glucosamine to be produced and in turn this alters gene expression (Chou, 2004).
Transcription factors such as Sp1 assist the process. Sp1 alters expression of
genes involved in glucose control such as transforming growth factor β1 (TGF – β1)
(Sysa, Potter, Liu, & Mezey, 2009) and plasminogen activator inhibitor 1 (PAI – 1)
(X.-L. Du, 2000). The overexpression of TGF – β1 leads to an increased production
of collagen matrix that culminates in endothelial fibrosis and decreased mesangial
cell proliferation. PAI – 1 overexpression is involved in atherosclerosis because it
encourages vascular smooth muscle cell proliferation (Y.-Q. Chen, 1998). It is also
overexpressed by the protein kinase C (PKC) pathway and hexosamine pathway.
The presence of hyperglycaemia produces excess NADP and overloads the
mitochondrial electron transport chain leading to oxidative stress, mitochondrial
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damage and activation of PARP. PARP acts with the hexosamine and PKC pathway
to induce inflammation and aberrant neuronal function.
GlcNAc also impairs beta cell function by adding to the oxidative stress of
the cell (K. Liu, Paterson, Chin, & Kudlow, 2000). Increased glutamine fructose-6
phosphate amidotransferase or glucosamine levels has been linked to insulin
resistance (Hebert Jr, 1996), increased hydrogen peroxide levels, reduced
expression of insulin, glucose transporter protein 2 and glucokinase genes (Kaneto,
2001).
1.9.2.3 Protein Kinase C Pathway
Hyperglycaemia is intrinsically involved in damaging tissues prone to
complications. The protein kinase C pathway is no exception. Increased levels of
glucose stimulate diacylglycerol which activates PKC. Excess levels of PKC β
isoform has been linked to increased levels of the angiogenic protein vascular
endothelial growth factor (VEGF), PAI-1, nuclear factor κB (NF-κB), TGFβ and other
diabetic complications such as retinopathy, nephropathy and cardiovascular
complications (Arikawa, 2007; Das Evcimen & King, 2007; Geraldes & King, 2010;
Veves & King, 2001).
The activation of the PKC pathway also affects capillary permeability and
vasoconstriction. This can lead to hypoxia, angiogenesis, endothelial proliferation
and thickening of the basement membrane (Williams, Gallacher, Patel, & Orme,
1997). These changes in the neurovascular blood flow are most likely how PKC is
involved in neuropathy (Way, Katai, & King, 2001). The sodium potassium ATPase
pump and other enzymes that are critical for nerve function are also targeted. PKC
isoforms negatively affect sodium potassium ATPase pumps (D. A. Greene,
Lattimer, & Sima, 1987; Ishii, Koya, & King, 1998; Koya & King, 1998). Inhibiting
PKC inhibition improves both nerve blood flow and nerve conduction velocity (Ishii,
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1996), (Das Evcimen & King, 2007), (Way, 2001). PKC isoforms also influence
insulin resistance (Griffin, 1999; J. K. Kim ., 2004).
1.9.2.3 Advance Glycation End Product Formation
These result from non-enzymatic reactions between reducing sugars and
proteins or lipids (Goh & Cooper, 2008). The AGE precursors are also known as
reactive dicarbonyls and are particularly harmful. Most commonly, the by-product of
these irreversible reactions form Schiff bases that degrade into additionally harmful
Amadori products or fructosamine. Reactive dicarbonyls such as glyoxal and
methyloxal can also modify proteins, lipids, and nucleic acids and are more
damaging. Thus reactive dicarbonyls are one of the main mechanisms to produce
AGEs, add to carbonyl stress and lead to complications (Jack & Wright,
2012),(Huebschmann, Regensteiner, Vlassara, & Reusch, 2006). Methylglyoxal, has
been linked to increasing the susceptibility to vascular damage in endothelial cells
(Yao, 2007).
AGEs go on to modify components of the cell and act via the receptor;
RAGE (Schmidt , 1996) which is expressed in a multitude of tissues (Brett, 1993).
The interaction of AGE with its receptors has consequences such as the activation
of the transcription factor nuclear factor κB (NF-κB). Upregulation of this factor can
increase expression of proinflammatory genes and alter neuronal function
(Sugimoto, Yasujima, & Yagihashi, 2008). Increased levels of AGE and RAGE are
found in diabetic tissue (Tanji, 2000). Diabetic mice with RAGE knockout showed an
improvement in the neuropathic state and had decreased expression of NF-κB and
PKC (Toth, 2008).
AGEs also result in decreased blood flow of nerves by altering vessel wall
structure and patency. AGEs are also implicated in affecting neurons by reducing
neurotrophic support (Wada & Yagihashi, 2005).
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1.9.2.5 PolyADP-ribose Polymerase Pathway
The enzyme poly ADP-ribose polymerase (PARP) is a nuclear membrane
enzyme that synthesizes poly ADP-ribose. This represents a cellular response
mechanism to DNA damage (S. Smith, 2001). PARP is activated by oxidative stress
and also appears to contribute to oxidative stress (Irina G Obrosova, 2005). The
action of PARP involves transfer of ADPribose from nicotinamide adenine
dinucleotide to nuclear proteins. This results in depleting NAD+, changes gene
transcription

and

expression,

increases

oxidative

stress

and

shunts

the

intermediates of the glycolytic pathways to pathological pathways PKC and
advanced glycation end product formation (Erdelyi, Bakondi, Gergely, Szabo, &
Virag, 2005; Soriano ., 2001)
The functional domains of PARP include a DNA binding domain at the amino
terminus, a catalytic domain at the carboxyl terminus and a central automodification
domain which accepts polyADP-ribose. The DNA binding domain recognizes and
binds to DNA strand breaks and has two zinc—finger motifs which are similar to the
motifs in DNA ligase III and DNA polymerase. When PARP binds to breaks in DNA
strands it triggers the polyADP ribosylation reaction (Jeggo, 1998; Süsse, Scholz,
Bürkle, & Wiesmüller, 2004)
Abnormalities that have been linked to PARP manifest clinically as decrease
in nerve conduction velocity, neurovascular abnormalities, small fiber neuropathy,
thermal and mechanical hyperalgesia, and tactile allodynia (F. Li, Drel, Szabó,
Stevens, & Obrosova, 2005; Irina G Obrosova, 2007; Pacher, 2002).
1.9.2.6 Oxidative Stress and Apoptosis
Most of the pathological mechanisms discussed above contribute to
oxidative stress in the cell. AGE and the polyol pathways reduce the redox capacity
of the cell by forming ROS or reducing availability of glutathione. The hexosamine,
PKC and PARP pathways cause damage via increased expression of inflammatory
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proteins. Based on the observation that diabetic neuropathy progresses in an axon
length-dependent manner (Said, 2007), the damage could origin in the axon. These
sites are more susceptible to damage by hyperglycaemia because of the large
number of mitochondria that they possess.

Against the backdrop of ischaemia,

hyperglycaemia overloads the capacity of the mitochondria and sets the stage for
oxidative stress. This further enhances mitochondrial damage which in turn leads to
axon degeneration and death (Leinninger, Edwards, Lipshaw, & Feldman, 2006).
Mitochondria are vulnerable to damage by reactive oxygen and nitrogen
species. Reactive oxygen species are produced by the mitochondria and usually
removed by cellular agents such as glutathione, catalase and superoxide dismutase.
Hyperglycaemia accentuates ROS production in the cell via mitochondrial activity
(Friederich, Hansell, & Palm, 2009; Leinninger ., 2006; Andrea M Vincent, Russell,
Low, & Feldman, 2004).
The main reactive nitrogen species, peroxynitrite is formed from the reaction
of nitric oxide and superoxide ion. Peroxynitrate is inherently unstable and results in
the formation of nitrate through isomerisation.

Reactive nitrogen species have

several cell damaging effects; including PARP activation and protein nitrosylation
(Patel, 1999).
The presence of excess superoxide ion inhibits GAPDH and upstream
glycolytic intermediates accumulate in the cell. These in turn enhance the Aldose
reductase, hexosamine, PKC pathway and AGE product formation increase cell
injury (Nishikawa, 2000),(X.-L. Du, 2000).
The vicious cycle of injury in cells prone to diabetic complication continues.
Hyperglycaemia leads to over activation of metabolic pathways and produce cellular
oxidative stress. Against the backdrop of decreased nerve blood flow and
ischaemia, the tissue suffers more injury. The production of reactive oxygen species
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produces oxidative stress which leads to further injury and also impairs the
protective antioxidative mechanisms of the cell.
Mitochondria are also important in determining cell viability (Friederich 2001).
The presence of oxidative stress initiates signalling pathways that destroy local
mitochondria. One of these utilizes the dynamin-related protein 1 (Drp 1). The usual
process of mitochondrial fission and fusion, a delicately balanced process essential
for mitochondrial viability (Knott & Bossy‐Wetzel, 2008) is often disrupted by Drp1
which translocates to the mitochondrial surface and tips the balance towards fission.
Irregular fission is associated with mitochondrial death and apoptosis.

Diabetic

neuropathy is associated with increased levels of Drp1 (Figueroa-Romero, Sadidi, &
Feldman, 2008; Frank, 2001; Knott & Bossy‐Wetzel, 2008). There is evidence of
apoptosis in the cell body of neurons and the presence of neuroaxonal dystrophy
(Russell, Sullivan, Windebank, Herrmann, & Feldman, 1999). Recurrent injury in the
face of hyperglycaemia activates cell death pathways which are beyond the scope
of glial support and repair. This initiates mitochondrial damage and redistribution till
the axons die back towards the cell body (Srinivasan, Stevens, & Wiley, 2000),
(Leinninger, 2006).
1.9.2.7 Inflammation
Inflammation is linked to diabetic neuropathy, substances such as C-reactive
protein and plasma levels of TNF-α are in higher concentrations in diabetics and
appear to correlate with the incidence of diabetic neuropathy, amongst other
neuropathies, and are also linked to other diabetic complications. HSP27, an
intermediate in the TNF-α induction of the inflammatory mediators; cyclooxygenase2 (COX-2), Interleukin 6 (IL-6), and Interleukin 8 (IL-8), is also increased in diabetic
neuropathy (Empl ., 2001; González‐Clemente, 2005; Gruden, 2008; Jager, 1999;
Makino, 2005; Schalkwijk, 1999).
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Excess glucose is shunted to metabolic pathways that increase expression
of NF-κB and TGF-β (Esposito, 2002; G. L. King & Loeken, 2004). AGE
modifications bring about their own contributions, one of which includes the
formation of methylglyoxal which decreases the binding of transcription factors such
as Sp3 which is an angiotensin II repressor (Yao, 2007). Hyperglycaemia increases
tissue angiotensin II and activates vascular endothelial cells, which leads to
inflammatory cell recruitment, cytokine formation, ischaemia, increased ROS
formation etc (Lawrence J Coppey, 2006). Other AGE products utilize RAGE to
increase intracellular inflammatory signalling to upregulate NF-κB (Toth, 2008).
NF-kB is a very important transcription factor and regulates the expression of
many genes that are involved in inflammation such as COX-2 (L. A. J. O'Neill &
Kaltschmidt, 1997). COX-2 is upregulated in diabetic neuropathy and is a potential
target for treatment. COX-2, in turn, generates prostaglandin E2 and reactive
oxygen species that further activate NF-κB. Inhibition of COX-2 appears to prevent
harmful changes to peripheral nerves such as nerve conduction deficits, reduction of
blood flow, GSH depletion and increases in TNF-α production (Pop-Busui, Kellogg,
& Cheng, 2008).
NF-κB also regulates another enzyme involved in inflammation; inducible
nitric oxide synthase (eNOS) which in turn induces NF-κB further and similar to
COX-2 sets off a vicious cycle of inflammation (Y. Kim ., 2008). The nitric oxide (NO)
produced by iNOS increases nerve blood supply, modulates post injury changes in
microvasculature and is linked to neuropathic pain.

High levels of NO in

inflammation could damage growth cones and axons (N. E. Cameron, Eaton, Cotter,
& Tesfaye, 2001; McDonald, Cheng, Martinez, & Zochodne, 2007; Whittle, 1995;
Zochodne & Levy, 2005)
NF-κB is important in the inflammatory pathways of diabetic neuropathy.
With chronic activation of NF-κB, blood vessels and nerve cells are more prone to
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injury in ischaemia reperfusion. This is followed by infiltration of monocytes,
macrophages, and granulocytes into the peripheral nerves (Yanping Wang,
Schmeichel, Iida, Schmelzer, & Low, 2006). This macrophage recruitment is trigged
by the cytokine production induced by NF- κB in endothelial cells, Schwann cells
and neurons. Macrophages in turn contribute to diabetic neuropathy by producing
ROS, cytokines and proteases that degrade myelin and increase oxidative stress.
This also contributes to the impaired nerve regeneration in diabetic neuropathy
(Conti, 2002; Kennedy & Zochodne, 2005; Tesch, 2007; Yamagishi, 2008).
1.9.2.8 Growth Factors
Growth factors promote the growth and survival of neurons and determine
neurite outgrowth (Chiarelli, Santilli, & Mohn, 2000; Leinninger, Vincent, & Feldman,
2004; Tomlinson, Fernyhough, & Diemel, 1997). Since diabetic neuropathy exhibits
evidence of neuronal degeneration and Schwann cell damage (Russell, 1999),
alterations in growth factors such as nerve growth factor, insulin-like grown factor 1
(IGF-1) and neurotrophin 2 could be involved in the pathogenesis. These factors all
bind to tyrosine kinase receptors. The nerve growth factor (NGF) receptor is made
up of p75NTR and a specific trk tyrosine kinase, which confers ligand specificity.
Many growth factor levels are altered in diabetic neuropathy. Nerve growth
factor, the most widely studied factor, is produced by muscle cells and
keratinocytes. The nerve growth factor receptor; trkA receptor is expressed on
sensory and sympathetic neurons (Anand, 1996). Animal models of diabetic
neuropathy have shown altered expression of several growth factors and both NGF
levels and retrograde transport of the growth factor are reduced (R Hellweg &
Hartung, 1990).
The transport of NGF to the stoma is required for its neurotrophic effects to
occur (Rainer Hellweg, Raivich, Hartung, Hock, & Kreutzberg, 1994). However,
when glucose levels were normalized, NGF levels also return to normal suggesting
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a link between hyperglycaemia to growth factor levels (Rainer Hellweg, 1991).
Administering insulin appears to bring growth factor levels of several such as IGFI
and II back towards normal levels (Migdalis., 1995).
1.9.2.9 Lipid Abnormalities
The mechanisms by which plasma lipids influence neuronal injury have not
been fully elucidated but certain factors have been implicated. Correlations between
an altered lipid profile and the increased incidence of neuropathy have been
identified in both type1 and type 2 diabetics.
In animal models, a high fat diet fed to mice results in overexpression of
12/15 lipoxygenase in peripheral nerves even though these animals are glucose
tolerant

but

not

overly diabetic

(Irina G. Obrosova,

2007). Along

with

hyperglycaemia dyslipidaemia initiates neuronal injury (Rockenfeller, 2010). These
molecular altercations can also activate the endoplasmic reticulum unfolded protein
response in many types of cells, which can also lead to cell death(McAlpine, Bowes,
& Werstuck, 2010). It is unclear if elevated lipid levels have direct effects on the
peripheral neurons. Factors such as permeabilization of the lysosomal membrane
by cathepsin L leading to damage of the mitochondria and oxidative stress could be
important (Rockenfeller, 2010).
In diabetes, plasma lipoproteins are exposed to an oxidizing environment.
Peripheral neurons express scavenger receptors for oxidized LDLs including
oxidized LDL receptor 1 (LOX1) (Ishiyama, 2010) and Toll-like receptor 4 (Geng,
2010; Nowicki ., 2010; A. M. Vincent, 2009). These neurons also express RAGE,
which binds glycated LDL and internalizes oxidized LDL and glycated LDL, releasing
potentially injurious triglycerides and fatty acids within the cell that increase damage
(Honjo, 2008; Stielow, 2006; Andrea M. Vincent, Callaghan, Smith, & Feldman,
2011; A. M. Vincent, 2007). NADPH oxidase is also activated and adds to the
oxidative stress. Besides the other damaging effects, oxidative stress in diabetes

43
enhances expression of oxLDL and RAGE via p38 mitogen-activated protein kinase
MAPK signalling and adds to the damage (Toth, 2008), (Ishiyama, 2010).
Although treatments have been developed that target these pathogenetic
mechanisms (Figure 1) there is no clear evidence to suggest remarkable benefits
and thus early institution of optimal glycemic control remains the only available
measure with proven efficacy in preventing or slowing progression of diabetic
neuropathy (Boucek, 2006).

Figure 1: Therapeutic interventions based on hypothetic pathogenetic mechanisms
of diabetic neuropathy
Interventions with inhibitory effects are marked in red, with mainly supportive
effects in green. AGE: advanced glycation end products. GF: growth factor. DAG:
diacylglycerol. PKC: protein kinase C. PG: prostaglandin. NO: nitric oxide. ET:
endothelin (Boucek, 2006)
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1.10 Anatomy of the Autonomic Nervous System
The autonomic nervous system is a conduit between the central nervous
system and the viscera. It is organized in groups of ganglia, which can be grouped
schematically into

paravertebral, prevertebral, paravisceral, and intramural

(Paxinos, 2004). Ganglia are networks of bundled or connected somata and
dendritic structures which serve as relay points for the nervous system (Per, 2010).
Dorsal root ganglion (DRG), also called spinal ganglion, is the ganglion of
the posterior root of each spinal segmental nerve, containing the cell bodies of the
unipolar primary sensory neurons. These also lie on the side of the vertebral column
in close association with the spinal cord (Paxinos, 2004). These ganglia reside at
each segmental level of the spinal column within, the intervertebral foramen. The
DRG is interposed between the dorsal root that resides within the subarachnoid
space and the spinal nerve that proceeds to peripheral receptive fields. The sensory
neuron somata for all sensory modalities and types of fibers reside in the DRG
(Koopmeiners, Mueller, Kramer, & Hogan, 2013). The cell body of each sensory
neuron in the dorsal root ganglion has a long axon which extends from the dendrites
such as the skin, to the cell body in the dorsal root ganglion and then continues to
the spinal cord. The section of the axon that runs from the ganglion to the spinal
cord is bundled with similar axons. These bundles are called dorsal roots (Hart,
2010).
The axons of posterior root ganglion neurons are known as afferents
because they relay sensory information into the central nervous system (i.e. the
brain and the spinal cord). These neurons are of the pseudo-unipolar type; the axon
has two branches that act as a single axon and are termed as a distal process and a
proximal process. Unlike the majority of neurons found in the central nervous
system, an action potential in posterior root ganglion neuron may initiate in the distal
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process in the periphery, bypass the cell body, and continue to propagate along the
proximal process until reaching the synaptic terminal in the posterior horn of spinal
cord(R, 2010).
The distal section of the axon may either be a bare nerve ending or
encapsulated by a structure such as a Meissner's corpuscle or Pacinian corpuscle
to relay specific information to nerve. For example, corpuscle may encapsulate the
nerve ending, rendering the distal process sensitive to mechanical stimulation. The
dorsal root ganglia develops in the embryo from neural crest cells instead of the
neural tube. This gives rise to theories that regard the dorsal root ganglia as gray
matter of the spinal cord that became translocated to the periphery(R, 2010).
The beginning of somatosensory information transmission occurs when
peripheral receptors of the primary afferent neurons are activated. In cutaneous and
visceral nerves of the rat, the Aβ class of nerves is the fastest-conducting large
myelinated sensory fibers; the Aδ group is the slower-conducting, thinly myelinated
fibers and the slowest-conducting unmyelinated small fibers are C-fibers. C fibers
respond to stronger and possible painful stimuli. Several neurotransmitters are
postulated to be released from the afferent neurons after a painful stimulus.
Evidence points towards the excitatory amino acids (EAAs), aspartate and
glutamate and substance P amongst others (Budai, 2000). The transmission of
impulses from nociceptive afferents to the central nervous system, essential to
perceive pain depends on the release of certain neurotransmitters. These include
glutamate, substance P and calcitonin gene-related peptide (Duggan, 2002).
The autonomic ganglia house the cell bodies of

sympathetic or

parasympathetic motor neurons. The paravertebral ganglia are organized as the
sympathetic chains that lie on other side of the vertebral column. These neurons in
these ganglia receive synaptic input from preganglionic autonomic neurons whose
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cell bodies are located in the CNS. The autonomic motor neurons in the ganglia
send efferent fibers (postganglionic autonomic nerve fibers) to innervate cardiac
muscle fibers of the heart and smooth muscle fibers of body organs and glands.
Compared to the dorsal root ganglia, the neuron cell bodies in autonomic
ganglia are more widely dispersed, with a meshwork of nerve fibers lying between
them, and the nerve fibers generally are not as well organized. Unlike the dorsal root
ganglia, which have no synapses and therefore no neuropil, in sympathetic ganglia
many preganglionic sympathetic fibers from the spinal cord synapse on the
sympathetic neurons, and others travel through the ganglia without synapsing. The
cell bodies of sympathetic neurons are smaller than those of sensory neurons in the
dorsal root ganglion. The cells are multipolar with eccentrically placed nuclei. The
satellite cells (glial cells) are sparse and less apparent.
The pelvic ganglia, in the male rat, are usually located on the side of the
prostate, closely apposed to its fascia. The rat pelvic ganglia contain neurons
projecting to several urogenitary organs such as the bladder (Gu, 1984), penis (Y.Q. Ding, Takada, Kaneko, & Mizuno, 1995),(Y.-q. Ding, Wang, Qin, & Li, 1993) and
prostate (Kepper & Keast). The ganglion contains some cells bodies with the
characteristics of both adrenergic and non-adrenergic neurons. The latter contain
Vasoactive Intestinal Polypeptide and Galanin. Another group of neurons are the
small intensely fluorescent cells also termed as SIF cells (Paxinos, 2004) that
contain transmitters such as Substance P and Galanin (Dail, Galindo, Leyba, &
Barba, 1997; Keast, 1991). Substance P along with CCK are present in presynaptic
terminals at different sites in the ganglion. Two types of nerve endings, containing
SOM and/or CCK are preferentially associated with the non-noradrenergic
Neuropeptide Y neurons (Keast, 1991), and Substance P is present in axon
terminals on other non-noradrenergic neurons as well (Keast & Chiam, 1994).
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1.10.1 The Pain Pathway
The endogenous somatosensory system transduces sensory information
from the periphery to the central nervous system using a three neuron relay system.
The first order neurons are located in the peripheral nervous system with their cell
bodies in the dorsal root ganglia. Peripheral sensory neuron cell bodies give rise to
a pseudounipolar axon which is a single axon that terminates in sites within the
central and peripheral nervous systems. Pseudounipolar cells have two axons rather
than an axon and dendrite. One axon extends centrally toward the spinal cord; the
other axon extends toward the skin or muscle. Peripheral terminals of primary
afferent neurons innervate cutaneous and muscle tissues and transduce both
innocuous and noxious sensory information. Noxious (physical/mechanical),
thermal, or chemical stimuli preferentially activate specialized types of primary
afferent neurons which are termed nociceptors. Nociceptive primary afferent
neurons signal to the spinal cord, terminating on second order neurons in the gray
matter of the dorsal horn. The somatosensory system is a contralateral system, and
nociceptive signals cross the midline in the anterior white commissure at the level of
the spinal cord. The information that travels via axons in the lateral funiculus of the
ventral horn and one of its major termination sites is the thalamic nuclei. From the
thalamus, neurons project to multiple sites within the brain including the
somatosensory cortex, prefrontal cortex and anterior cingulate cortex which are
regions important for integrating, interpreting, and coordinating a relevant response
to the nociceptive information. In parallel to the ascending nociceptive system there
is a descending system that provides inhibitory and excitatory pain control. The
descending modulation of pain is when the integrated efferent message from the
brain is modulated by brainstem areas before reaching reaches the spinal cord. This
descending system provides communication, either directly or indirectly, from the
brain to the spinal cord to modulate pain and can promote both endogenous
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analgesia as well as facilitation of chronic pain states. The ascending and
descending pain modulatory systems code for both sensory/discriminative and
affective/emotional aspects of pain (Edelmayer, Brederson, Jarvis, & Bitner, 2014).
The figure below delineates the pain pathway (Edelmayer, Brederson, Jarvis, &
Bitner, 2014)

Figure 2: The pain pathway
In the most basic sense, the ascending somatosensory pathway consists of
a three neuron relay system. The first order neuron resides in the DRG. DRG cell
bodies give rise to a single pseudounipolar axon, which extends to peripheral and
central termination sites. In the periphery, nociceptors are a specialized type of
primary afferent neuron that is preferentially activated by noxious stimulation and
transmits nociceptive signals to the central nervous system. The afferent fibers
synapse on second order neurons in the gray matter in the dorsal horn region of the
spinal cord. Second order neurons cross the mid line and nociceptive signals
continue to be relayed to thalamic neurons. Third order neurons in the thalamus
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have multiple terminal projection sites. The descending system consists of
brainstem nuclei that project to the spinal cord, either directly or indirectly, to
influence endogenous analgesia.
Several sensory abnormalities occur in conditions of chronic pain,
hyperalgesia and allodynia. These have been linked to the possible plasticity of
dorsal horn circuits. Sensitization of primary afferent fibers can be linked to primary
hyperalgesia while allodynia could be due to sensitization of neurons in the dorsal
horn. Hyperalgesia, allodynia and chronic pain sensation after peripheral tissue
injury depends on the increase in sensitivity of primary afferent nociceptors at the
site of the injury; peripheral sensitization, and on an increase in the efficiency of the
synapses between primary afferent fibers and the dorsal horn neurons; central
sensitization (Yaksh, Hua, Kalcheva, Nozaki-Taguchi, & Marsala, 1999)
1.11 The Glutamate Signalling Pathway
The main excitatory neurotransmitter of the nervous system is glutamate that
acts via its receptors. The released glutamate from the presynaptic terminal is
transduced to biochemical and electrical events in the postsynaptic neuron for
functions such as neuronal excitability modulation and synaptic transmission.
The excitatory action of glutamate in the mammalian brain and spinal cord
has been known since the 1950s (Curtis & Watkins, 1960). Since it is present in high
concentration and is relatively evenly distributed throughout the different areas of
the brain, it was only recognized as a neurotransmitter by the 1970s. It is one of the
main excitatory neurotransmitters in the central nervous system of mammals
(Meldrum, 2000). By the mid-1980s, glutamate was shown to have largely filled the
four main criteria to be classified as a neurotransmitter; presynaptic localization,
release by physiologic stimuli, identical in action to a naturally occurring transmitter
and mechanism for quick termination of its action. Further studies strengthened the
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concept that glutamate is a neurotransmitter. These included the demonstration of
ATP-dependent selective transport of glutamate into synaptic vesicles (Shigetaka
Naito & Tetsufumi Ueda, 1985) , the presence of high concentrations of glutamate in
synaptic vesicles isolated from the brain (Orrego & Villanueva, 1993) and a calcium
dependent exocytotic release of glutamate from isolated nerve terminals(Nicholls,
1995).
1.11.1 The Biochemistry of Neurotransmitter Glutamate
The metabolism of glutamate is complicated as it involves neurons and glial
cells. The neurotransmitter glutamate can be synthesized through different
metabolic pathways, and different populations of glutamatergic neurons may differ in
different aspects of glutamate metabolism.
The formation and degradation of glutamate is part of the general energy
metabolism of the brain because glucose is the main substrate for the brain.
Glucose is one of the most important precursors for transmitter glutamate via the
tricarboxylic (TCA) cycle.
The cerebral TCA cycle activity is 15-20nmol min-1 mg-1 protein (Mason,
Rothman, Behar, & Shulman, 1992) and this activity corresponds to the whole brain
activity of alpha ketoglutarate dehydrogenase, and it is lower than all other enzyme
activities of the TCA cycle as measured in vitro. Alpha dehydrogenase which
converts alpha ketoglutarate into succinyl-CoA, is a rate limiting step of the TCA
cycle (Lai, Walsh, Dennis, & Clark, 1977). This bottleneck allows alpha ketoglutarate
to accumulate. Alpha ketoglutarate is transaminated to glutamate by the highly
active

transaminases

such

as

aspartate

aminotransferase

and

alanine

aminotransferase (Mason, 1992). These enzymes use aspartate or alanine as the
amino group donor (Mason, 1992). Alanine is exported from astrocytes, taken up by
neurons and then metabolized to glutamate (Westergaard ., 1993). Other amino
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group donors such as leucine from the circulation are also used (Yudkoff, 1997).
The large pool of glutamate present in the glutamatergic neurons is maintained by
the bottleneck function of alpha ketoglutarate dehydrogenase in the TCA cycle, the
very

high

activities

of

transaminases

compared

to

alpha

ketoglutarate

dehydrogenase and the abundant supply of amino group donors in transamination
actions.
Glutamate is the precursor of GABA. However, glutamate is present in low
levels in the GABAergic neurons and astrocytes and this could be because the
alpha ketoglutarate dehydrogenase bottleneck is bypassed in these cells. In
GABAergic neurons glutamate enters the GABA shunt and is converted
successively into GABA, succinic semialdehyde and succinyl-coA. In astrocytes,
glutamate is diverted from the bottleneck of alpha ketoglutarate dehydrogenase by
the formation of glutamate which then exits the cells. This leads to the levels of both
glutamate and aspartate to be low in astrocytes (Ottersen & Storm-Mathisen, 1985).
Thus all brain cells contain glutamate as a byproduct of energy metabolism.
A neuron can be identified as glutamatergic on an immunocytochemical basis only
after detection of glutamate in synaptic vesicles.
Glutamate is pooled in various parts of the brain and these pools
communicate with each other, as and when required. The transmitter pool is located
in the vesicles of glutamatergic terminals, the GABA precursor pool that is present in
GABAergic neurons, the glutamine precursor pool that is located in glia and the
lastly the metabolic pool of glutamate which is present in all cells. These pools
communicate in various instances; when glutamate is diverted form the metabolic
pool to become transmitter or precursor of GABA and glutamine, or when the amino
acid transmitters return to the metabolic pool and are processed to become carbon
dioxide and water. There is also

extensive transport of glutamate and its

derivatives, GABA and glutamine, between cell types(Fonnum, 1993). Glutamate is
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synthesized directly from glutamine, 1-pyrroline-5-carboxylate (P5C) or alpha
ketoglutarate (2-oxoglutarate) in the CNS. The formation of glutamate from
glutamine is an energy saving process that is catalyzed by phosphate-activated
glutaminase (PAG), which could play a major role in the production of transmitter
glutamate. P5C is derived from ornithine through glutamic semialdehyde by the
catalysis of ornithine delta-aminotransferase (OAT) or from proline by proline
oxidase (PO), then converted to glutamate by P5C dehydrogenase (P5CDH).
Glutamine is an important precursor for transmitter glutamate. The
transmitter pool of glutamate is preferentially supplied from glutamine (Bradford,
Ward, & Thomas, 1978). In the brain, glutamine synthetase is located in the
astroyctes and oligodendrocytes (Martinez-Hernandez, Bell, & Norenberg, 1977;
Tansey, Farooq, & Cammer, 1991). Approximately 60% of alpha ketoglutarate
formed in astrocytes is converted to glutamate and then to glutamine (Akiyama,
Kaneko, Mizuno, & McGeer, 1990). Glutamine is formed from glutamate by
amidation.
The enzyme glutaminase is located on the external aspect of the inner
mitochondrial membrane and is an amidohydrolase enzyme that generates
glutamate from glutamine. Since glutamine is an important energy substrate for
neurons, most of the glutamate that is formed from glutamine enters the
mitochondria (Bradford, 1978). After glutamine is converted to glutamate, it is
packed in the secretory vesicles and awaits release.
The astrocytic export of glutamine implies a continuous loss of alpha
ketoglutarate from the astrocytic TCA cycle but this is not the case. The
intermediates of the TCA cycle have restricted access across the blood-brain barrier
and so the anaplerotic process of pyruvate carboxylation continually replenishes the
loss. Anaplerosis is the process of converting pyruvate, which is derived from
glucose via glycolysis, to oxaloacetate or malate. Astrocytes express the enzymes
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pyruvate carboxylase and cytosolic and mitochondrial malic enzyme (A. C. Yu,
Drejer, Hertz, & Schousboe, 1983). Observations that neurons and subpopulations
of neurons have the ability to replenish their TCA cycle by carboxylating pyruvate
can explain why some glutamatergic pathways have a low level of glutaminase,
whereas others have high levels, and it explains how transmitter glutamate can be
formed from neuronal precursors (Hassel & Brathe, 2000a). Neurons can thus
carboxylate pyruvate and not depend on glutamine as a precursor for transmitter
glutamate.
The glutamine cycle, the 1:1 exchange between astrocytes and neurons of
glutamine for glutamate and GABA was conceptualized in the 1970s (van den Berg
& Garfinkel, 1971). In this cycle, astrocytes take up glutamate released from
neurons, convert it to glutamine in an energy dependent process and then supply
glutamine to the extracellular fluid to maintain a high concentration of glutamine
which is approximately 0.3mM. Neurons consume glutamine and convert it to
glutamate by glutaminase.
1.11.2 Vesicular Uptake of Transmitter Glutamate
The transmitter pool of glutamate is estimated to be about 20-30% of the
total brain glutamate content (Karlsen & Fonnum, 1978). Glutamate formed in the
nerve terminals is transported into the vesicles via the vesicular transporter. This
transporter has a low affinity for glutamate with a Km around 1mM (S. Naito & T.
Ueda, 1985). This is approximately 1000 times higher than the Km of the plasma
membrane transporters, which correlates with the concentration of glutamate being
1000-fold higher in the cytosol than extracellular fluid. Glutamate transport into
vesicles is driven by an electrochemical gradient. This is generated by a proton
pump that depends on ATP and magnesium and is stimulated by a chloride
concentration of 4-10mM, similar to the cytosolic release (S. Naito & T. Ueda, 1985).
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Glutamate in the vesicles has a concentration of approximately 100mM (Burger,
1989).
1.11.2 Mechanism of Glutamate Release
The depolarization of glutamatergic neurons allows calcium to enter the
terminal and trigger glutamate exocytosis. The vesicular release of glutamate is a
Ca2+ dependent mechanism that involves N- and P/Q-type voltage-dependent Ca2+
channels (Birnbaumer, 1994) and these channels appear to be closely linked to
vesicle docking sites. The vesicular membrane fuses with the plasma membrane
proteins, an ATP dependent process (Esser, 1998) that is regulated by protein
phosphorylation (Hanson, Heuser, & Jahn, 1997). Rapid application of glutamate to
neuronal membrane patches at a concentration that is estimated to be similar to a
physiologic synapse, brings about the postsynaptic response when excitatory
synapses are activated (Bergles, Diamond, & Jahr, 1999; J. D. Clements, Lester,
Tong, Jahr, & Westbrook, 1992).
Releasing a single release vesicle produces an excitatory postsynaptic
potential (EPSP) that is related primarily to glutamate receptor activation. The
synaptic release of glutamate is controlled by a wide range of presynaptic receptors.
After its release, glutamate must be cleared from the synaptic cleft. It is rapidly
cleared from the cleft and internalized into astrocytes. It can now enter two major
biochemical pathways. First, glutamate may become amidated to glutamine by
glutamine synthetase in the cytosol. This pathway is important, which is indicated by
the presence of glutamine synthetase in astrocytic processes that are near
glutamatergic synapses (Derouiche & Frotscher, 1991). Second, glutamate may
enter

the

mintochondria

of

astrocytes

to

become

transaminated

(by

aminotransferases) or deaminated (by glutamate dehydrogenase) to alpha
ketoglutarate and may be oxidized successively to succinate, fumarate and malate.
Malate, after leaving the mitochondria, may then be decarboxylated to pyruvate by
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cytosolic malic enzyme (Kurz, Wiesinger, & Hamprecht, 1993). The magnitude of
the flux of the transmitter glutamate from neurons to astrocytes may be roughly
estimated from the formation of glutamine from transmitter glutamate. GABA and
alpha ketoglutarate derived from the astrocytic TCA cycle also contribute to
glutamine formation.
Astrocytes are metabolically coupled with excitatory neurons and serve them
by supplying precursor glutamine and by de novo synthesis of glutamate from alpha
ketoglutarate and ammonia by using energy. Inhibitory neurons appear to use
glutamate formed from alpha ketoglutarate as the immediate precursor of GABA.
Glutaminase is mostly found in excitatory neurons, although it is also found in a
limited number of GABAergic neurons in certain areas of the brain (Kaneko,
Shigemoto, & Mizuno, 1988).
Forming and degrading transmitter glutamate is an ATP dependent process.
The fusion of the vesicular membrane with the plasma membrane needs protein
phosphorylation and needs ATP. The uptake of glutamate by astrocytes is coupled
to the influx of three molecules of sodium which are cleared by the Na/K-ATPase,
leading to the use of one molecular of ATP per molecule of internalized glutamate.
Formation of glutamine from glutamate requires one ATP per molecule (Levy, Warr,
& Attwell, 1998). The uptake of glutamine across the neuronal plasma membrane
goes against a concentration gradient and is sodium dependent. One molecule of
glutamine needs the entry of three sodium or hydrogen ions, which implies that one
ATP is used up by the Na/K-ATPase. Therefore, one transmitter glutamate cycle of
vesicular uptake and release, astrocytic uptake and amidation, and neuronal uptake
of glutamine, could use at least four molecules of ATP per molecule of glutamate;
two in neurons and two in astrocytes. This calculation does not include the ATP
expenditure inherent in the depolarization of presynaptic membrane which triggers
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the transmitter release and the depolarization of postsynaptic membranes caused
by glutamate receptor activation.
Assuming a flux of transmitter to glutamate to astrocytes, which makes up
approximately 30% of the cerebral TCA cycle rate, it means that less than 3% of the
energy extracted form serum glucose is used in the handling of transmitter
glutamate. The uptake of glutamate into cultured astrocytes increases Na/K-ATPase
activity and also an increase in glucose uptake and lactate export (Magistretti,
Pellerin, Rothman, & Shulman, 1999).
In summary, glutamate is synthesized from glutamine and also from
neuronal precursors that are supplied by neuronal pyruvate carboxylation.
Transmitter glutamate is mostly taken up into astrocytes for conversion to glutamine,
but some part of the glutamate is metabolized by the astrocytic TCA cycle either
fully to CO2 and water or only partially to form malate that is converted to pyruvate
and lactate. The uptake of glutamate into astrocytes stimulates the astrocytic uptake
of serum glucose and exports lactate. Glutamine is shunted to neurons where it is
mostly converted to CO2 and water and some of it is converted to transmitter
glutamate. The uptake processes that are related to the handling of transmitter
glutamate and glutamine, in addition to the formation of glutamine uses up
approximately 3% of the total energy of the serum glucose that is taken up by the
brain.
The location of glutaminase, on the external side of the inner mitochondrial
membrane, could play a role in events after cell damage occurs. When trauma or
hypoxia damages the cell, the enzyme can leak out of neurons and into the
extracellular space where it can covert extracellular glutamine to glutamate. This
can contribute to a continuous and excitotoxic glutamatergic stimulation of neurons.
This has been demonstrated in vitro and may occur in vivo as well (Driscoll, Deibler,
Law, & Crane, 1993).
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1.12 Glutamate Receptors
The glutamate receptors transduce the glutamate released from the
presynaptic terminal into biochemical and electrical events in the postsynaptic
neuron. Glutamate receptors are critical for transducing the vast amount of
excitatory neurotransmission and regulating the strength of both excitatory and
inhibitory transmission in the nervous system (Vandenberg, 1998).
The glutamate receptors are broadly classified into the ligand-gated
ionotropic glutamate receptors (iGluRs) and G protein-coupled metabotropic
(Meldrum, 2000) glutamate receptors (mGluRs).
The ionotropic glutamate receptors were the first to be discovered and
mediate the fast excitatory transmission in the postsynaptic neuron. These receptors
comprise of a diverse group of ion channels that are mainly gated by the binding of
glutamate. The metabotropic glutamate receptors are composed of seven
transmembrane-domain

proteins

that

depend

on

heterotrimeric

guanosine

triphosphate (GTP)-binding proteins to activate intracellular signalling pathways
(Greenamyre & Porter, 1994). The glutamatergic systems are dysfunctional in most
neuropathologies and receptor dysfunction appears to play a role in many
neurologic disorders. In depth information about these receptors in terms of
structure and function could play an important role.
1.12.1 Ionotropic Glutamate Receptors
In the early 1990s, the cloning of cDNAs that encoded the glutamate
receptor subunits helped the field immensely (Hollmann & Heinemann, 1994).
Ionotropic glutamate receptors are classified as; NMDA (N-methyl-D-aspartate),
AMPA

(α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic

acid)

and

kainate

receptor classes, named originally according to their preferred, synthetic, agonist.
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Further studies showed that the receptors are encoded by at least six gene
families based on sequence homology. Further details are in Table 4.
The similarity in sequence indicates a common evolutionary origin for these
receptors. The gene families consist of a single family for AMPA receptors, two for
kainate, and three for NMDA. The genes are located over several chromosomes but
GRIA4 and GRIK4 genes are located on the long arm of chromosome 11 and
GRIK5 and GRIN2D on chromosome 19. The table below is for the glutamate
receptor subunits and corresponding genes (Dingledine, Borges, Bowie, &
Traynelis, 1999)
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Group

Receptor

Subunit

Gene

Family

Chromosome

GenEMBL Accession No.

human

Mouse

Rat

Human

1

AMPA

GluA1

GRIA1

5q33

X57497

X17184

I57354

1

AMPA

GluA2

GRIA2

4q32-33

X57498

M85035

A46056

1

AMPA

GluA3

GRIA3

Xq25-26

M85036

X82068

1

AMPA

GluA4

GRIA4

11q22-23

M36421

U16129

2

Kainate

GluK1

GRIK1

21q21.1-22.1

X66118

M83560

U16125

2

Kainate

GluK2

GRIK2

6q16.3-q21

D10054

Z11715

U16126

2

Kainate

GluK3

GRIK3

1p34-p33

M83552

U16127

3

Kainate

GluK4

GRIK4

11q22.3

X59996

S67803

3

Kainate

GluK5

GRIK5

19q13.2

D10011

Z11581

S40369

4

NMDA

GluN1

GRIN1

9q34.3

D10028

X63255

X58633

5

NMDA

GluN2A

GRIN2A

16p13.2

D10217

D13211

U09002

5

NMDA

GluN2B

GRIN2B

12p12

D10651

M91562

U28861

5

NMDA

GluN2C

GRIN2C

17q24-q25

D10694

D13212

5

NMDA

GluN2D

GRIN2D

19q13.1qter

D12822

D13214

6

NMDA

GluN3A

GRIN3A

9q31.1

7

NMDA

GluN3B

GRIN3B

19p13.3

8

Delta

δ

GRID1

9

Delta

δ

GRID2

4q22

U77783

L34938

D10171

Z17238

D13266

Z17239

Table 4: Glutamate receptor subunits and their genes
Ionotropic glutamate receptors are integral membrane proteins that have four
large subunits. These subunits that constitute the receptors have more than 900
residues and together form a central ion channel pore. Receptor heterogeneity
within each class arises from the homo-oligomeric, or hetero-oligomeric, assembly
of distinct subunits into cation-selective tetramers. The subunits contain four
domains; the extracellular amino-terminal domain (ATD), the extracellular ligandbinding domain (LBD), the transmembrane domain (TMD), and an intracellular
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carboxyl- terminal domain (CTD). The receptor has a 2-fold symmetry perpendicular
to the plane of the membrane. The glutamate receptor TMD consists of three
transmembrane helices which are M1, M3 and M4 and a cytoplasm-facing re-entrant
membrane loop; M2. The M2 segment of the NMDA receptors is somewhat similar
to potassium channels and contains residues that influence the permeation
properties of the ion channel. M1, M2 and M3 form a structure that is similar to an
inverted K+ channel pore and M4 mainly makes contacts with the TMD of an
adjacent subunit (Dingledine, 1999).
The C terminus faces intracellularly while the N terminus extracellularly. The
mechanism by which a receptor protein is threaded through the membrane during
synthesis determines which segments will face the extra or intracellular areas and
this in turn specifies the protein domains that will be available for ligand recognition,
cytoplasmic modification, phosphorylation and interactions between the receptor
and cytoplasmic proteins (Dingledine, 1999).
Receptors, ion channels and several other types of proteins that are involved
in transmembrane signalling are usually composed of different subunits. This varies
based on the cell state, availability of subunit types which depends in turn on protein
production and subcellular localization. Based on subunit availability and interaction
affinity, complexes may form in one or more fixed stoichiometries or form with
heterogeneous stoichiometries. Based on the subunit composition, it is clear that
multiple subtypes exist within the ionotropic receptor families. Glutamate receptors
are grouped into four distinct classes based on pharmacology and on structural
homology. These include the AMPA receptors (GluA1-GluA4), the kainate receptors
(GluK1-GluK5), the NMDA receptors (GluN1, GluN2A-GluN2D, GluN3A and
GluN3B), and the δ receptors (GluD1 and GluD2). Please refer to Table 5 for
previously utilized nomenclature.
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NMDARs are composed of various combinations of GluN1 and GluN2 or
GluN2A–GluN2D subunits and, in some cases, GluN3 or GluN3A and GluN3B
subunits. These subunits differ in the length of their C-termini, with the longest ones
found in GluN2A and GluN2B and the shortest in GluN1 and GluN3B. GluN2
subunits are the major determinants of the functional properties of NMDARs,
including single-channel conductance, calcium permeability, magnesium sensitivity,
agonist affinity and deactivation kinetics. The non-GluN1 subunits determine unique
physiological properties that lead to functional diversity. GluN2 subunits bind
glutamate and form GluN1/GluN2 receptors that require glycine and glutamate for
activation. GluN3 subunits bind glycine and GluN1/GluN3 receptors are gated by
glycine alone; however, excitatory glycine receptors have not yet been observed in
neurons expressing the GluN3 subunit. The genes encoding GluN1, GluN2 and
GluN2A–GluN2D are GRIN1, GRIN2A GRIN2B, GRIN2C, GRIN2D and GRIN3A
(glutamate receptor, ionotropic, NMDA) (Stephen F Traynelis, 2010).
The AMPA receptor subunits GluA1 to GluA4 can form both homo- and
heteromers. The subunits combine to form tetramers. Most AMPA receptors are
heterotetrameric, consisting of symmetric 'dimer of dimers' of GluA2 and either
GluA1, GluA3 or GluA4. AMPA receptor subunits differ most in their C-terminal
sequence, which determines their interactions with scaffolding proteins. All AMPA
receptors contain post synaptic density protein (PDZ)-binding domains, but which
PDZ domain they bind to differs. The AMPA receptors permeability to calcium and
other cations, such as sodium and potassium, is governed by the GluR2 subunit. If
an AMPAR lacks a GluA2 subunit, then it will be permeable to sodium, potassium,
and calcium. The presence of a GluA2 subunit will almost always render the channel
impermeable to calcium. The receptor subunits of AMPARs are encoded for by
separate but related genes that form a single gene family. The receptor subunits are
encoded by similarly distinct families of genes. The genes encoding GluA1-4 are
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GRIA1-4 (glutamate receptor, ionotropic, AMPA). The overall size of these genes is
likely to be >200 kilobases and the translated protein subunits contain approximately
850-900 amino acids (Stephen F Traynelis, 2010).
Kainate (KA) receptors are tetramers made up of homo or heteromeric
association of the subunits; GluK1-5. GluK1-3 homomers are functional kainate
gated ion channels, GluK4 and GluK5 only form functional channel as heteromers.
The Kainate recetors are formed from the products of encoding genes denoted
GRIK1 – GRIK5 (gluatamate receptor, ionotropic, kainate) (Stephen F Traynelis,
2010).
The receptors classified as Delta (δ) ionotropic glutamate receptors form a
tetrameric stoichiometry. GluD2 has been found to form heteromers with AMPA or
kainate receptors and can modify the channel properties of these receptors. Genes
encoding these receptors are GRID1 and GRID2 (Glutamate receptor, ionotropic,
Delta). The δ1 and δ2 subunits of GRID1 and GRID2 have only 18–25% amino acid
identity of the other glutamate receptor subunits. These subunits do not form
functional channels themselves or modify the function of other subunits. The
importance of the δ2 subunits was highlighted in knockout mice that showed loss of
activity-related depression of the parallel fiber-Purkinje cell synapse (Kashiwabuchi,
1995). The genetic mouse model of excitotoxcity; Lurcher has been shown to be
caused by a mutation of the δ2 which makes the receptor into a constitutively leaky
cation channel (Vogel, Caston, Yuzaki, & Mariani, 2007). Heteromeric assembly of
edited and unedited subunits is a mechanism of functional modulation.
There have been many different nomenclature schemes for the ionotropic
glutamate receptors. The following table gives the new nomenclature, agreed in
Paris in 2008 by the IUHPAR (International Union of basic and clinical
pharmacology) (S. F. Traynelis, 2010).
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NMDA

AMPA

Kainate

Delta

NR1 = GluN1

GluRA = GluR1 =

GluR5 = GLUK5 = GluK1

δ1 = GluD1

NR2A = GluN2A

GluA1

GluR6 = GLUK6 = GluK2

δ2 = GluD2

NR2B = GluN2B

GluRB = GluR2 =

GluR7 = GLUK7 = GluK3

NR2C = GluN2C

GluA2

KA1 = GLUK1 = GluK4

NR2D = GluN2D

GluRC = GluR3 =

KA2 = GLUK2 = GluK5

NR3A = GluN3A

GluA3

NR3B = GluN3B

GluRD = GluR4 =
GluA4

Table 5: Nomenclature for Ionotropic glutamate receptors
Studies have implicated the NMDA receptors in many neurologic disorders
and neurodegenerative diseases including the seizure spread in epilepsy (Kullmann,
Asztely, & Walker, 2000) ischemic brain damage, Huntington’s chorea, and
amyotrophic lateral sclerosis (Heath & Shaw, 2002; Kawahara & Kwak, 2005; Kwak
& Kawahara, 2005), Parkinson’s (M. J. O'Neill, 2005) and Alzheimer’s diseases
(Marenco & Weinberger, 2006). These receptors have also been linked to several
neurodevelopmental disorders such as Fragile X mental retardation (Bear, Huber, &
Warren, 2004) schizophrenia (Marenco & Weinberger, 2006), and the proliferation of
glioblastoma tumours (Maas, Patt, Schrey, & Rich, 2001) depression, and
Rasmussen's syndrome (Granata, 2003).
Glutamate

at

elevated

concentrations

transitions

from

being

a

neurotransmitter to a neurotoxin (Gill & Pulido, 2001). The neurotoxicity of glutamate
depends on the cellular expression of the glutamate receptors and their excessive
activation (Choi, 1992; Gasic & Hollmann, 1992; Peng, Taylor, Finch, Switzer, &
Ramsdell, 1994). A neurotoxic phenomenon ensues, termed as excitotoxicity.
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Diabetes is linked to altered activity and regulation of neurotransmitter
receptors and cellular enzymes. Certain gene expression studies in diabetic rats
have shown interesting outcomes such as the down-regulation of the enzyme
glutamate decarboxylase (GAD) mRNA and glutamate aspartate transporter
(GLAST). GAD is the rate limiting enzyme that catalyses the decarboxylation of
glutamate. There are studies that report glutamate mediated excitoxicity linked to
neuronal damage and to diabetic complications such as retinopathy (Delyfer, 2005).
GLAST contains cysteine residues that develop cysteine bridges in the
presence of oxidative stress and leads to glutamate flux inhibition through the
transporters (Trotti, Danbolt, & Volterra, 1998). The presence of hydrogen peroxide,
superoxide anion and peroxynitrite anion can inhibit glutamate uptake through
GLAST (Zeng, 2010).
Hyperglycaemia has also been linked to diminished blood flow to nerves and
neural ischaemia is an important factor contributing to diabetic neuropathy (L. J.
Coppey, Davidson, Dunlap, Lund, & Yorek, 2000). This is due to the deranged
mitochondrial function, which is further damaged by the presence of excitotoxic
glutamate (Srinivasan, 2000). Over activity of glutamate induced by ischaemia is
linked to neuronal damage in neurological conditions such as stroke, amytorphic
lateral sclerosis and neuropathic pain. Limitation of toxic glutamate receptor
activation is expected to be neuroprotective (Zhang, 2002).
The glutamate receptors, via a common injury pathway, are involved in
inflammation and cellular injury. In the CNS, receptor overstimulation allows excess
calcium influx into the neuron and subsequent neuronal injury (Choi, 1992; Erdő,
1992; Lipton, 1993; Lipton & Rosenberg, 1994; Meldrum, 1994). The iGluRs permit
entry of ions such as Na+, K+ and Ca2+ and sustained stimulation allows excessive
ion and water entry leading to osmotic injury. The increased intracellular calcium
activates

several

enzyme

pathways

and

signalling

cascades

including
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phospholipases, protein kinase C, proteases, protein phosphatases, nitric acid
synthases and generates free radicals (Asztely & Gustafsson, 1996; Barb,
Campbell, Armstrong, & Cox, 1996; G. Bertrand, Gross, Puech, LoubatieresMariani, & Bockaert, 1992; H.-O. Bertrand, Bessis, Pin, & Acher, 2002; Bruni, Bose,
Pinsky, & Glavin, 1991; Burns, Stephens, & Benson, 1994; Butcher, Sandberg,
Hagberg, & Hamberger, 1987; Carlton, Hargett, & Coggeshall, 1995; Castelli,
Ingianni, Stefanini, & Gessa, 1999; Chaudhari, 1996; Dierkes, Hochstrate, & Schlue,
1996; Lipton, 1993; Lipton & Rosenberg, 1994; Meldrum, 1994). Protein kinase C
translocates from the cytoplasm to the membrane and this leads to phosphorylation
of membrane proteins via PKC. This further destabilizes the regulatory mechanisms
for calcium homeostasis and toxicity (Choi, 1992). Arachidonic acid is generated
when phospholipase A2 is activated. Platelet-activating factors increase the calcium
levels in neurons by stimulating glutamate release. Arachidonic acid potentiates
NMDA evoked currents and inhibits glutamate reabsorption into astrocytes and
neurons. This feeds forward when free radicals are formed during arachidonic acid
metabolism and further phospholipase A2 activation occurs. This increases the
concentration of extracellular glutamate which activates the GluRs (Choi, 1992;
Conn & Pin, 1997).
As a consequence, cysteine transport is then inhibited and this decreases
intracellular reducing sulphydryls, more free radicals are produced and cell death
ensues. Nuclear enzymes such as endonucleases are also activated and lead to
nuclear chromatin condensation, DNA fragmentation and nuclear breakdown. This
leads to apoptosis. The presence of free radicals adds to DNA fragmentation. The
raised calcium concentration activates nitric oxide synthetases and produces more
nitric oxide and free radicals. Nitric oxide has been observed in peripheral tissue,
ganglion cells, nerve fibers and so on. These are also sites where glutamate
receptors are present (Gill & Pulido, 2001).
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Pain is one of the most common symptoms of diabetic neuropathy and is
experienced in varying types and degrees of intensity. Glutamate has been
implicated in the generation and maintenance of neuropathic pain. Certain drugs
that modulate glutamate neurotransmission have been linked to neuropathic pain
relief in animal models of peripheral neuropathy (Bordi & Quartaroli, 2000; Bruno .,
1995). In animal models, chronic diabetic pain is postulated by increased
spontaneous firing of afferent neurons (Burchiel, Russell, Lee, & Sima, 1985). This
is associated with the presence of increased voltage-dependent calcium currents in
dorsal root ganglion cells and leads to increased calcium concentrations in the
neurons. This is added to by the opening of glutamate-regulated calcium channels
(Kawamata & Omote, 1996; Thayer & Wang, 1995; White, 2000).
However, depending on the type of mGluR subtype activated the
consequence can be neuroprotective or neurotoxic (Glaum & Miller, 1994; Lin,
Chong, & Maiese, 2002; Trombley & Westbrook, 1992). In animal models, activation
of certain mGluR subtypes such as Group II and III, protects cells against neuronal
insults such as NMDA excitotoxicity, brain injury due to trauma, stroke, glucose
deprivation, oxygen deprivation and oxidative stress (Aarts & Tymianski, 2003;
Baskys & Blaabjerg, 2005; Berent-Spillson, 2004; Blaabjerg, Fang, Zimmer, &
Baskys, 2003; Cai, Xiao, Fratkin, & Rhodes, 1999; Chong, Li, & Maiese, 2005;
Kalda, Kaasik, Vassiljev, Pokk, & Zharkovsky, 2000; Leker & Shohami, 2002; Lin,
Vincent, Shaw, Maynard, & Maiese, 2000; Sagara & Schubert, 1998; A. M. Vincent,
Mohammad, Ahmad, Greenberg, & Maiese, 1997; Zhu, DeCoster, & Bazan, 2004).
A role of these receptors in preventing hyperglycaemia induced neuronal injury has
been observed (Berent-Spillson, 2004; Berent-Spillson & Russell, 2007).
Group II and III inhibit voltage gated calcium entry and regulate glutamate
release. These receptors act as neuroprotective presynaptic autoreceptors that
control glutamate release from presynaptic terminals. Group II mGluRs regulate
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glutathione (GSH), an important component of cellular antioxidant defence. The
glutathione homeostasis is maintained by oxidation reduction pathways that recycle
GSH from oxidized glutathione disulfide and synthesis by the gamma glutamyl cycle.
Cysteine uptake and the formation of cysteine is important in the GSH cycle. This is
linked to glutamate transporters (Baker, Xi, Shen, Swanson, & Kalivas, 2002;
Bender, Reichelt, & Norenberg, 2000; Moran, Melendez, Baker, Kalivas, &
Seamans, 2003; Shanker & Aschner, 2001; Tang & Kalivas, 2003). Glia synthesize
GSH and support nearby neurons. The released GSH is degraded to precursors that
are taken up by neurons and synthesized. Activating mGluR3 on Schwann cells and
glia, where these receptors are prevalent, increases neuronal GSH. The GSH
synthesis inhibitor; buthionine sulfoximine blocks the protective action of mGluR3
(Berent-Spillson & Russell, 2007).
The enzyme glutamate carboxypeptidase II, formerly NAALADase is a
neuropeptidase primarily expressed in glial cells. The enzyme converts N-acetylaspartyl-glutamate (NAAG) to NAA. NAAG protects neurons by acting as an
mGluR3 agonist. Direct and indirect activation of mGluR3 receptor by inhibiting
glutamate carboxypeptidase II (GCPII) protects from glucose induced neuronal
injury. The GCP II inhibitor; 2- phosphonomethyl pentanedioic acid (2-PMPA)
protects the dorsal root ganglia neurons against glucose-induced cell injury and
neurite degeneration (Berent-Spillson ., 2004), (Spillson & Russell, 2003). Another
agonist APDC has activity at mGluR2 as well as mGluR3, suggesting mGluR2 could
also be neuroprotective. In animal models of diabetic neuropathy, evidence of
neuroprotection is observed. GCPII inhibitors have shown to be beneficial against
the hyperalgesia and neurophysiological and structural degenerative diabetic
neuropathy changes in inbred type 1 diabetic BB/Wor rats (Zhang, 2002).
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1.13 Glutamate Transporter Proteins
Glutamate is continuously being released from cells and is continuously
being removed from the extracellular fluid. It is of critical importance that the
extracellular glutamate concentration is kept low. Its receptors are found on most of
the cellular elements such as dendrites, nerve terminals, neuron cell bodies and glial
cells. The importance of keeping glutamate at a low concentration is not just limited
to the synaptic clefts.
Maintaining a low extracellular glutamate concentration is essential to
preventing glutamate neurotoxicity that may occur under many pathological
conditions such as diabetic neuropathy. A low extracellular glutamate concentration
is required for a high signal-to-noise (background) ratio in synaptic as well as in
extrasynaptic transmission. The clearance of extracellular glutamate via glutamate
metabolism or diffusion is not significant (Danbolt, 2001), the regulation of
extracellular glutamate depends on a highly efficient glutamate transporter system
consisting of high-affinity membrane-bound glutamate transporters. The transporter
proteins represent the only significant mechanism to remove glutamate from the
extracellular fluid and their importance for the long-term maintenance of low and
non-toxic concentrations of glutamate is now well documented.
1.14 Gene Expression
Gene expression is a process involving fundamental cell processes such as;
transcription, mRNA degradation, translation and protein degradation. Each step is
controlled by gene regulatory events (Schwanhausser, 2013). Gene expression
profiling is the measurement of the activity or the expression of thousands of genes
at once, to create a global picture. Changes in gene expression in diabetes presents
a different pathway involved in diabetic pathogenesis. The results of alterations in
gene expression lead to molecular and consequently functional changes that
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malfunction as time goes on. Studying gene expression might indicate how
therapies can be developed that can prevent or at the least slow down the
complications of chronic diabetes (Klein & Waxman, 2003).
For experimental work, single stranded DNA; complementary DNA or cDNA
is often used because it is more stable than RNA. It is generated by reverse
transcription which uses single stranded RNA as a template and the ability of the
enzyme reverse transcriptase to synthesis the DNA from the 3' end of the primer
using the RNA sequence as template. Primers are integral to this process and there
are several types available, the choice depends on the end result required. An
oligo(dT) primer will allow the synthesis of cDNA from most mRNAs because it can
bind to the poly(A) tail. Random primers can be used for non-polyadenylated RNA
because they anneal throughout the target RNA. Gene specific primers are used to
reverse transcribe specific mRNA (Life science technologies, 2013).
1.15 Hypothesis and Aim of the Study
Based on the preliminary data, the hypothesis was that glutamate pathways
are likely to be involved in diabetic neuropathy particularly neuropathic pain.
Pathways were investigated to look for changes that might reflect neuropathic pain
and fit with previously established pharmacological evidence. The aim of this project
was to identify changes in expression of genes and their protein products that are
involved in glutamate signalling in diabetes. This will help to further the
understanding of the mechanisms of diabetic neuropathy.
1.16 Animal Models
Animal models allow control in vivo the genetic and environmental factors
that influence the development of diabetes and its complications. Rodents are
preferable due to advantages such as short generation intervals, economic viability,
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ease of care and housing compared to larger models. Animal models develop
diabetes either spontaneously or by using chemical, surgical, genetic or other
techniques (Chatzigeorgiou, Halapas, Kalafatakis, & Kamper, 2009). For type 1
diabetes, the animal models range from spontaneously developing autoimmune
diabetes to chemical ablation of pancreatic beta cells. Type 2 diabetes is modeled in
both obese and non-obese animal models with varying degrees of insulin resistance
and beta cell failure (A. J. King, 2012). For the importance of relevance to the study,
the characteristics of the animal model should reflect the pathophysiology and
natural history of diabetes or the model should develop diabetic complications with
an etiology similar to humans (Cefalu, 2006). However, no one animal model fits all
these criteria. Using several different models to check for changes that affect a
broad range of diabetic models can be considered a suitable approach.
In type 2 diabetes, a popular model is the Goto-Katazaki (GK) rat which is a
nonobese and has a decrease beta cell mass. It is characterized, similar to humans,
by the presence of liver and skeletal muscle insulin resistance. The fasting blood
glucose shows only a moderate increase (Cefalu, 2006). The streptozotocin (STZ)
model is created by injecting the rats with drugs such as streptozotocin to destroy
the Langerhans islets beta cells. It represents a model, with limitations, for type 1
diabetes and its subsequent complications (Akbarzadeh, 2007) (Rossini, 1977).
Although diabetic complications such as neuropathy are typically associated
with a chronic duration of the diabetes itself, studies have also indicated the early
presence of abnormalities which could represent a premature development of these
complications in autonomic and peripheral nerves (Pfeifer, 1984), (R. J. Young,
Ewing, & Clarke, 1983), (Schaan, 2004).
In the STZ model, early neuropathic changes are detected as early as 2
weeks of developing diabetes, as can be linked to mechanical hyperalgesia and
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thermal hypoalgesia, tested by observing as paw withdrawal thresholds to
mechanical stimuli or tail flick latencies to thermal stimuli (Sugimoto, Rashid, Shoji,
Suda, & Yasujima, 2008).
The GK model showcases a more chronic scenario of neuropathy. This is
similar to humans as there is a strong correlation between duration of the diabetes
and development of neuropathy (Dyck, 1999), (Dyck, 2011). Early stages of this
model show little change in nerve conduction velocity and few morphometric
abnormalities such as atrophy or axonal loss. However, at later stages abnormalities
in these areas begin to manifest and are indicators of neuropathic changes.
Decreased expression of nerve growth factor, its receptor, susbstance P and
calcitonin gene-related protein can be observed in the dorsal root ganglia
(Murakawa, 2002).
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Chapter 2: Material and Methods
2.1 Ethical Approval
The protocol of the experiment was approved by the Faculty of Medicine and
Health Sciences Animal Ethics Committee, which uses protocols based on those of
the National Institutes of Health in the USA.
2.2 Groups of Animals and Conditions of Animal Care
Proper housing and management of the animals are essential to the wellbeing of the animals, the quality of research data and testing. Good management of
the animals also helps to minimize the variations that affect research results
(Research, 1996).
Blood glucose levels were measured in all groups of rats by Accu-check
performa blood glucose Monitoring System (Roche Diagnostics) using ∼2 μl of
whole blood collected from the tail tip after a 25-G needle puncture of unrestrained
rat.
All animals were maintained under specific pathogen free conditions at 22–
25°C ambient temperature and relative humidity at 50% with a 12 h light-dark cycle
(1800-0600 h). The cages were polycarbonate cages with wood chip bedding. There
was free access to water and Harlan-Teklad rat chow was provided.
The rats belonged to different rat models; streptozotocin treated and GotoKakizaki.
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2.2.1 Streptozotocin Treated Rats
Experiments were performed on tissues of adult male Wistar rats (200–250
g; bred inhouse) which had been given intraperitoneal injection of STZ (Sigma, St
Louis, MO, USA) at the dose 60 mg/kg at 8 weeks of age. The STZ was dissolved in
a citrate buffer solution (0.1 mol/l citric acid, 0.1mol/l sodium citrate; pH 4.5). Agematched controls received an equivalent volume of the citrate buffer solution alone.
Both groups of animals were maintained on the same diet and water ad libitum until
they were used.
Blood glucose (mg/dl) for the control rats were (78.3±2.5, n=9) and STZ rats
(366.7±23.8, n=9). The body weights of the diabetics were significantly less than the
controls, by approximately 35% at 12 weeks and 24% at 20 weeks of age.
2.2.2 Goto-Kakizaki Rats
Young adult male (5 weeks) GK rats and age-matched Wistar controls with
initial body weights of 150–180 g were obtained from a commercial colony (Taconic
City, Germantown, NY, USA).
Blood glucose concentrations 120 min following a glucose challenge in GK
rats (236.27 ± 15.12, n = 15, mg/dl) was significantly (p<0.01) higher than blood
glucose in sedentary controls (93.93 ± 2.32, n = 15, mg/dl). Body weight and nonfasting blood glucose, measured immediately before experiments, were significantly
(p<0.01) increased in GK compared to control rats
The control blood glucose concentrations were in the range 53–70 mg/dL
(mean 62 mg/dL) and the diabetic levels were 125–375 mg/dL (mean 225 mg/dL).
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The body weights of the diabetics were more than the controls, by
approximately 12% at 10months. This was also the point when the animals were
sacrificed.
2.2.3 Goto-Kakizaki Rats – Sucrose Fed
Five week GK rats were obtained (Taconic City, Germantown, NY, USA).
The seven-week-old GK rats were fed with 100 mM for 4 weeks, 200 and 300 mM
sucrose for 4 weeks each and 400 mM sucrose solutions thereafter till termination.
The objective was to induce more severe hyperglycemia. Their condition was
compared with that of age-matched GK rats that were not given sucrose were used
for comparison. All rats received normal rat chow and drinking water ad libitum.
Body weight, non-fasting blood glucose, food and water consumption were
measured periodically.
At the beginning of the study, the GK Sucrose rats had a non-fasting blood
glucose value of 142 mg dl-1 compared with 115 mg dl−1 in GK Control rats. By the
end of the study, the blood glucose had risen to 254 mg dl−1 in GK Sucrose rats,
compared with 143 mg dl−1 in GK control rats.
The non-fasting blood glucose in GK Sucrose rats (254.25 ± 20.51 mg dl−1,
n = 5) was significantly (P < 0.05) higher than that in GK (143.06 ± 6.67 mg dl−1, n =
5). The animals were sacrificed at 10months of age. Gene expression experiments
began after 8 months of dietary intervention.
The body weights were; GK Sucrose (445.08 ± 8.98 g, n = 5) and GK rats
(442.38 ± 6.08 g, n = 5). Liquid consumption in GK Sucrose rats was (164.65 ± 5.76
ml per rat day−1, n = 5) compared to GK (50.06 ± 0.97 ml per rat day−1, n = 5).
A glucose tolerance test (GTT) was performed at the end of the experiment
(after 12 weeks of treatment) for each rat. All the rats were made to fast overnight
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(at least 18hr) prior to the test. Glucose 10ml/kg/wt, was given intraperitoneally to
the animals on the day of the GTT. Blood samples were collected from the tail veins
of the rat at time 0 (prior to the glucose load), 30, 60, 120 and 180min after glucose
load. All animals are weighed before termination. Tissues were removed with the
utmost rapidity possible after dissection to ensure RNA quality and samples placed
in RNALater RNAlater (AM7021; Applied Biosystems, Carlsbad, CA, USA) and kept
overnight at 4ºC to allow thorough penetration of the tissue. The samples were then
stored in -20°C till further processing.
Neural tissue
Spinal cord; Cervical, Upper thoracic, Lower thoracic, Lumbar, Sacral
Thoracic dorsal root ganglia (TDRG); 1-3, 4-6, 9-12
Thoracic sympathetic ganglia (TSG); 1-6, 7-12
Pelvic ganglia
Lumbar dorsal root ganglia (LDRG)
Sacral dorsal root ganglia (SDRG)
Non neural tissue
Retina and Lens
Penis
Bladder
Kidney
Tail skin and foot skin

Table 6: The list of tissue samples harvested from animals

2.3 Dissection Technique
Animals are sacrificed using the guillotine method (Suckow A M).
Decapitation yields tissues uncontaminated by chemical agents.

A specialized

rodent guillotine was used after ensuring it is in good, clean condition with sharp
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blades. If correctly handled, rats do not show evidence of hypothalamic-pituitaryadrenal axis activation from this method or from being present when other rats are
similarly terminated (A. V. M. Association).
Many autonomic ganglia can be recognized without a microscope as
swelling or protrusions along nerve trunks or as knots within a mesh of nerves.
Certain ganglia are connected in a sequence or ganglionated chain such as the
paravertebral sympathetic chain, while other ganglia are connected by a mesh of
nerve trunks with which they form a plexus. Many microscopic ganglia are buried
within a nerve or embedded in the wall of the viscera. In contrast the sensory
component consists mainly of neurons located in dorsal root ganglia (and in the
nodose ganglion of the vagus nerve); in addition, afferent neurons are present within
enteric ganglia.
2.3.1 Thoracic Sympathetic Ganglia
In the thorax, the sympathetic chains lie ventral to the head of the ribs and
dorsal to the parietal pleura. Each chain is made up of some 10-12 ganglia. The
lowermost ganglion lies opposite the 10th intercostal space. In the abdomen the
sympathetic chain is retroperitoneal and is embedded in the psoas muscle. Once
identified under the dissecting scope, the sympathetic chain was isolated from its
adherent tissue. The use of micro dissecting forceps was of the utmost importance.
The chain was divided based by counting the ribs.

77

Figure 3: Removal of thoracic sympathetic ganglia.
This is beginning from the start of the rib cage. The black rectangle represents the
location of the sympathetic ganglia before removal.

Figure 4: Removal of thoracic sympathetic ganglia from its adherent tissue
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2.3.2 Pelvic Ganglia
In the male rat, the main component of the pelvic plexus is a single, large,
bilaterally symmetric ganglion, the right and left pelvic ganglia. The ganglion is
diamond-shaped, measuring about 2×4 mm, and lies on the side of the prostate,
closely apposed to its fascia, ventral to the rectum, and caudal to the ureter and vas
deferens. It shows lobulations that protrude in the direction of the surrounding
organs. The ganglion is accompanied by a few, small, accessory ganglia, mainly
related to the seminal vesicles and the vas deferens. Once identified, the ganglia
was separated as much as possible from its adherent tissue and isolated. The
encircled area represents the location in the picture below.

Figure 5: Location of pelvic ganglia.
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2.3.3 Dorsal Root Ganglia
Parallel cuts using micro-dissecting scissors were made through the
verterbrae adjacent to the spinal cord and any overlying muscle and bone were
removed. The entry point for the scissors was between the vertebral column and
spinal canal at rostral end and this allowed easier access to cut the vertebral
column. The right and left halves of the vertebral column were separated to expose
the spinal cord and DRGs. The spinal cord was lifted from the dorsal structures by
grasping the spinal cord at the rostral end while carefully cutting behind and around
the dorsal root ganglia to sever the adherent tissues. The dorsal root ganglia were
present along either side of the spinal column, in small “pockets” in the bone. Each
dorsal root ganglion was identified under the dissecting scope as being a round
structure with small pieces of nerve root on either side. The dorsal roots are very
short at cervical and upper thoracic levels, and the ganglia lie closely opposed to the
spinal cord. The last thoracic ganglion (T13) and the L4 ganglion which is the largest
ganglion were identified for orientation with respect to the whole rat. The
thoracolumbar transition is easily identified because T13 is just caudal to the last rib.
L4 is generally the largest lumbar ganglion. The dorsal root ganglia were grasped
with micro forceps, then cut root on either side with micro scissors. All visible nerve
roots were snipped away before removing dorsal root ganglia from cords. Using
established anatomical landmarks and visual identification, the dorsal root ganglia
were divided into thoracic, lumbar and sacral ganglia.
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Figure 6: Removal of dorsal root ganglia from its location.

2.4 RNA Extraction
Extracting RNA allows the study of genes of interest amongst the myriad of
coding and non-coding sequences is by following the mRNAs that correspond to the
genes of interest. At the moment of extraction, being able to identify a particular
mRNA means its corresponding gene is being expressed (Peirson & Butler, 2007).
Tissue homogenization was using the Polytron mechanical homogenizer
(POLYTRON® PT 2100 Homogenizers, Kinematica, Switzerland). Total RNA was
extracted by using the Trizol method (15596-026, TRIzol® Reagent, Life
Technologies, Thermo Fisher Scientific, USA) which allows the simultaneous
isolation of RNA, DNA, and protein from the same sample. This is an important
consideration because most of the samples of ganglia weigh 1mg and less.
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Sample homogenizations were done at intermittent intervals with samples
kept in ice in between to avoid RNA and protein degradation. Intermittent
homogenization is one of the best methods available to assist complete retrieval of
RNA and protein from such small sample (Haimov-Kochman, Fisher, & Winn, 2006).
Homogenization was done until till no clear visible homogenate particles were
observed. The generator was cleaned in between samples in the following
sequence; DNase/RNase free distilled water, 70% ethanol in DNase/RNase free
distilled water, followed by DNase/RNase free distilled water. This was to prevent
cross-contamination.
The total RNA was then precipitated using ethanol and processing of RNA
isolation was completed using the SV Total RNA Isolation System (Promega,
Madison, USA) according to manufacturer instructions.
2.4.1 RNA Purity
The concentration and purity of RNA samples was measured by checking
absorbance at 260 nm A260 and the ratio of the absorbance at 260 and 280 nm
using ND-1000; NanoDrop (ND-1000 NanoDrop, Thermo Scientiﬁc, Wilmington, DE,
USA). Only ratios ≥ 1.8 were accepted. RNA samples were kept on ice during
processing and quality check and then stored at -80º C pending further processing.
Purity of the extracted RNA was also checked by running RNA samples on a
1% agarose gel and observing the 18S and 28S bands. These ribosomal RNA
bands are 5.0 kb and 1.9 kb in size respectively. The RNA was also treated with the
DNase protocol by Invitrogen which should improvement in the purity of the RNA.
Post DNase treated RNA was also run on a gel for quality check (Wieczorek D,
2012).
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2.5 Reverse Transcription
Using a High Capactiy cDNA Reverse Transcription Kit by Applied
Biosystems (High Capacity cDNA Reverse Transcription Kit; 4374966; Applied
Biosystems, Carlsbad, CA, USA), using the manufacturer’s instructions. The total
RNA was converted into cDNA. Samples were diluted to make a final concentration
of 4ng in a 30 μl PCR reaction.
Reverse Transcription
Components

Master

Mix Volume
1x

10 x RT Buffer

3.0 µl

25 x dNTP Mix

1.2 µl

10 x RT Random Primers

3.0 µl

Multiscribe™ Reverse Transcriptase

1.0 µl

RNASE Inhibitor

1.0 µl

RNase Free H2O

= 30 - 9.2 - vol of RNA template used µl

Total Volume Reaction

30.0 µl

Table 7: Reverse Transcription Master Mix Components

The above reaction gives a final cDNA concentration of = 1ug/30µl = 16ng/µl. Each
cDNA sample were then diluted to 4ng/µl and stored in -20º C.
Reverse transcription reaction was carried out in a Veriti thermal cycler (Life
Technologies, Applied Biosystems, USA) using the following parameter values:
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Step 1

Step 2

Step 3

Step 4

Temp ºC

25 ºC

37 ºC

85 ºC

4 ºC

Time

10 minutes

120 minutes

5 minutes

∞

Table 8: Reverse Transcription Reaction paramater values
2.6 Protein Extraction
The organic phase that was obtained during trizol extraction of RNA was
processed using the manufacturer’s recommended method. Samples were then
quantified using BCA method (Pierce) and stored in -80 till further processing.
2.7 Low Density Arrays
These allowed screening to identify genes that showed altered expression.
Gene expression arrays were performed by first loading 100ng of cDNA (RNA
equivalent) with an equal amount of TaqMan© Gene Expression Master Mix for a
total of 100 μl/port. The cDNA and master mix were mixed by inversion and spun
briefly in an Eppendorf microcentrifuge. After the cards reached room temperature,
100 µL of the pooled control and pooled diabetic samples was loaded into each of
the 8 ports on the TaqMan Low-Density Array. The cards were placed in Sorvall®
Custom Buckets and centrifuged for 1 min at 1580g. This was repeated after
checking the fluid level in the cards. Immediately after centrifugation, the cards were
sealed using an array sealer to prevent cross-contamination and run on the ABI
7900HT Fast Real-Time PCR system with thermal cycling conditions:
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Purpose
of step

Activate uracil- Activation
DNA
glycosylase

Denaturation

Annealing and
Extension

Temp ºC

50 ºC

94.5 ºC

59.7 ºC

59.7 ºC

Time

02 minutes

10 minutes

30 sec cycles

1 minute

Table 9: Fast Real-Time PCR system thermal cycling conditions
Analyses were restricted to genes that were expressed at detectable levels.
2.8 Real Time Polymerase Chain Reaction (RT–PCR) Gene Expression Assay
Gene expression is a process involving fundamental cell processes such as;
transcription, mRNA degradation, translation and protein degradation. Each step is
controlled by gene regulatory events (Schwanhausser ., 2013). Gene expression
profiling is the measurement of the activity or the expression of thousands of genes
at once, to create a global picture. Changes in gene expression in diabetes presents
a different pathway involved in diabetic pathogenesis. The results of alterations in
gene expression lead to molecular and consequently functional changes that
malfunction as time goes on. Studying gene expression might indicate how
therapies can be developed that can prevent or at the least slow down the
complications of chronic diabetes (Klein & Waxman, 2003).
For experimental work, single stranded DNA; complementary DNA or cDNA
is often used because it is more stable than RNA. It is generated by reverse
transcription which uses single stranded RNA as a template and the ability of the
enzyme reverse transcriptase to synthesis the DNA from the 3' end of the primer
using the RNA sequence as template. Primers are integral to this process and there
are several types available, the choice depends on the end result required. An
oligo(dT) primer will allow the synthesis of cDNA from most mRNAs because it can
bind to the poly(A) tail. Random primers can be used for non-polyadenylated RNA
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because they anneal throughout the target RNA. Gene specific primers are used to
reverse transcribe specific mRNA (technologies, 2013).
Low density arrays are effective approaches to gene expression profiling.
These are more sensitive and focused than gene chips and offer higher throughput
than more established approaches (Goulter, Harmer, & Clark, 2006).
The TaqMan© Low Density Array is an easy-to-use micro fluidic card for
real-time PCR. The micro fluidic technology utilizes eight sample-loading ports, each
connected to 48 reaction chambers. These function as an array of reaction vessels
for the PCR step. The wells contain custom TaqMan© Gene Expression Assays and
are used to detect the real-time amplification of user-specified targets. Relative
levels of gene expression will be determined from the fluorescence data generated
during PCR (Biosystems, 2010).
The expression levels of mRNA were analyzed using target specific
TaqMan® gene expression assays and performed in a 7900HT Fast ABI Prism
7900HT Sequence Detection System.
On a 96 well optical reaction plate (4306737, Applied Biosystems, USA), 2ng
of cDNA is used in a 10ul reaction and the following components were added; 20x
TaqMan© Gene Expression Assay, 2x TaqMan© Gene Expression Master Mix, and
the endogenous control or gene of interest. This was then run in the 7900HT Fast
Real-Time PCR system (Applied Biosystems, USA).
Analyzing the data from TaqMan© Gene Expression Assays required
viewing the amplification plots for the entire plate, setting the baseline and threshold
values and then using the relative standard curve or the comparative CT method to
analyze the data.
The TaqMan® primers and probes kits were from Applied Biosystems:
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Assay ID

Gene symbol

Gene name

1

Rn00689046_m1

Gclc, rCG26075

glutamate-cysteine
subunit

2

Rn00583547_m1

Gria3, rCG53210

glutamate receptor, ionotropic, AMPA 3

3

Rn00709588_m1

Gria1, rCG34336

glutamate receptor, ionotropic, AMPA 1

4

Rn00561341_m1

Grin2a, rCG49797

glutamate receptor, ionotropic, N-methyl
D-aspartate 2A

5

Rn00583322_m1

Grip1, rCG49164

glutamate receptor interacting protein 1

7

Rn00570130_m1

Slc1a3, rCG50959

solute carrier family 1 (glial high affinity
glutamate transporter), member 3

8

Rn00583283_m1

Slc1a6, rCG29419

solute carrier family 1 (high affinity
aspartate/glutamate
transporter),
member 6

9

Rn00564705_m1

Slc1a1, rCG48035

solute carrier family 1 (neuronal/epithelial
high affinity glutamate transporter,
system Xag), member 1

10

Rn00561285_m1

Gls, rCG22604

Glutaminase

11

Rn00566625_m1

Grm1, rCG57330

glutamate receptor, metabotropic 1

12

Rn01436038_m1

Grin1, rCG45539

glutamate receptor, ionotropic, N-methyl
D-aspartate 1

13

Rn00710532_m1

Grik3, rCG30794

glutamate receptor, ionotropic, kainate 3

14

Rn00561331_m1

Grik4, rCG57905

glutamate receptor, ionotropic, kainate 4

15

Rn00568514_m1

Gria2, rCG62437

glutamate receptor, ionotropic, AMPA 2

16

Rn00568544_m1

Gria4, rCG24522

glutamate receptor, ionotrophic, AMPA 4

17

Rn00515053_m1

Grid2, rCG55329

glutamate receptor, ionotropic, delta 2

18

Rn00691548_m1

Slc1a2, rCG26600

solute carrier family 1 (glial high affinity
glutamate transporter), member 2

19

Rn00561244_m1

Gad2, rCG40828

glutamate decarboxylase 2

Table 10: TaqMan® primers and probes kits

ligase,

catalytic
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The reaction mix of 10µl containing a total cDNA of 4ng/reaction was prepared using
TaqMan® H Fast Universal PCR Master Mix, No AmpErase H UNG (Life
Technologies #4352042, Applied Biosystems, USA) as follows:
Real Time PCR Master Mix Reaction

Volume
1x

DNase/RNase free H2O

3.5 µl

cDNA (stock concentration 2ng/µl)

1 µl

2 X TaqMan H Fast Universal PCR Master
Mix

5 µl

20 X Gene of Interest (GOI)

0.5 µl

Table 11: Real Time PCR Master Mix Reaction Components
Quantitative real-time PCR assay for the gene of interest was performed in
duplicates and in a singleplex PCR reaction.
The PCR thermal cycling parameters were run in fast mode as follow:
Step 1

Step 2

Step 3

Step 4

Temp ºC

50º C

95 º C

40 cycles of 95 º C

60 º C

Time

2 minutes

20 seconds

1 second

20 seconds

Table 12: Real Time PCR Master Mix Reaction Components
Results were initially analyzed with the ABI Prism 7900HT SDS program
v2.4, all remaining calculations and statistical analysis were performed by the SDS
RQ Manager 1.1,4 software using the 2
RQmin/RQmax confidence set at 95%.

-∆∆Ct

method with a relative quantification
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The endogenous control used was rat β-actin. Other expression related
guidelines were followed from the MIQE guidelines (Bustin ., 2009).
2.9 Statistics
Results are expressed as the means ± S.E.M. of ‘n' observations. Statistical
comparisons will use either Student's unpaired t test or ANOVA followed by
Bonferroni corrected t tests for multiple comparisons, as appropriate. A value of P <
0.05 will be considered to indicate a significant difference. Statistical analyses were
done using the GraphPad Prism Software and SPSS (v21).
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Chapter 3: Results
3.1. General Characteristics of Animal Groups Studied
3.1.1 General Characteristics of Control and Goto-Kakizaki Rats; GK Group
The general characteristics of the animals are shown in Table 13.
The bodyweights of GK (443.64 ± 7.94 g, n=18) were significantly (p<0.05)
higher than Control (371.73 ± 11.80 g, n=18) rats.
The non-fasting blood glucose in GK rats (161.29 ± 12.77, n=18) was
significantly (p<0.05) higher than Control (89.67 ± 1.58 mg/dl, n=18).
Control

GK

Bodyweight (g)

371.73 ± 11.80

443.64 ± 7.94

Non-fasting blood
glucose (mg/dl)

89.67 ± 1.58

161.29 ± 12.77

Table 13: Body weight measurements and fasting blood glucose values of GK group
Data are mean±SEM. Number of animals in each group = 18. Significance
values refer to numbers in parenthesis.
3.1.2 General Characteristics of Control and Goto-Kakizaki Rats; GK Sucrose
Group

The general characteristics of the animals are shown in Table 14.
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Bodyweight (g)
Non-fasting

Control Sucrose

GK Sucrose

362.33±17.91

444.33 ± 18.37

blood 106.67±15.81

223.00 ± 30.04

glucose (mg/dl)

Table 14: Body weight measurements and fasting blood glucose values of GK
Sucrose group
Data are mean±SEM. Number of animals in each group = 5. Significance
values refer to numbers in parenthesis.
The bodyweights of GK Sucrose (445.08±8.98 g, n=5) were significantly
(p<0.05) higher than Control Sucrose (421.28±13.36 g, n=5) rats.
The non-fasting blood glucose in GK Sucrose (254.25±20.51, n=5) was
significantly (p<0.05) higher than Control Sucrose (110.93±1.76 mg/dl, n=5).
3.1.3 General Characteristics of Control and Streptozotocin Rats;
Streptozotocin 20wk Group

The general characteristics of the animals are shown in Table 15.
Body weights were significantly (P<0.05) lower in STZ 20wks rats
(259.05±8.67 g, n=9 rats) compared to Controls (351.05±8.47 g, n=10 rats).
Non-fasting blood glucose was significantly (P< 0.05) elevated in STZ rats
(440.38±24.56 mg/dl, n =9 rats) compared to Controls (98.00±2.47 mg/dl, n =10
rats).
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Bodyweight (g)
Non-fasting

blood

Control

STZ 20wk

351.05±8.47 g

259.05±8.67 g

glucose 98.00±2.47 mg/dl

440.38±24.56 mg/dl

(mg/dl)

Table 15: Body weight measurements and fasting blood glucose values of
STZ20wks
Data are mean±SEM. Number of animals in each group = 9. Significance values
refer to numbers in parenthesis.
3.1.4 General Characteristics of Control and Streptozotocin Rats;
Streptozotocin 30wk Group
The general characteristics of the animals are shown in Table 16.
Body weight was significantly (P<0.001) lower in STZ 30wk rats (266±10 g,
n=5) as compared to control (426±13 g, n=5) rats.

Bodyweight (g)
Non-fasting

blood

Control

STZ 30wk

426±13 g

266±10 g

glucose 110±4 mg/dl

554±25 mg/dl

(mg/dl)

Table 16: Body weight measurements and fasting blood glucose values of
STZ30wks
Data are mean±SEM. Number of animals in each group = 5. Significance
values refer to numbers in parenthesis.
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3.2 Low Density Array Results

GENE
GENE
TDRG LDRG
NAME
9-12
Neuropeptides and enzymes regulating neurotransmitters production,
metabolism or transport
0.62
3.73
Calcb
calcitonin-related polypeptide, beta

SDRG

2.76

Cholecystokinin

0.61

3.73

2.79

vasoactive intestinal polypeptide

0.22

0.24

6.39

Tac2

tachykinin 2

0.57

4.27

1.93

Npy

neuropeptide Y

0.79

1.56

3.05

Nos1

nitric oxide synthase 1, neuronal

0.92

1.69

3.08

Nos3

nitric oxide synthase 3, endothelial cell

0.41

0.93

1.48

Maob

monoamine oxidase B

0.49

0.97

1.64

0.31

1.37

3.90

NA

0.81

4.03

0.40

1.82

8.54

0.45

0.72

0.86

CCKar

cholinergic receptor, nicotinic, alpha 3
(neuronal)
cholecystokinin A receptor

0.59

1.31

1.58

Npyr1

neuropeptide Y receptor Y1

0.45

0.70

2.74

Sstr2

somatostatin receptor 2

0.18

1.66

3.99

Tacr2

tachykinin receptor 2

0.25

0.92

5.31

Vipr2

vasoactive intestinal peptide receptor 2

6.42

1.32

2.53

P2rx4

purinergic receptor P2X, ligand-gated ion
channel 4
purinergic receptor P2X, ligand-gated ion
channel, 7

0.45

1.31

1.78

0.44

0.93

1.57

Accn2

acid-sensing (proton-gated) ion channel 1

0.42

1.73

2.26

Scn3a

sodium channel, voltage-gated, type III,
alpha subunit

0.39

0.79

2.33

CCK
Vip

Slc6a2

solute carrier family 6 (neurotransmitter
transporter), member 2
Slc6a4
solute carrier family 6 (neurotransmitter
transporter), member 4
Slc18a3
solute carrier family 18 (vesicular
acetylcholine transporter), member 3
Receptors for neuropeptides and neurotransmitters
Chrna3

P2rx7
Ion channels
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GENE
GENE
NAME
Ion channels
Trpv1

transient receptor potential cation channel,
subfamily V, member 1
Slc12a5
solute carrier family 12 (potassium-chloride
transporter), member 5
Growth factors and their receptors
Ntrk1

neurotrophic tyrosine kinase, receptor, type
1
Ntrk2
neurotrophic tyrosine kinase, receptor, type
2
Ntrk3
neurotrophic tyrosine kinase, receptor, type
3
Microtubule associated proteins

TDRG
9-12

LDRG

SDRG

0.45

2.16

1.65

NA

4.74

4.48

NA

1.78

2.06

0.37

1.34

2.40

0.41

1.47

2.34

Map1a

microtubule-associated protein 1A

0.43

1.65

2.02

Map2

microtubule-associated protein 2

0.32

1.24

1.67

Mapt

microtubule-associated protein tau

0.32

0.94

2.35

Nrtn

Neurturin

NA

6.39

3.04

Pdyn

Prodynorphin

NA

2.95

1.09

Table 17: STZ 20wks low density array results

GENE

TDRG 9 12

LDRG

SDRG Pelv G

Gad2 Glutamate decarboxylase

2.17

6.28

8.95

NE

Grip2 glutamate receptor interacting protein
1

1.04

1.26

1.14

0.45

Grip1 glutamate receptor interacting protein
2

1.24

1.45

2.65

3.93

Grm5 Glutamate receptor 5

1.48

3.88

1.95

NE

Grin1 glutamate receptor, ionotropic

1.12

1.77

1.22

0.36

Grin2a glutamate receptor, ionotropic

1.62

0.61

1.58

NE
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GENE

TDRG 9 12

LDRG

SDRG Pelv G

Grin2b glutamate receptor, ionotropic

1.03

1.36

1.22

NE

Gria1 glutamate receptor, ionotropic,
AMPA1

0.89

1.23

1.41

NE

Gria2 glutamate receptor, ionotropic,
AMPA2

0.98

0.59

0.77

0.67

Grik3 glutamate receptor, ionotropic,
kainate 3

0.99

1.43

1.09

0.47

Table 18: STZ 20wks results of genes involved in glutamate signalling pathways.
Thoracic dorsal root ganglia 9 – 12 TDRG 9 – 12, Lumbar dorsal root ganglia
LDRG, Sacral dorsal root ganglia SDRG, Pelvic ganglia PelvG with fold changes
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3.3 Individual Gene Expression Results
CLASSIFICATION

GENE

GLUTAMATE RECEPTORS
Gria1
Gria2
Ionotropic glutamate receptors AMPA
Gria3
Gria4
Grik3
Ionotropic glutamate receptors Kainate
Grik4
Grin1
Iontropic glutamate receptors NMDA
Grin2A
Ionotropic glutamate receptors Delta 2

Grid 2

GLUTAMATE TRANSPORTERS
Slc1a1
Slc1a2
Solute carrier family
Slc1a3
Slc1a6
ENZYMES INVOLVED IN THE GLUTAMATE CYCLE & GLUTAMATE RECEPTOR
INTERACTING PROTEIN
Glutamate decarboxylase

Gad 2

Glutamate-cysteine ligase

Gclc

Glutaminase

Gls

Glutamate receptor interacting protein

Grip1

Table 19: Classification of genes that were studied for levels of specific mRNA
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3.3.1 Genes expressing Glutamate Receptors – Ionotropic AMPA
Genes encoding for the ionotropic glutamate receptors AMPA are Gria1,
Gria2, Gria3 and Gria4. These are shown in Figures 7 – 12. Figure 7 and 8 shows
gene expression of individual genes; Gria1 and Gria3 in GK rats (diabetic vs
control). Figures 9 - 12 show gene expression of individual genes; Gria2 and Gria4
in GK rats (diabetic vs control) in comparison to GK Sucrose rats (diabetic vs
control).
Gria1 showed a significant decrease in expression (p<0.05) in TDRG1-4 and
TDRG5-8. There was a significant increase in expression (p<0.05) in the LDRG of
GK 10months compared to control rats. Gria1 showed no significant change in
expression in GK Sucrose rats compared to control rats.
Gria2 showed a significant decrease in expression (p<0.05) in TSG1-6 of GK
compared to control rats.
Gria3 showed a significant increase in expression (p<0.05) in LDRG of GK
compared to control rats.
Gria4 showed a significant increase in expression (p<0.05) in both TDRG5-8
of GK compared to control rats and in TDRG9-12 in GK Sucrose compared to
control rats.
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2.5

2.5

1.5

1.5

1.0

1.0

0.5

0.5

0.0
CONT

2.5
2.0

DIAB

TDRG 5-8
P 0.0211

*

1.5
1.0
0.5
0.0
CONT

2.5

DIAB

TDRG 9-12
P 0.1992

2.0
1.5
1.0
0.5
0.0
CONT

2.5

TDRG 1-4
P 0.2682

2.0

DIAB

LDRG
P 0.4072

2.0

Expression relative to control

Expression relative to control

2.0

TDRG1-4
P 0.0359
*

0.0
CONT

TDRG 5-8
2.5

P 0.7282

2.0
1.5
1.0
0.5
0.0
CONT

2.5

DIAB

TDRG 9-12
P 0.6026

2.0
1.5
1.0
0.5
0.0
CONT

2.5
2.0

1.5

1.5

1.0

1.0

0.5

0.5

0.0

DIAB

DIAB

LDRG
P 0.0269
*

0.0
CONT

DIAB

Figure 8: Expression of Gria1 in
dorsal root ganglia in GK rats
and controls

CONT

DIAB

Figure 7: Expression of Gria3 in
dorsal root ganglia in GK rats and
controls
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2.5

TDRG1-4

2.5

P 0.1841

2.0

2.0

1.5

1.5

1.0

1.0

0.5

0.5

0.0

0.0
CONT

2.5

DIAB

CONT

TDRG 5-8

2.5

P 0.0543

2.0

1.5

1.5

1.0

1.0

0.5

0.5

P 0.0642

0.0
CONT

DIAB

TDRG 9-12
P 0.2298

2.0
1.5
1.0
0.5
0.0
CONT

DIAB

LDRG
P 0.9959

2.0
1.5
1.0
0.5
0.0
CONT

DIAB

SDRG
Reliable data
not available

Expression relative to control

Expression relative to control

0.0

2.5

DIAB

TDRG 5-8

2.0

2.5

TDRG 1-4
P 0.1057

CONT

2.5

DIAB

TDRG 9-12
P 0.3459

2.0
1.5
1.0
0.5
0.0
CONT

2.5

DIAB

LDRG
P 0.7578

2.0
1.5
1.0
0.5
0.0
CONT

2.5

DIAB

SDRG
P 0.6274

2.0
1.5
1.0
0.5
0.0
CONT

2.5
2.0

TSG 1-6
P 0.0307
*

2.5

TSG 1-6
P 0.2363

2.0

1.5

1.5

1.0

1.0

0.5

0.5
0.0

0.0
CONT

2.5

DIAB

CONT

DIAB

TSG 7-12
P 0.2125

2.5

2.0

2.0

1.5

1.5

1.0

1.0

0.5

0.5

0.0

DIAB

TSG 7-12
P 0.2125

0.0
CONT

DIAB

Figure 9: Expression of Gria2 in
dorsal root ganglia and thoracic
sympathetic ganglia in GK rats
and controls

CONT

DIAB

Figure 10: Expression of Gria2 in
dorsal root ganglia and thoracic
sympathetic ganglia in GK
sucrose fed rats and controls

99

2.5

TDRG1-4

2.5

P 0.1154

2.0

2.0

1.5

1.5

1.0

1.0

0.5

0.5

0.0

0.0
CONT

2.5
2.0

DIAB

CONT

TDRG 5-8

2.5

P < 0.0001

***

1.5
1.0

0.5

0.5
0.0
CONT

DIAB

TDRG 9-12
P 0.2318

2.0
1.5
1.0
0.5
0.0
CONT

DIAB

LDRG
P < 0.0001

2.0
1.5
1.0
0.5
0.0
CONT

DIAB

SDRG

2.5

P 0.4881
2.0
1.5

Expression relative to control

Expression relative to control

0.0

CONT

2.5
2.0

P 0.0049
**

1.0
0.5
0.0
CONT

2.5

DIAB

LDRG
P 0.7578

2.0
1.5
1.0
0.5
0.0
CONT

2.5

DIAB

SDRG
P 0.6274

2.0
1.5
1.0

0.5

0.5
0.0

0.0
CONT

DIAB

TSG 1-6
P 0.2856

CONT

2.5

2.0

2.0

1.5

1.5

1.0

1.0

0.5

0.5

DIAB

TSG 1-6
P 0.9354

0.0

0.0
CONT

2.5

DIAB

TDRG 9-12

1.5

1.0

2.5

P 0.2728

2.0

1.0

2.5

DIAB

TDRG 5-8

1.5

2.5

TDRG 1-4
P 0.5013

CONT

DIAB

TSG 7-12
P 0.1776

2.5

2.0

2.0

1.5

1.5

1.0

1.0

0.5

0.5

0.0

DIAB

TSG 7-12
P 0.1776

0.0
CONT

DIAB

Figure 12: Expression of Gria4 in
dorsal root ganglia and thoracic
sympathetic ganglia in GK rats
and controls

CONT

DIAB

Figure 11: Expression of Gria4 in
dorsal root ganglia and thoracic
sympathetic ganglia in GK
sucrose fed rats and controls
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3.3.2 Gene Expressing Glutamate Receptors – Ionotropic KAINATE

Genes encoding for the ionotropic glutamate receptors kainate are Grik3 and
Grik4. These are shown in Figures 13 – 16. The figures show gene expression of
individual genes; Grik3 and Grik4 in GK rats (diabetic vs control) in comparison to
GK Sucrose rats (diabetic vs control).
Grik3 showed a significant decrease in expression (p<0.05) in TDRG1-4,
TDRG5-8, TDRG9-12, LDRG, SDRG, TSG1-6 and TSG7-12 of both GK 10months
rats and GK Sucrose rats in comparison to control rats.
Grik4 showed a significant decrease in expression (p<0.05) in TDRG1-4,
TDRG5-8, TDRG9-12, LDRG and SDRG of both GK rats and GK Sucrose rats in
comparison to control rats. Grik4 did not show a significant change in expression in
TSG1-6 and TSG7-12 of both GK and GK Sucrose rats compared to control rats.
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2.5
2.0

TDRG1-4

2.5

P < 0.0001
***

2.0

1.5

1.5
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CONT
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***

2.0
1.5
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1.0

0.5
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DIAB
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P < 0.0001
***

1.5
1.0
0.5
0.0
CONT

2.5
2.0

DIAB

LDRG
P < 0.0001
***

1.5
1.0
0.5
0.0
CONT
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SDRG

2.5
2.0

P < 0.0001
***

1.5

CONT

2.5
2.0

0.5
0.0
CONT

2.5
2.0

P < 0.0001
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Figure 14: Expression of Grik3
in dorsal root ganglia and
thoracic sympathetic ganglia in
GK rats and controls
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Figure 13: Expression of Grik3 in
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Figure 15: Expression of Grik4
in dorsal root ganglia and
thoracic sympathetic ganglia in
GK fed rats and controls
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Figure 16: Expression of Grik4 in
dorsal root ganglia and thoracic
sympathetic ganglia in GK
sucrose fed rats and controls
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3.3.3 Gene Expressing Glutamate Receptors – Ionotropic NMDA and DELTA 2
Genes encoding for the ionotropic glutamate receptors NMDA are Grin1 and
Grin2A. The gene encoding for the ionotropic glutamate receptor Delta 2 is Grid2.
These are shown in Figures 17 – 20. Figure 17 shows gene expression of
individual genes; Grin1 in GK (diabetic vs control) in comparison to control rats.
Figure 18 shows Grid2 in GK (diabetic vs control) in comparison to control rats.
Figure 19 shows Grin2A in GK rats (diabetic vs control) in comparison to Figure 20
which shows Grin2A in GK Sucrose rats (diabetic vs control).
Grin1 showed a significant decrease in expression (p<0.05) in TDRG1-4,
LDRG and SDRG of GK rats in comparison to control rats.
Grid2 showed a significant increase in expression (p<0.05) in TDRG5-8 in
GK rats in comparison to control rats.
Grin2A showed a significant decrease in expression (p<0.05) in TDRG1-4,
TDRG5-8, TDRG9-12, LDRG and SDRG of both GK rats and GK Sucrose rats in
comparison to control rats.
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Figure 19: Expression of Grin2A in

Figure 20: Expression of Grin2A in

dorsal root ganglia and thoracic
sympathetic ganglia in GK rats and
controls

dorsal root ganglia and thoracic
sympathetic ganglia in GK sucrose
fed rats and controls
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3.3.4 Genes Expressing Glutamate Transporters
Genes encoding for glutamate transporters are Slc1a1, Slc1a2, Slc1a3 and
Slc1a6. These are shown in Figures 21 – 27. Figure 21 shows gene expression of
individual genes; Slc1a1 in GK (diabetic vs control) and Figure 22 shows GK
Sucrose in comparison to control rats. Figure 23 shows the expression of Slc1a2 in
GK (diabetic vs control) in comparison to control rats. Figure 24 and 25 show the
expression of Slc1a3 in both GK rats (diabetic vs control) and GK Sucrose rats
(diabetic vs control). Figure 26 and 27 show the expression of Slc1a6 in both GK
rats (diabetic vs control) and GK Sucrose rats (diabetic vs control).
Slc1a1 showed a significant increase in expression (p<0.05) in TDRG1-4 of
GK rats in comparison to control rats. Slc1a1 showed a significant increase in
expression (p<0.05) in TDRG5-8 and TDRG9-12 in both GK and GK Sucrose rats
in comparison to control rats. Slc1a1 showed a significant increase in expression
(p<0.05) in LDRG, SDRG and TSG1-6 in GK Sucrose rats compared to control.
Slc1a2 showed no significant change in expression in GK rats compared to
control rats.
Slc1a3 showed a significant increase in expression (p<0.05) in TDRG1-4
and TSG1-6 in GK rats compared to control. Slc1a3 showed a significant increase
(p<0.05) in expression in TDRG5-8 in both GK and GK Sucrose rats compared to
control rats. Slc1a3 showed a significant increase in expression (p<0.05) in
TDRG9-12 and SDRG in GK Sucrose rats compared to control rats.
Slc1a6 showed a significant decrease in expression (p<0.05) in TDRG1-4
and LDRG in GK and GK Sucrose rats compared to control rats. Slc1a6 showed a
significant decrease in expression (p<0.05) in TDRG5-8 and TDRG9-12 in GK rats
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compared to control rats. Slc1a6 showed a significant decrease in expression
(p<0.05) in TSG1-6 in the GK Sucrose rats compared to control.
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Figure 21: Expression of Slc1a1
in dorsal root ganglia and
thoracic sympathetic ganglia in
GK rats and controls
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Figure 22: Expression of Slc1a1
in dorsal root ganglia and
thoracic sympathetic ganglia in
GK sucrose fed rats and controls
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Figure 23: Expression of Slc1a2
in dorsal root ganglia and
thoracic sympathetic ganglia in
GK rats and controls
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Figure 24: Expression of Slc1a3
in dorsal root ganglia and
thoracic sympathetic ganglia in
GK rats and controls
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Figure 25: Expression of Slc1a3
in dorsal root ganglia and
thoracic sympathetic ganglia in
GK sucrose fed rats and controls
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Figure 26: Expression of Slc1a3
in dorsal root ganglia and
thoracic sympathetic ganglia in
GK rats and controls
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Figure 27: Expression of Slc1a3
in dorsal root ganglia and
thoracic sympathetic ganglia in
GK sucrose fed rats and controls
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3.3.5 Gene Expressing Enzymes involved in the Glutamate Cycle and
Glutamate Receptor Interacting Proteins
Genes encoding for enzymes that are involved in the synthesis glutamate
and metabolism of glutamate include; Gad2, Gclc and Gls. These are shown in
Figures 26 – 33. Figure 26 and 27 shows gene expression of individual genes;
Gad2 in GK (diabetic vs control) and GK Sucrose in comparison to control rats.
Figure 28 and 29 shows the expression of Gclc in GK (diabetic vs control) and GK
Sucrose in comparison to control rats. Figure 30 shows the expression of Gls in GK
rats (diabetic vs control) in comparison to figure 31 that shows GK Sucrose rats
(diabetic vs control). Figure 32 shows the expression of Grip1 in GK rats (diabetic
vs control) in comparison figure 33 that shows GK Sucrose rats (diabetic vs
control).
Gad2 showed a significant decrease in expression (p<0.05) in TDRG1-4 and
TDRG9-12 of GK rats compared to control rats. Gad2 showed a significant
decrease in expression (p<0.05) in TDRG5-8 and a significant increase in
expression (p<0.05) in TSG7-12 in GK Sucrose rats compared to control rats.
Gclc showed a significant increase in expression (p<0.05) in TDRG1-4,
TDRG5-8, LDRG and SDRG in GK rats and GK Sucrose rats compared to control
rats.
Gls showed a significant decrease in expression (p<0.05) in TDRG9-12 in
GK rats compared to control rats. Gls showed a significant decrease in expression
(p<0.05) in LDRG and TSG1-6 in GK Sucrose rats compared to control rats. Gls
showed a significant increase in expression (p<0.05) in TSG7-12 in GK rats
compared to control rats.
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Grip1 showed a significant decrease in expression (p<0.05) in TDRG1-4 of
GK rats compared to control rats. Grip1 also showed a significant decrease in
expression (p<0.05) in LDRG and TSG1-6 in both GK and GK Sucrose rats
compared to control rats.
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Figure 29: Expression of Gad2
in dorsal root ganglia and
thoracic sympathetic ganglia in
GK rats and controls
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Figure 28: Expression of Gad2 in
dorsal root ganglia and thoracic
sympathetic ganglia in GK
sucrose fed rats and controls
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Figure 30: Expression of Gclc in
dorsal root ganglia and thoracic
sympathetic ganglia in GK rats
and controls
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Figure 31: Expression of Gclc in
dorsal root ganglia and thoracic
sympathetic ganglia in GK
sucrose fed rats and controls

116

2.5

TDRG1-4

2.5

P 0.1400

2.0

2.0

1.5

1.5

1.0

1.0

0.5

0.5

0.0

0.0
CONT

2.5

DIAB

CONT

2.5
2.0

1.5

1.5

1.0

1.0

0.5

0.5
DIAB

TDRG 9-12
P 0.0117
*

1.5
1.0
0.5
0.0
CONT

2.5

DIAB

LDRG
P 0.3158

2.0
1.5
1.0
0.5
0.0
CONT

DIAB

SDRG

2.5

P 0.8729
2.0
1.5

CONT

2.5

1.0
0.5
0.0
CONT

2.5
2.0

DIAB

LDRG
P 0.0045
**

1.5
1.0
0.5
0.0
CONT

DIAB

SDRG

2.5

P 0.7553
2.0
1.5
1.0
0.5
0.0

0.0
CONT

DIAB

TSG 1-6

CONT

2.5

P 0.6625
2.0

2.0

1.5

1.5

1.0

1.0

0.5

0.5

DIAB

TSG 1-6
P 0.0251
*

0.0

0.0
CONT

2.0

P 0.0633

1.5

0.5

2.5

DIAB

TDRG 9-12

2.0

1.0

2.5

P 0.2140

0.0
CONT

Expression relative to control

Expression relative to control

0.0

2.0

DIAB

TDRG 5-8

TDRG 5-8
P 0.2758

2.0

2.5

TDRG 1-4
P 0.3601

CONT

DIAB

TSG 7-12
P 0.0002
***

2.5

DIAB

TSG 7-12
P 0.7078

2.0

1.5

1.5

1.0

1.0

0.5

0.5

0.0

0.0
CONT

DIAB

Figure 33: Expression of Gls in
dorsal root ganglia and thoracic
sympathetic ganglia in GK rats
and controls

CONT

DIAB

Figure 32: Expression of Gls in
dorsal root ganglia and thoracic
sympathetic ganglia in GK
sucrose fed rats and controls

117

2.5
2.0

TDRG1-4

2.5

P 0.0450
*

2.0

1.5

1.5

1.0

1.0

0.5

0.5

0.0

0.0
CONT

2.5

DIAB

CONT

2.5
2.0

1.5

1.5

1.0

1.0

0.5

0.5
DIAB

TDRG 9-12
P 0.0886

2.0
1.5
1.0
0.5
0.0
CONT

2.0

DIAB

LDRG
P 0.0082
**

1.5
1.0
0.5
0.0
CONT

DIAB

SDRG

2.5

P 0.1891
2.0
1.5

CONT

2.5

1.0
0.5
0.0
CONT

2.5
2.0

DIAB

LDRG
P 0.0034
**

1.5
1.0
0.5
0.0
CONT

2.5

DIAB

SDRG
P 0.1100

2.0
1.5

0.5

0.5
0.0

0.0
CONT

DIAB

TSG 1-6
P 0.0422
*

CONT

2.5
2.0

1.5

1.5

1.0

1.0

0.5

0.5

DIAB

TSG 1-6
P 0.0010
**

0.0

0.0
CONT

2.5

TDRG 9-12
P 0.8922

1.5

1.0

2.0

DIAB

2.0

1.0

2.5

P 0.3864

0.0
CONT

Expression relative to control

Expression relative to control

0.0

2.5

DIAB

TDRG 5-8

TDRG 5-8
P 0.6435

2.0

2.5

TDRG 1-4
P 0.0994

CONT

DIAB

TSG 7-12
P 0.7938

2.5

2.0

2.0

1.5

1.5

1.0

1.0

0.5

0.5

0.0

DIAB

TSG 7-12
P 0.5201

0.0
CONT

DIAB

Figure 34: Expression of Grip1
in dorsal root ganglia and
thoracic sympathetic ganglia in
GK rats and controls
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3.4 Analysis of Variance
Using ANOVA followed by Bonferroni post hoc test for multiple comparisons, the
following results were obtained. P <0.05 was considered to indicate a significant
difference (IBM SPSS statistics, v21).
Gene

F value

P value

Gria2

107.159 (4, 160)

0.000

Gria4

44.603 (4, 200)

0.001

Slc1a1

24.684 (4, 200)

0.000

Slc1a3

5.445 (4,200)

0.831

Slc1a6

5.350 (4,200)

0.000

Grik3

2805.8 (4,200)

0.000

Grik4

50.002 (4,200)

0.000

Grin2A

2.675 (4, 200)

0.115

Gclc

64.227 (4, 200)

0.000

Gls

43.895 (4, 200)

0.000

Grip1

12.779 (4, 200)

0.000

Gad2

3.303 (4, 120)

0.888

Table 20: Analysis of variance for the effect of dorsal root ganglia on gene
expression
In the case of Gria2, concentration in SDRG were different from all levels of
the dorsal root ganglia.
For Gria3 and Gria4, concentration in LDRG were different from all levels of
the dorsal root ganglia.

119
For Slc1a1, concentration in LDRG and SDRG were different from all levels
of the dorsal root ganglia.
For Slc1a3 and Slc1a6, Grik3, Grip1 and Grin2A there was no significant
difference in the any of the dorsal root ganglia across the levels.
For Grik4 and Gclc and Gls, concentration in TDRG 5-8 were different from
all levels of the dorsal root ganglia.
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Chapter 4: Discussion

While diabetic peripheral neuropathy affects at least 50% of older type 2
diabetic patients, its pathogenesis is not clearly understood. Considering the large
number of individuals afflicted with diabetes, this is an issue of epic proportions.
Diabetic patients suffering from neuropathic complications can experience a range
of symptoms. For some there are extremely painful symptoms but others, usually
those with a more marked deficit, there may be no symptoms at all. Typical
neuropathic symptoms can include burning sensations, knife-like pain, electric
sensations of shock, throbbing pain and allodynia. On the other end of the spectrum,
patients can experience sensations such as feeling the part of the body is asleep or
‘dead’, numbness, tingling and prickling sensations.
The diabetic patients that experience pain frequently exhibit one or more
kinds of stimulus-evoked pain, including increased responsiveness to noxious
stimuli (hyperalgesia) as well as a hyper-responsiveness to normally innocuous
stimuli (allodynia) that are often concurrent with a paradoxical loss of stimulusevoked sensation.
Clinical examination of patients with chronic diabetic peripheral neuropathy
usually reveals a symmetrical sensory loss to all modalities in a stocking distribution.
This may well extend into the mid-calf level and may also affect the upper limbs in
more severe cases.
Changes in the expression of mRNA, caused by diabetes and/or changes in
diet, if translated into changes in proteins may cause alterations to the architecture
of glutamate receptors which may in turn have implications for diabetic neuropathy.
Studies involving gene expression suggest that chronic neuropathic pain is
associated with strong activation of certain neuronal genes and defining these gene
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profile

can

further

the

understanding

of

neuropathic

pain

etiology(Rodriguez Parkitna, 2006).
The pathogenesis of diabetic neuropathy has several theories that endeavor
to explain it. When several theories orbit a condition, it suggests that there is no
unifying hypothesis. The pathological signalling pathways associated with diabetic
neuropathy are complex and this influences the development of targeted therapies.
Despite extensive investigations and development of multiple theories the
mechanism involved in the development of diabetic neuropathy are still not
completely understood. In order to shed light on this process we decided to
investigate changes in gene expression in the ganglia that is crucial for the
neuropathic process. Preliminary investigations using low density arrays comprised
of genes involved in neurotransmitter production and degradation, neuropeptides,
receptors, post receptor signalling and transport showed several promising results.
The most interesting results involved the genes that are involved in the glutamate
pathway. Genes for glutamate receptor expression, glutamate processing enzymes
and glutamate transporter proteins showed significant changes in expression.
Furthermore, existing studies have focused predominantly on the spinal cord
and peripheral tissue, the dorsal root ganglia have not received such in-depth
attention and scrutiny. This could be due to the inherent difficulty in harvesting the
tissue intact from animal models because of the extremely small size of the ganglia.
The results in this study are unique in addressing the role of genes involved in the
glutamate signalling pathway in diabetic neuropathy. The changes observed will be
discussed in relation to symptoms of diabetic neuropathy, particularly in light of the
substantial evidence that glutamate is involved in neuropathic pain. The cellular and
molecular signalling pathways revealed in this study could provide strategies for the
development of analgesics and management of diabetic neuropathy. This study
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identifies that the genes involved in the expression of glutamate receptors, genes
that are involved in the expression of enzymes regulating glutamate concentrations
and transporter of the neurotransmitter glutamate could play a role in the
development of diabetic neuropathy and its physical manifestations.
4.1 Animal Model
This study investigated the expression of genes involved in glutamate
signalling and their possible role in the development of diabetic neuropathy. The
experiments utilized an animal model that represents type 2 diabetes; the most
common type of diabetes in humans.
Two of the animal groups studied were Goto-Kakizaki diabetic animals who
exhibit modestly elevated glucose levels and their litter mate controls. In order to
investigate the effect of increased hyperglycaemia, we also studied the same two
groups of animals following a sucrose enriched diet. Thus there are four study
groups overall: Control animals (Cont), GK diabetic animals (GK), Control Sucrose
fed (Cont-Suc), GK Sucrose fed (GK-Suc). The longer the duration of exposure to
risk factors, the worse are the effects of T2DM on the nervous system as well as the
whole body. The combination of subtle and pronounced changes in expression of
genes encoding the receptors, enzymes and transport proteins involved in the
glutamate signalling pathway suggests an important role that these play in the
development of diabetic neuropathy.
4.2 Glutamate Receptors and Neuropathic Pain
The metabotropic glutamate receptors (mGluRs) have received more
attention that the fast acting ionotropic glutamate receptors (iGluRs) in terms of their
role in neuropathic pain. The fast acting iGluRs have not been as explored in their
potential roles in causing the symptoms of diabetic neuropathy. Furthermore the
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iGluRs are also involved in glutamate toxicity while certain subtypes of mGluRs are
actually neuroprotective. Since most fast excitatory synaptic neurotransmission in
the mammalian nervous system is mediated by glutamate, it is plausible that many
neurological disorders may be associated with abnormalities in the glutamatergic
signalling system, and that therapeutic benefits might be attainable through the
manipulation of this system. We therefore conducted a study to characterize the
expression of messenger RNAs (mRNAs) coding for subunits of α-amino-3-hydroxy5-methyl-4-isoxazole propionic acid (AMPA) receptors, N-methyl-d-aspartate
(NMDA) receptors, Kainate receptors, glutamate transporters and enzymes involved
in glutamate regulation such as glutaminase and glutamate cysteine ligase in the
dorsal root ganglia in two rat models of diabetic neuropathy.
It is generally assumed that neuropathic pain is caused by changes in
expression and function of receptors, enzymes, and voltage-dependent ion channels
in peripheral nerves and DRG neurons. The changes at synapses in the nociceptive
pathway in the central nervous system also contribute(W. Wang, Gu, Li, & Tao,
2011)
There are possibly a variety of modified alterations in pain-related gene
expression in DRG neurons that underlie the neural plasticity in neuropathic pain.
What role does the glutamatergic system play in diabetic peripheral neuropathy?
This is akin to asking how large a hole can be made in a ship without sinking it.
What the ship tolerates depends on the capacity of its pumps to remove water, the
energy for the pumps, the weather, the mass and properties of the cargo, the skills
of the crew as well as a number of other factors. As long as one variable is not
extreme, it will be the combination of several factors that will determine whether the
ship will sink.
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Collectively, the different responses of glutamate and its receptors in DRG
neurons to neuropathic pain could be promoting or conquering the overexcited
neuronal transmission that may be substantially associated with corresponding gene
expression modifications. Alterations in gene expression may function as
pathological contributor to the development and maintenance of neuropathic
symptoms in diabetic neuropathy.

Figure 36: MAP-kinase signalling along pain pathways in experimental rodent
models.
Pathological pain signalling can be a dual process of activation and
sensitization which has the potential to become self-perpetuating and ultimately
bidirectional. Activation begins with an increase in the presynaptic release of
nociceptive transmitter-mediators from presynaptic neuron terminals or glia. These
include neuropeptides (substance P or calcitonin gene related product) chemokines
(fractalkine), amino acids (glutamate), neurotrophins (nerve growth factor or brainderived neurotrophic factor). Further activation occurs due to the postsynaptic
stimulation of nociceptors located on neurons or glia that include: GPCRs (G-protein
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coupled receptors) that bind neuropeptides and chemokines, LGICs (ligand-gated
ion channels) that bind amino acids (such as glutamate; NTR (neurotrophin
receptor) tyrosine kinases that bind the neurotrophins (e.g. NGF and BDNF) and
cytokine receptors. Nociceptor stimulation activates of various second-messenger
signal

transduction

cascades

that

converge

to

‘‘turn-on’’

MAPKs

via

phosphorylation, regarded as a key component in nociceptive sensitization.
Activation (phosphorylation) of MAPKs leads to transcriptional regulation on DNA
producing gene products, as well as non-transcriptional regulation that enhances the
excitatory properties of nociceptive activation and sensitization. The combination of
these factors underlie the generation and maintenance of chronic pain(Edelmayer,
2014).
4.3 Mechanisms of Neuropathic Pain
Neuropathic pain can be caused by changes in the expression and function
of receptors, enzymes, and ion channels in peripheral nerves and DRG neurons, as
well as at the synapses in the nociceptive pathway of the central nervous system.
There dynamic interactions between peripheral and central mechanisms are
implicated in neuropathic pain(Gracely, Lynch, & Bennett, 1992)
The dorsal root ganglia express many different kinds of ion channels and
receptors. Broadly their functions are; transduction (sodium channels and ATPsensitive receptors expressed in the peripheral terminals of DRG neurons that
transduce noxious stimuli into electric impulses), conduction (e.g., sodium and
potassium channels are involved action potential propagation) and synaptic
transmission modulation (e.g. glutamate receptors expressed on presynaptic
terminals of the primary afferents in dorsal horn to regulate neurotransmitter
release). The abnormal activity of neurons in conditions of neuropathic pain could be
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related to changes in the density, distribution, and functional activities of glutamate
receptors in the dorsal root ganglia neurons.
The most important changes responsible for the induction of neuropathic
pain are found in the altered gene/protein expression in primary sensory neurons.
After damage to peripheral sensory fibers, upregulated expression of certain
receptors can contribute to hyperalgesia; while the downregulation of other
receptors in unmyelinated neurons is responsible for the phenotypic switch in pain
transmission (Sapunar, Kostic, Banozic, & Puljak, 2012).
The major cellular mechanisms that have been studied in diabetic
neuropathy include ectopic or spontaneous nerve activity, peripheral and central
hyperexcitability, phenotypic changes in the pathways that conduct pain and
morphological reorganization. Understanding the relationship between symptoms
and key cellular and molecular mechanisms is vital to develop strategies to direct
rational drug therapy rather than following clinical serendipity. Antinociceptive gene
therapies that involve the glutamate signalling pathway to treat diabetic peripheral
neuropathies have been met with some success in reducing neuropathic pain in
animal models of diabetes after gene transfer to the dorsal root ganglion(Y. Wang,
2013)
Mechanistic and molecular-based understanding of chronic neuropathic pain
has relied heavily on animal studies using a disease or mechanism-related models
that emphasize key symptomatic characteristics such hyperalgesia and mechanical
allodynia. Most of these models have involved peripheral nerve lesions such as
sciatic nerve ligation or L4 and L5 spinal nerve ligation. However, there are relatively
fewer studies from other disease-related models such as diabetic neuropathy to
provide a balanced view about the ubiquity of key mechanisms.
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The pathogenesis of peripheral and central neurological complications of
diabetes is likely to share many features. The pathogenesis of peripheral
neuropathy is multifactorial and involving metabolic alterations, such as increased
polyol pathway flux, oxidative stress and non-enzymatic protein glycation. There is
also evidence for vascular dysfunction, leading to decreases in nerve blood flow and
hypoxia and alterations in neuronal functions. Increases in polyol pathway flux,
leading to accumulation of sorbitol and fructose, accumulation of advanced glycation
end products and increased concentrations of the by-products of lipid peroxidation
have all been demonstrated in the neural tissue of diabetic rats.
Neuropathic pain most often originates from a lesion in the nervous system
and diabetic neuropathy is one type. A characteristic of neuropathic pain is that the
aberrance leading to pain must directly involve the nociceptive pathways. Painful
diabetic neuropathy is length dependent which means the longest axons in the
peripheral nerve are most vulnerable. Patients also complain of bilateral burning
pain in the toes and feet. Quantitative sensory testing reveals decreased pain
sensibility (with or without decreased touch sensibility).
Although physiological pain has a protective effect, pathological pain is pain
that has lost its original biological signalling function and does not serve the survival.
Pathological pain is characterized by exaggerated responses to all suprathreshold
and eventually subthreshold stimuli. The pain is elicited by stimuli which is otherwise
innocuous and the pain spreads from the site of injury to the surrounding unaffected
area. This type of pain also persists even in the absence of any apparent stimuli.
4.4 Hyperalgesia and Allodynia
In physiological terms hyperalgesia and allodynia refer to a dramatic
decrease in the threshold of pain elicited by unmyelinated C-fibre afferents
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(hyperalgesia) and that of Aβ myelinated fibres that are activated normally only by
mechanical stimuli and carry non-nociceptive information.
However, hyperalgesia and allodynia are two major forms of sensitized
behavioural responses assessed in animal models of neuropathic pain. Diabetic
patients often experience hyperalgesia which is abnormally heightened sensitivity to
pain and can be classified into primary and secondary. Primary hyperalgesia occurs
at tissue injury site and is mediated by primary afferent nociceptor sensitization
which shows as increased response to stimuli such as heat. Secondary
hyperalgesia occurs in uninjured tissue surrounding site of injury and is linked to
central sensitization and shows an increased response to mechanical stimuli.
Mechanical hyperalgesia can manifest as pain to light-stroking stimuli (i.e. allodynia)
and enhanced pain to punctate stimuli. In summary hyperalgesia is when
nociceptive responses to noxious stimuli are significantly enhanced while in
allodynia, previously non-noxious stimuli such as cold stimuli or mechanical touch
leads to nociceptive responses. Hyperalgesia and allodynia are often concurrent
with a paradoxical loss of stimulus-evoked sensation.
The pain in diabetic neuropathy is complex and involves numerous cellular
receptors, channels and chemicals. Hyperexcitability of primary afferent neurons
after injury could be due to a change in the expression of ion channels(Passmore,
2005). This makes ion channel subunits, particularly those predominantly expressed
in nociceptive neurons, novel targets to better understand the mechanisms behind
diabetic neuropathy and for future therapeutic targeting. Most studies of ion
channels have been carried out in dissociated DRG neurons in culture because of
the ease with which neurons in culture can be experimentally manipulated. Studies
done on DRG harvested from various diabetic models such as the Goto-Kakizaki
and Streptozotocin rat model are relatively uncommon.
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4.5 The Role of Dorsal Root Ganglia in the Pain Pathway
The cell body of sensory neurons is an interesting model to study the
properties of afferent terminals. Experimentally, the soma of neurons is more
accessible that the terminals and may serve as a model of mechanisms that are at
play in the terminals. Studying the dorsal root ganglia cells are unique because the
responses of the somas of these cells to neurotransmitters may reflect those of the
synaptic terminals of the primary afferent neurons. The dorsal root ganglia have also
been subject to being used as targets for cell therapy treating neuropathic pain(H.
Yu, 2015). Many mediators like neurotransmitters, ionic channels and cytokines
have been identified being involved in the regulation of pain through functioning on
the DRG neurons. As the entrance site of pain transmitted into the CNS, DRG
possesses a pivotal role in the functional regulation of context of chronic pain.
Alterations in the expression of neurotransmitters and corresponding
receptors play a significant role in sensitizing or desensitizing DRG neurons. The
imbalanced levels of excitatory and inhibitory transmitters including their receptors
make the whole DRG be easier to sensitize to stimulation due to a reduced
threshold or spontaneous activity.
In a regional approach to understanding the role of pain signalling though the
glutamate pathways, the dorsal root ganglia present unique targets. The DRG is
located between the dorsal root and the spinal nerve and contains pseudounipolar
neurons that convey sensory information from the periphery to the CNS. Following
nerve injury or inflammation, these neurons may become an important source of
increased nociceptive signalling through increased neuronal excitability and the
production of ectopic discharges. The DRG also lacks a protective surrounding
capsular membrane and has a permeable connective tissue capsule which can
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make it a good choice for drug application. Its permeability is due to a very high
density of blood capillaries in the ganglion tissue(Sapunar, 2012).
When nociceptive signals are produced at distal nerve fibers, the signals
travel through DRG neurons to the CNS. When the nerves are injured, the DRG
neurons become hyperexcitable, generating spontaneous action potentials or
abnormal high-frequency activity that contributes significantly to neuropathic pain.
The development of chronic pain was considered as a mixed result of multiple
factors that involve the neurons and neurons and glia. Supporting glial cells of the
peripheral nervous system include satellite cells of dorsal root ganglia and Schwann
cells of peripheral nerves. Pathological alterations in the plasticity and homeostasis
of the neural micro-environment give way to hypersensitivity.
Theories such as the phenotypic switch predict neurons repeatedly
stimulated by noxious stimuli activate genes resulting in transcription factors that
enhance the expression of various neurotransmitters and receptors which
perpetuate the dysfunction(Neumann, Doubell, Leslie, & Woolf, 1996).
The neurons in DRG are typically divided according to the size of their cell
soma; small, medium and large. The neurons with a cell body diameter less than 30
μm are putative nociceptors and large diameter neurones (>30 μm) are regarded as
non-nociceptive. Non-myelinated C-fibres, that transmit noxious information, arise
from neurons with small cell bodies, while myelinated Aα- and Aβ-fibres, which
convey low-threshold non-noxious information, are from large cell body neurons. Aδfibres, which can also be nociceptive, are from neurons with cell bodies that are
medium in size(Passmore, 2005).
Glutamate has been shown to play a role also in the transduction of sensory
input at the periphery and its involvement in peripheral neuropathies has been
suggested on the basis of experimental studies in animals.
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At spinal level the most intense glutamate immunoreactivities can be found
in the superficial laminae (I, II) of the dorsal horn, in the dorsal root ganglion cells
and their efferent axons(Szekely, Torok, & Mate, 2002)
In neuropathic pain, neurons are important but so are the glia cell responses
that alter neuronal function in the peripheral and central nervous system. Neurons in
the DRG are surrounded by satellite glial cells (SGCs), which carry receptors for
numerous neuroactive agents and can therefore receive signals from other cells and
respond to changes in their environment. Activating these cells can influence nearby
neurons, and thus SGCs may participate in signal processing and transmission in
sensory ganglia. Damage to the axons of sensory ganglia contributes to neuropathic
pain. Such damage also affects SGCs so these cells have a role in the pathological
changes in the ganglia(Hanani, 2005)
4.6 The Role of Ionotropic Glutamate Receptors in Neuropathic Pain
Glutamate receptors (GluRs) are widely expressed in the membrane of
spinal neurons postsynaptic to nociceptive afferents. AMPA, KA and NMDA
receptors are expressed in the rat DRG neurons(Sato, Kiyama, Park, & Tohyama,
1993). In addition to this, subunits of both ionotropic and metabotropic glutamate
receptors that are translated and synthesized in dorsal root ganglion (DRG) neurons
are transported to peripheral and central locations(Carlton, 1995; Coggeshall &
Carlton, 1998; Lu, Hwang, Phend, Rustioni, & Valtschanoff, 2003). The peripheral
transport of GluRs is suggested by immunoreactivity for NMDA, kainate, or AMPA
receptors detected on nerve fibers and endings in the rodent and human
skin(Carlton ., 1995; Coggeshall & Carlton, 1998; Kinkelin, Brocker, Koltzenburg, &
Carlton, 2000). Peripheral GluRs can be activated by using agonists and these
receptors function as sensors of glutamate released by peripheral terminals,
contributing to sensitization after injury. The central terminals of DRG neurons
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release glutamate, so presynaptic iGluRs expressed by these terminals may act as
autoreceptors. Activation of presynaptic autoreceptors in central endings of DRG
neurons decreases the release of glutamate from these terminals (Bardoni, Torsney,
Tong, Prandini, & MacDermott, 2004; Kerchner, Wilding, Huettner, & Zhuo, 2002; C.
J. Lee ., 2002).
AMPA-receptor antagonists, NMDA-receptor antagonists, and mGluR
antagonists have all been shown to ameliorate correlates of hyperalgesia and
allodynia in other animal models of diabetes such as the streptozotocin model
(Calcutt & Chaplan, 1997; Gupta, Singh, Sood, & Arora, 2003; Malcangio &
Tomlinson, 1998).
Ionotropic glutamate receptors are essential to the appropriate function of
the mammalian CNS. They mediate chemical synaptic transmission at the vast
majority of excitatory synapses, underlie cellular models of learning and memory,
modulate neuronal network excitability, and are required for maturation of synaptic
connections during early development.
4.6.1 AMPA Ionotropic Glutamate Receptors and Neuropathic Pain
In the dorsal root ganglia there were no significant changes in expression of
Gria1, Gria2 and Gria3. With regard to Gria4, statistically significant but modest
increase in expression was seen in TDRG 5-8 and LDRG of the GK group and in
TDRG 9-12 of the GK Sucrose group. The other levels of DRG showed a trend for
increased expression but did not reach statistical significance. Therefore, the
biological importance of the significant changes might be minimal.
The modest increase in mRNA expression of Gria4 in the lumbar dorsal root
ganglia, considering its role of presynaptic inhibition, could be an adaptive response.
This suggests the possibility of a compensatory mechanism to reduce the increased
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activity of these receptors. This would serve the purpose of reducing the synaptic
sensitivity to glutamate and tempering the information flow from the peripheral
nervous system to the central nervous system. Increasing Gria1 containing AMPA
receptors at progressively more distal synapses can help to normalize synaptic
strength by compensating for increased dendritic filtering of synapses more distal to
the cell body. This down-regulation might be related to epigenetic gene silencing.
This information suggests that the development of sensitization could require
glutamate transmission and it also suggests mechanistic similarities to other forms
of neuronal plasticity.
Antagonists that target AMPA receptors are more effective in abolition of
hyperalgesia seen during experimental inflammation although NMDA antagonists
are more potent in experimental models of neuropathic pain (Székely, Torok, &
Mate, 2002).
In low doses glutamate receptor antagonists have been observed to elevate
the threshold of the physiological pain sensation. This leads to suppression of
pathological sensitisation i.e. lowering of the pain threshold seen upon excessive or
lasting stimulation of C-fiber afferents. Both NMDA and AMPA/kainate receptors
inhibit wind up i.e. lasting activation of the polymodal, second-order sensory
neurones in the deeper layers of the dorsal horn. During sensitisation the resting
Mg++ blockade of transmembrane Ca2+ channels is abolished, certain second
messenger pathways are activated, the transcription of many genes is enhanced
leading to overproduction of glutamate and other excitatory neurotransmitters and
expression of Na+ channels in the primary sensory neurons activated at lower level
of depolarisation. This cascade of events can lead to increased excitability of the
pain pathways (Szekely, 2002).

134
AMPA receptors are transported to the central terminals of DRGs and are
present in different DH laminae. The AMPA receptors are most prominently located
near central terminals of primary afferent fibers. This is unusual for ionotropic
receptors on DRG neurons since most other families of ionotropic receptor are
found both at the terminals and on the cell bodies (C. J. Lee ., 2002). The AMPA
receptors are expressed by small diameter dorsal root ganglion neurons (C. J. Lee .,
2002) and these neurons are involved in nociception. These receptors are detected
at the level of the soma and are strongly expressed near the primary afferent central
terminals. Glutamate is released from the terminals of these central primary
afferents, upon nociceptor stimulation, onto the dorsal horn neurons. Prolonged
stimulation of nociceptors, such as after nerve damage, can lead to the continuous
release of glutamate.
Activation of presynaptic AMPA receptors inhibits the release of glutamate
from the terminals which suggests that primary afferent depolarization is also
mediated by glutamate acting on presynaptically localized AMPA receptors (C. J.
Lee, 2002). Thus AMPA receptors on primary afferent central terminals mediate
primary afferent depolarization and modulate glutamate release.
Glutamate released from central terminals of primary afferents into the spinal
cord in response to nociceptor stimulation primarily activates the AMPA receptors on
dorsal horn neurons. Prolonged stimulation of nociceptors that often occurs after
nerve damage can lead to a continuous release of glutamate that can cause longlasting depolarization of the nerve membrane and consequently activation of NMDA
receptors by glutamate (Chizh, 2002).
The AMPA receptors play a very important role in presynaptic inhibition. The
mechanism that drives AMPA receptor-mediated presynaptic inhibition at the
primary afferent to dorsal horn neuron synapse is probably primary afferent
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depolarization (PAD) (Rudomin & Schmidt, 1999) and is accompanied by an
enhanced excitability of afferent fiber terminals. This is a slow negative potential and
when it reaches firing threshold it produces dorsal root reflexes (DRRs) and is also
implicated in generating neurogenic inflammation (C. J. Lee ., 2002; Lobanov &
Peng, 2011; Willis, 1999). It tempers the flow of information from the peripheral
nervous system to the central nervous system.
Besides, GABAA receptors, evidence now suggests that ionotropic glutamate
receptors at the presynaptic terminals of afferent fibers also contribute to PAD
(Rudomin & Schmidt, 1999). The expression of AMPA and kainate receptors by
nociceptors makes it plausible to predict that these receptors participate in activitydependent generation of PAD in Aδ and C fibers. The mechanism can be blocked
by GABAA and non-NMDA glutamate receptor antagonists (Evans & Long, 1989;
Willis, 1999). Directly activating these presynaptic AMPA receptors results in a
strong inhibition action on the amount of glutamate released from some primary
afferent terminals in the superficial dorsal horn of the spinal cord.
The pain system in the spinal cord is phylogenetically primitive and exhibits
behavioral changes such as hyperalgesia in response to inflammation. The use of
AMPA receptor antagonists has been linked to suppressing inflammation-induced
structural changes in the dendrites in the spinal dorsal horn(Matsumura, Taniguchi,
Nishida, Nakatsuka, & Ito, 2015).
Glutamate signalling through the AMPA receptors plays important roles in
central pain circuits. The subunits of AMPA receptors are dynamic at synaptic sites
and trafficking to the plasma membrane has been implicated in pathological
conditions. The protein product of Gria1 and its accumulation has been hinted at
playing a role in sensory modulation at the level of the spinal cord.
Pharmacologically induced down regulation of the Gria1 receptor in the spinal dorsal
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horn can help ameliorate hyperaglesia (Y. Z. Li ., 2014). Pharmacological
compounds such as AMPAkines have been linked to help alleviate pain
hypersensitivity in rat models of persistent neuropathic pain and inflammatory
associated pain (Le, Lee, Su, Zou, & Wang, 2014).
Several studies suggest that receptor encoded for by Gria1 may play distinct
roles in the regulation of AMPA receptor trafficking and synaptic plasticity (Toyoda,
2009). The Gria1 receptor is required for NMDA receptor-dependent synaptic
delivery of AMPA receptors in LTP (Yang, Wang, Frerking, & Zhou, 2008). Longterm potentiation (LTP) in nociceptive spinal pathways also shares several features
with hyperalgesia and has been proposed to be one of the cellular mechanisms of
pain amplification in chronic pain states.
Previous studies have suggested that peripheral Gria1 receptors located at
sensory nerve endings in the skin are involved in nociceptor activation and
sensitization. Using an antibody that recognizes the three low-affinity kainite
receptor subunits Gria1/2/3 that one or more of these receptor subunits is likely
expressed on 28% of unmyelinated fibers in the digital nerve from normal rats, and
that this increases to roughly 40% acutely following Freund’s adjuvant-induced
inflammation. In addition to this, injection of kainate in the hindpaw induced acute
mechanical hypersensitivity, and that an AMPA/Kainate receptor antagonist (CNQX)
injected in the paw could reduce inflammation-induced mechanical hypersensitivity
(J. Du, Zhou, & Carlton, 2006).
Gria1 containing AMPA receptors are thought to be involved in the regulation
of synaptic strength. The Gria1 containing receptors are also the predominant type
of ionotropic glutamate receptor expressed by the small-diameter sensory neurons
in dorsal root ganglia (Qiu ., 2011).
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There is a pool of AMPA receptors that recycle rapidly between the plasma
membrane and intracellular vesicles, the processes of exocytosis and endocytosis
have important roles in transporting these receptors to and from synapses. Studies
on subunit specific AMPA receptor transportation routes suggest Gria2/3 subunit
containing receptors are delivered by direct insertion and are continuously recycled
within the synapse. This is important to determine basal synaptic strength. Gria1/2
subunit containing receptors, on the other hand, are thought to initially insert into the
extrasynaptic membrane and then move laterally into the postsynaptic density
depending on the activity pattern of the synapse (Andrásfalvy, Smith, Borchardt,
Sprengel, & Magee, 2003). AMPA receptor trafficking in complex and involves
vesicular trafficking, lateral diffusion and protein-protein interactions to determine the
distribution of AMPA receptors on the neuronal surface.
The pain pathway also involves the higher centers in the brain and includes
one of the most significant parts; the acute cingulate cortex. Certain pathological
conditions such as peripheral chronic inflammation or nerve injury is linked to a long
term potentiation of excitatory synaptic transmission in the acute cingulate cortex.
AMPA subunits are dynamic at synaptic sites and their trafficking onto the plasma
membrane has shown to be important in synaptic potentiation such as long term
potentiation (T. Chen, 2014). Long term potentiation (LTP) is a major form of
synaptic plasticity and is linked to chronic pain (Sandkuhler, 2007). It results in a
long term increase in synaptic strength and has two stages that depend on the
duration and involvement of signal transduction; early and late. While the early
phase lasts only for a few hours, the late phase involves protein synthesis and
involves structural changes at synapses that can last the life span of the animal.
LTP can be expressed pre- and/or postsynaptically. This means the synaptic
strength can increase if the neurotransmitter release is enhanced or if the
postsynaptic effects of the neurotransmitter are enhanced. Recent studies have
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shown that LTP can also be induced in pain pathways and may contribute to
hyperalgesia caused by inflammation, trauma or neuropathy. Induction of LTP at C
fiber synapses also requires the activation of ionotropic glutamate receptors and the
influx of calcium via the AMPA receptors (Hartmann ., 2004). When glutamate binds
to the AMPA receptors, it allows sodium to flow into the postsynaptic cell and bring
about depolarization. NMDA receptors which also play a role in LTP cannot open
directly because at resting membrane potential these receptors are blocked by Mg 2+
ions and only open when a depolarization from the AMPA receptor activation leads
to repelling of the Mg2+ cation out into the extracellular space and the pore can then
pass current. The NMDA receptors are permeable to both Na+ and Ca2+ and when
Ca2+ that enters the cell it triggers the upregulation of AMPA receptors to the
membrane, which results in a long-lasting increase in excitatory postsynaptic
potential

size

underlying

LTP.

The

calcium

entry

also

phosphorylates

Ca2+/calmodulin-dependent protein kinase II (CaMKII), which phosphorylates AMPA
receptors and increases their single-channel conductance. AMPA receptors
increase in ratio to NMDA receptors after high-frequency stimulation. A nonsynaptic
pool of AMPA receptors is present adjacent to the postsynaptic membrane and
without the need for protein synthesis in early LTP, these receptors are rapidly
trafficked into the postsynaptic membrane when the appropriate LTP-inducing
stimulus arrives (Malinow, 2003). Gria1 has been implicated in playing a role in
cortical plasticity and persist pain using the ERK-dependent signalling pathway.
During long term LTP, transcribed mRNA of AMPA receptors must reach the
intended dendritic spine and can be transported even to synapses that did not
receive the LTP-inducing stimuli. The neuronal soma can synthesize receptor
mRNA in the nucleus, package it within a transport ribonucleoprotein complex (a
subtype of an RNA complex), initiate transport, prevent translation during transport,
and deliver the complex to the appropriate dendritic spine (Bramham & Wells,
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2007). The synaptic tagging hypothesis partly explains how mRNA is trafficked to
the appropriate dendritic spine and signalling the mRNA-RNP complex to dissociate
and enter the dendritic spine (Martin & Kosik, 2002).
At the synaptic level, hyperalgesia and allodynia may be mimicked by
changes in synaptic transmission in spinal cord dorsal horn or cortical synapses. For
hyperalgesia, enhanced synaptic responses, mainly by postsynaptic modification of
AMPA receptors, may directly contribute to enhanced sensory responses to stimuli.
A synaptic amplifier of nociception has been identified at the synapses between
primary afferent C-fibres, many of which are nociceptive, and neurons in the
superficial dorsal horn of the spinal cord in rodents(R. Ruscheweyh, Wilder-Smith,
Drdla, Liu, & Sandkuhler, 2011). In the case of allodynia, the recruitment of ‘silent’
synapses, or increases in synaptic AMPA receptors may explain why subthreshold
sensory stimulation can activate nociceptive neurons.
Central sensitization is an enhanced responsiveness of nociceptive neurons
in the CNS to their normal afferent input. Some forms of central sensitization could
contribute to hyperalgesia and/or allodynia (Sandkuhler, 2007). Initiation and
maintenance of central sensitization is a consequence of evoked or spontaneous
and this is suggested by the ability of transient local anesthesia to end hyperalgesia
in animal models of central sensitization (Reichling & Levine, 2009) Sensitization
and its role in neuropathic pain can be understood at some fundamental mechanism
such as increased release of excitatory neurotransmitter (e.g., glutamate) and/or
enhanced synaptic efficacy. These mechanisms may relate to several cellular
events that are divided into changes that are at the presynaptic, postsynaptic
changes and interneuron level. There is also evidence of sensitization being subject
to changes in descending modulation of pain (Campbell & Meyer, 2006)
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Summation determines whether or not an action potential will be triggered by
the combined effects of postsynaptic potentials. Spatial summation requires the
input from multiple presynaptic cells while temporal summation is when a high
frequency of action potentials in the presynaptic neuron elicits postsynaptic
potentials that overlap and summate with each other. In terms of nociceptive
stimulation, spatial summation integrates painful input from large areas while
temporal summation integrates repetitive nociceptive stimuli. Widespread and long
lasting pain are characteristics of many chronic pain syndromes such as diabetic
neuropathy and this suggests that both types of summation could play a role.
Through pressure stimulation experiments, it has been shown that spatial
summation facilitates temporal summation of nociceptive inputs, specifically
pressure pain. The AMPA receptor-mediated excitatory postsynaptic potentials
(EPSPs) have a half-time of less than 10 ms (Swanson & Sakai, 2009). This allows
the receptors to be available for re-activation during periods of relatively high
frequency input. The ionotropic glutamate receptors respond to both spatial and
temporal summation.
Along with the presynaptic kainate receptors, AMPA receptors should prove
to be an important regulator of synaptic transmission in the pain pathway as well as
an important modulator of non-noxious sensory transmission.
Activation of presynaptic ionotropic glutamate receptors may reduce
neurotransmitter release. As autoreceptors in terminals of Aδ and C afferent fibers in
the spinal cord laminae I–III, presynaptic ionotropic glutamate receptors may play a
role in inhibiting nociception. As heteroreceptors in GABAergic terminals in the same
laminae, on the other hand, presynaptic ionotropic glutamate receptors may have an
opposite role and contribute to central sensitization and hyperalgesia (Lu ., 2005).
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4.6.2 NMDA Ionotropic Glutamate Receptors and Neuropathic Pain
In the present study, a marked and highly significant reduction in Grin2A
expression was seen at all levels of the DRG. In addition there was a small
reduction in expression of Grin1 throughout the DRG which reached statistical
significance in TDRG 1-4, LDRG and SDRG. These reductions in expression may
reflect adaptive changes that protect the neurons from excitotoxicity and
overstimulation.
In neurons, alterations in the level of intracellular calcium regulates electrical
activity, neuropeptide secretion, synaptic transmission, and gene expression. The
sensory neurons located in the dorsal root ganglia express numerous voltage-gated
and ligand-gated calcium channels important in transducing nociceptive signals from
the periphery to the spinal cord. Studies point towards a prolonged, small increase
in basal [Ca2+]i that exists in the DRG neurons of diabetic animal and a reduction in
the Ca2+ dynamics of diabetic animals (Biessels, ter Laak, Hamers, & Gispen, 2002).
Glutamate is released simultaneously with substance P (SP) and calcitonin
gene related peptide (CGRP) since they are stored in the same terminals. The wind
up in sensitization could be because of the concerted actions of glutamate with
neuropeptides such as substance P and CGRP. The short-lasting excitation induced
by glutamate could be extended and amplified by the co-released peptides. The
EPSPs induced by them lead to enough depolarisation to abolish the voltage
dependent Mg++ blockade of NMDA receptor controlled channels. These channels
upon opening allow Ca2+ influx into the cell, activating intracellular biochemical
cascades that lead to long lasting depolarisation of the postsynaptic cell membrane
i.e. hyperexcitability (Szekely, 2002).
The NMDA receptors deserve particular attention in the study of neuropathic
pain due to their crucial roles in excitatory synaptic transmission, plasticity, and
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neurodegeneration in the nervous system. NMDA receptors have certain unique
properties that distinguish them from other ligand-gated ion channels. These
receptors controls a cation channel that is highly permeable to monovalent ions and
calcium. Second, simultaneous binding of glutamate and glycine, the coagonist, is
required for efficient activation of NMDA receptors. Third, at resting membrane
potential the NMDA receptor channels are blocked by extracellular magnesium and
open only on simultaneous depolarization and agonist binding.
The NMDA receptors are regulated by protein kinases as well and protein
kinase C mediated channel phosphorylation can either enhance or suppress the
activity of NMDA receptors depending on the Grin2 subunits and the Grin1 splice
variants involved. Phosphorylation can alter the ion channel kinetics or alter the
number of functional receptors on the cell surface by trafficking of channels in and
out of the plasma membrane. The NMDA receptors are also able to couple to other
signal transduction pathways such as PKC, calmodulin kinase II, nitric oxide
synthase, and mitogen-activated protein kinases (MAP kinases) (Chaban, 2004).
Experimental pain models have shown sustained MAPK activation in nociceptive
primary sensory neurons located in dorsal root ganglia (DRG) (Reichling & Levine,
2009) and initial MAPK activation has been postulated to be involved in the initiation
and maintenance of pathological pain. As the diabetic neuropathy progresses the
decrease in MAPK phosphorylation observed in relevant tissues such as DRG from
experimental

neuropathic

models

can

be

viewed

as

a

biochemical

marker/phenotype of adaptive nociceptive signalling.
In the peripheral nervous system receptors NMDA receptors are expressed
on the central and peripheral terminals of primary afferent neurons which are
involved in nociception. Nerve injury can result in altered peptide expression in the
dorsal root ganglia and in the dorsal horn of the spinal cord. The mRNA of different
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ion channels can be downregulated at the nerve membrane and the dorsal root
ganglion.
The situation that arises in pain experienced by diabetics is even more
complex by the phenomenon of central sensitization if it is induced. Excitation of
unmyelinated C fibers produces slow excitatory postsynaptic potentials that release
glutamate which then acts on its receptors such as NMDA receptors. The NMDA
receptor is an important receptor in the mechanisms of chronic neuropathic pain.
The receptor consists of a Grin1/Grin2 heterodimer and physiologically the receptor
and its associated ion channel is blocked my magnesium. When the membrane is
depolarized and sensitized, magnesium is removed and different ions pass through
that induce an intracellular second messenger and result in pain. The variability in
the modulation of these neural processes has made it difficult for therapeutic
interventions to be effective (Devulder & De Laat, 2000).
Studies show that nociceptor sensitization depends on glutamate release at
the DRG and subsequent NMDA receptor activation in satellite glial cells (Ferrari,
2014) which supports the idea that peripheral hyperalgesia is an event that is
modulated by the DRG glutamatergic system.
NMDA receptors containing Grin2A or Grin2B subunits contribute to most of
the NMDA receptor currents (Zhuo, 2014). Physiologically, the expression of Grin2A
expression increases with age (Shipton & Paulsen, 2014).
Evidence suggests that Grin1-containing NMDARs are localized synaptically
while Grin2A-containing receptors are usually localized perisynaptically or
extrasynaptically (Townsend, Yoshii, Mishina, & Constantine-Paton, 2003). Studies
have shown that during over activity, calpain cleaves the Grin2 subunits of NMDA
receptors that are on the cell surface. This serves to down regulate the function of
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NMDA receptors which provides a neuroprotective mechanism against NMDA
receptor overstimulation (Andrásfalvy, 2003).
Wind-up is a frequency-dependent increase in the excitability of spinal cord
neurons that occurs due to electrical stimulation of C-fiber primary afferent nerves.
The low-frequency stimulation of C fiber afferents leads to an increased response in
the dorsal horn cell. This increase is excitability is due to temporal summation of
slow postsynaptic potentials and spatial summation because of the convergence of
the afferent fibers of different modalities on the same population of postsynaptic
neurons.

Windup lasts tens of seconds and represents a short-term form of

sensitization. It amplifies the nociceptive message that arrives from peripheral
nociceptors. The receiving neurons become consequently responsive to otherwise
subthreshold stimulation induced by afferents that carry even non-nociceptive
information. The fact that these second order multireceptive cells demonstrate wind
up shows that the basis of this phenomenon is simultaneous activation of afferents
of different modalities. However, not all the multireceptive neurons are sensitised,
some actually become desensitised upon repeated stimulation and this has been
shown by directly applying glutamate or kainate to the primary sensory neurons of
the dorsal root ganglia (Szekely ., 2002).
Blocking

NMDA

receptors

with

ketamine

or

(2R)-amino-5-

phosphonopentanoate can inhibit the wind-up phenomenon of spinal dorsal horn
neurons and reduce the hypersensitivity of spinal dorsal horn neurons in
neuropathic pain models (Dickenson & Sullivan, 1987).
In neuropathic pain, nociceptors with unmyelinated axons (C-nociceptors)
are sensitized such that they discharge spontaneously, respond to normally
innocuous stimuli, and have a supernormal response to noxious stimuli. Nociceptor
sensitization underlies the spontaneous pain and hypersensitivity of the injured site.
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The area surrounding the injured site also becomes a source of pain and
hypersensitivity, and this is now known to be due, at least in part, to an NMDA
receptor-mediated hyperexcitability in spinal neurons evoked by C-nociceptor input
from the injured site. The chronic pain syndromes due to peripheral neuropathies
are now believed to be related, in part, to a similar NMDA receptor-mediated
hyperexcitability in spinal neurons. Axotomized C-nociceptors begin to discharge
ectopically, and this has the same effect as the discharge of sensitized Cnociceptors it evokes NMDA receptor-mediated central hyperexcitability. NMDA
receptor antagonists block neuropathic pain in animals, and early clinical trials
suggest that they are effective drugs for human painful peripheral neuropathies.
High levels of activity at NMDA receptors in the nervous system are known to lead
to neuronal death or dysfunction. There is evidence that pain-evoked glutamate
release is excitotoxic to small, presumed inhibitory interneurons, in the spinal dorsal
horn.
Mitochondrial dysfunction, which is implicated in diabetic neuropathy, can
lead to secondary excitotoxicity. Metabolic impairment depletes ATP, depresses
Na+/K+-ATPase activity and can lead to graded neuronal depolarization. This
relieves the voltage-dependent Mg2+ block of the NMDA receptor and allows
apparently innocuous levels of glutamate to become toxic. Mitochondrial impairment
also disrupts cellular calcium homeostasis. Increased activation of the NMDA
receptor, in turn, leads to further mitochondrial impairment and damage. The
calcium that enters a neuron through NMDA receptors now has can access to
mitochondria and lead to free radical production and mitochondrial depolarization.
This suggests the presence of a feed-forward cycle where the mitochondrial
dysfunction activates NMDA receptor and to further mitochondrial impairment. In this
scenario,

NMDA

(Ankarcrona, 1995)

receptor

antagonists

could

possibly

be

neuroprotective
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4.6.3 Kainate Ionotropic Glutamate Receptors and Neuropathic Pain
In the present study, there was a highly significant and marked
downregluation in expression of both Grik3 and Grik4 in all the dorsal root ganglia in
both groups of animals versus their control counterparts. Furthermore, these
reductions were seen at all levels of the dorsal root ganglia. Marked Grik3
downregulation was also seen in the thoracic sympathetic ganglia (TSG 1-6, TSG 712). However, no significant change was seen of Grik4 in these sympathetic ganglia.
This consistent finding is in line with the possibility that downregulation of the genes
expressing these receptors is an adaptive response. Adaptive responses are
appropriate reactions to a cellular event and at the gene level, this is very important
for the neuronal cell bodies to cope with sustained stress. Kainate receptor
activation is linked to neuronal excitability and subsequent reduction in firing
threshold and KA antagonists reduce mechanical

allodynia and thermal

hyperalgesia. The location of KARs in DRG neurons, specifically in neurons that
give rise to thinly myelinated or unmyelinated Aδ and C fibers is highly suggestive of
the role that these receptors play in pain. The presynaptic location of KARs also
suggests a role in inhibition of neurotransmission. Since pre-synaptic KA receptors
is also expressed on spinal cord inhibitory interneurons and activate inhibitory
transmission, a downregulation in the production of KARs could further propagate
the phenomenon of sensitization along the pain pathway and increase the
perception of pain to the lightest stimuli. This is manifested as hyperalgesia and
allodynia.
Kainate receptors are specifically localized on small to intermediate diameter
DRG neurons that give rise to thinly myelinated or unmyelinated Aδ and C fibers
including nociceptive fibers. This information paved the way to study the role of KA
receptors in the transmission of nociception and the perception of pain. Behavioural
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studies also show antinociceptive effects of specific KA receptor antagonists in
models of persistent pain. SYM2081, a KA antagonist, reduces mechanical allodynia
and thermal hyperalgesia in the chronic constriction injury model and cold injury
model of neuropathic pain. LY293558 has been shown in human studies to reduce
spontaneous pain and mechanical allodynia after capsaicin injection into the skin.
The permeability to calcium of some KA receptors increases the intracellular
concentration of calcium. This brings about reactions such as excitoxicity and
synaptic plasticity.
The Kainate receptors show functional diversity from the subunit composition
and also their association with auxiliary subunits such as the neuropilin and tolloidlike proteins.
Besides depolarizing neuronal membranes when glutamate binds, there is a
second signalling mode unique to KARs and this is mediated by G protein-coupled
activation of protein kinases. Although the metabolic pathways are not clearly
understood it is known that this dual mode of signalling, ionotropic and
metabotropic, plays a role in modulating neural circuits. Some of the mechanisms of
this modulation arise from postsynaptic depolarizing of a subset of synapses,
presynaptic modulation of glutamate and GABA releases as well as direct alteration
of voltage gated ion channels that regulate action potential firing.
Kainate receptors located on the central endings of dorsal root ganglia
neurons regulate glutamatergic transmission. Kainate receptors are located both
postsynaptically (mainly mediating excitatory neurotransmission) and presynaptically
(modulating excitatory and inhibitory transmissions). Pre-synaptic KA receptors
expressed on spinal cord inhibitory interneurons activate inhibitory transmission (F.
Wang, Stefano, & Kream, 2014).
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Pain begins from a series of signalling events that occurs at multiple levels of
the nervous system. Acute pain signals begin when the peripheral stimulation of A
delta and C-fiber nociceptors are activated. These action potentials are propagated
through the cell soma of the DRG neurons to the dorsal horn of the spinal cord,
thalamus and higher order processing centers. This pathway also plays a role in
analgesia through the stimulation of endogenous opiod receptors and modulating
the inhibitory GABA tone on nociceptive dorsal horn neurons. This sensory
transduction pathways allows nociceptors to respond to noxious stimuli and assists
us in protecting ourselves. The perception of pain is altered by modulating the signal
transduction in peripheral and nociceptive pathways. Persistent pain arises from
pathologic increases in excitability, or sensitization, of one or more of the peripheral
or central parts of pain pathways. Peripheral sensitization is due to a reduction in
firing threshold and an increased responsiveness of peripheral nociceptors. This is
linked to neurogenic factors such as inflammatory factors; calcitonin gene related
peptide, substance P, ATP and serotonin. Central sensitization can be when the
dorsal horn neurons in the spinal cord become hyperexcitable and this can be
because of pre and postsynaptic changes and changes in the postsynaptic
membrane excitability. Long-term alteration in neuronal excitability is linked to
persistent pain and can be from adaptive changes in structure and function of
several brain regions that are implicated in the higher processing of pain related
input (Bhangoo & Swanson, 2013).
Activation of ionotropic glutamate receptors increases energy consumption
because the resultant influx of Na+ and Ca2+ requires energy to be pumped out of
the cell again. Neurons become more vulnerable to glutamate after energy
deprivation or after inhibition of the Na+K+-ATPase. Early mitochondrial damage
plays a key role in induction of glutamate neurotoxicity and glucose level fluctuations
that result in hypoglycaemia and hyperglycaemia are also harmful (Novelli, Reilly,
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Lysko, & Henneberry, 1988). Too high glucose levels also increase the neuronal
vulnerability to ischemia (Kelleher, Chan, Chan, & Gregory, 1993). Glutamate
receptor activation also enhances the rates of generation of reactive oxygen species
and potentiates the toxic effects of H2O2 and of mutant superoxide dismutase.
Metabolic inhibition predisposes neurons to glutamate mediated damage and
pathological conditions such as diabetic neuropathy can be associated with a
hypersensitivity to glutamate due to for example impaired cellular energy
metabolism or aberrant expression of glutamate receptors (J. G. Greene &
Greenamyre, 1996). Several different primary events or changes may share a final
common pathway.
Vicious cycles can ensue if the glutamatergic system malfunctions. High
extracellular glutamate can activate glutamate receptors causing further glutamate
release. Glutamate receptor activation increases energy consumption and free
radical production which may impair energy production and glutamate uptake and
lead to even reversing the transporters and causing even more glutamate to be
released. The ion influx can lead to cell edema, ischemia and a compromised
energy supply and so on.
4.6.4 Ionotropic Glutamate Receptor – Delta 2
Expression of Grid2 was significantly in TDRG 5-8 of the GK rats. The
receptor that this gene codes for forms heteromeric assemblies with other types of
iGluRs including AMPA and Kainate receptors to form functional channels. Since it
requires the involvement of the types of iGluRs that are implicated in neuropathic
pain, it is tempting to speculate the increased expression of this gene might also
contribute to neuropathic pain.
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4.7 The Role of Glutamate Transporters in Glutamate Toxicity
Some changes were seen in expression of the genes coding for glutamate
transporter proteins. Slc1a1 expression was significantly increased in TDRG 1-4, 58, 9-12, LDRG and SDRG. We found the mRNA levels of Slc1a3 to be significantly
upregulated in TDRG1-4, TDRG 5-8 and TSG1-6 of GK animals and TDRG 5-8,
TDRG9-12 and SDRG of GK Sucrose animals. It was also significantly upregulated
in TDRG5-8 of both GK and GK Sucrose animals. Expression of Slc1a2 was not
altered. Slc1a6 was downregulated in TDRG 1-4, 5-8, 9-12 in GK animals and in
TDRG 1-4 and LDRG of GK Sucrose.
Besides the essential glutamate removal role, the glutamate transporters
also play a role in neurotransmission modulation. These transporters modify the
time course of synaptic events, the extent and pattern of activation and
desensitization of receptors outside the synaptic cleft and at neighboring synapses
(intersynaptic cross-talk). The glutamate transporters provide glutamate for
synthesis of important molecules such as GABA and glutathione. Glutamate uptake
can be modulated on all possible levels i.e. DNA transcription, mRNA splicing and
degradation, protein synthesis and targeting, and actual amino acid transport activity
and associated ion channel activities. A variety of molecules besides glutamate
(such as cytokines and growth factors) also influence glutamate transporter
expression and activities.
A decrease in expression of glutamate transporters would lead to an
extracellular build-up of glutamate which would, via glutamate receptors, increase
Na+ and Ca2+ influx, energy consumption and free radical production.
However, extracellular glutamate overload occurs after CNS traumatic injury
and causes excessive Ca2+ influx into neurons through overactivation of neuronal
ionotropic glutamate receptors, leading to neuronal excitotoxicity. Additionally,
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numerous

glutamate-induced

CNS

neurodegenerative

disorders,

such

as

amyotrophic lateral sclerosis (ALS), epilepsy, ischemia and traumatic brain injury,
have been reported to associate with dysfunction of astrocytic glutamate
transporters. Therefore, the function of glutamate transporters, especially astrocytic
glutamate transporters especially the astrocytic glutamate transporters (glutamate
aspartate transporter; GLAST/EAAT-1) and glutamate transporter-1 (GLT-1/EATT-2)
is of great importance for protecting neurons from glutamate-induced excitotoxicity.
Studies demonstrate that rat peripheral sensory terminals and dorsal root
ganglia (DRG) express molecules which are involved in glutamate signalling,
including high-affinity membrane-bound glutamate transporters Slc1a1 (EAAC1,
EAAT3),

Slc1a2

(GLT-1,

EAAT2),

Slc1a3 (EAAT1,

GLAST)

and

Slc1a6

(EAAT4)(Berger & Hediger, 2000). Evidence suggests in DRG, satellite cells
express Slc1a2 whereas sensory neurons were positive for Slc1a1. Slc1a3 is
localized in both neurons and satellite cells (V. A. Carozzi, 2008). EAAC1, GLAST,
and GLT-1 are particularly relevant for regulating glutamate uptake in many of the
central nervous system regions including the spinal cord (Danbolt, 2001).
Transporters located inside the synaptic cleft directly affect the glutamate
concentration there and transporters located outside the cleft, such as on glia or
non-synaptic parts of neurons indirectly affect glutamate concentrations by reducing
or increasing the amount of extrasynaptic glutamate that can diffuse back into the
synaptic clefts.
Defects in glutamate uptake due to alterations in the function and/or in the
expression of these transporters have been implicated in several neurologic and
neurodegenerative disorders in the central nervous system (V. Carozzi, 2011) but
there are not extensive studies about the uptake activity of the glutamate receptors
in the peripheral nervous system in diabetic neuropathy.
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Depending on whether transporters are located in relation to the synapse,
these transporters either take up glutamate to concentrate into presynaptic vesicles
or recycle glutamate through intracellular metabolic reactions to return back to the
neurons (nerve endings) in the form of a precursor such as glutamine. The transport
of glutamate and precursors of glutamate across plasma membranes is a
strategically positioned mechanism to terminate glutamate and also be part of its
recycling. Several protein molecules act as glutamate transporters and regulate the
function of the glutamatergic synapses. Glutamatergic neurotransmission can be
weakened if glutamate is removed/inactivated before it can adequately interact with
its postsynaptic receptors. Thus, hyperactive glutamate transport can contribute to
temper excessive glutamate neurotransmission. The expression of glutamate
transporters is influenced by a number of neuropeptides and growth factors (Figiel,
Maucher, Rozyczka, Bayatti, & Engele, 2003).
Alterations in the expression and/or functionality of glutamate transporters
have been implicated in several models of peripheral neuropathy, neuropathic pain
and hyperalgesia. Thus the effects of altered expression and glutamate uptake
activity of glutamate transporters in dorsal root ganglia is likely to be mediated via
changes

in

regional

glutamate

homeostasis.

Evidence

demonstrates

that

functionally active glutamate transporters can be studied in dorsal root ganglia and
help to further understand the role of glutamatergic transport in the peripheral
nervous system (V. Carozzi ., 2011).
Under physiological conditions, the extracellular concentration of glutamate
strongly depends on its re-uptake into cells through specific transporters located in
neurons such as Slc1a1 and on the membrane of glial cells Slc1a2 and Slc1a3 (V.
A. Carozzi, 2008).
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Slc1a1 is considered to be the predominant transporter in neural tissues
outside the blood-brain barrier and in the peripheral nervous system. Slc1a1
expression has been observed in the satellite cells surrounding the ganglion
neurons and these cells are the corollary to astrocytes in the peripheral nervous
system. Expression of Slc1a1 in DRG has been localized in the nuclei and
cytoplasm of sensory neurons (V. A. Carozzi, 2008). The function of Slc1a1
expression by the dorsal root ganglia neurons is likely to take up the glutamate that
is released from glutamatergic nerve terminals innervating the ganglion neurons
(Berger & Hediger, 2000)
Previous studies have demonstrated Slc1a3 mRNA was expressed by
satellite cells in DRG (Berger & Hediger, 2000).
The overactivity of glutamate transporters has been implicated in the
pathophysiology of schizophrenia and other mental illnesses, whilst underactivity is
seen in ischemia and traumatic brain injury. Several mechanisms could contribute to
increased expression of the glutamate transporters. The pathological release of
glutamate from primary afferents may serve as a positive feedback on glutamate
transporter expression. Expression of neurotrophic factors in dorsal root ganglia and
spinal cord is also upregulated dramatically under pathological conditions.
Neurotrophic factors such as Brain derived neurotrophic factor which modulate Nmethyl-D-aspartate (NMDA)-evoked responses and nociceptive sensory inputs in
the spinal cord (Ha, Kim, Hong, Kim, & Cho, 2001).
Glial cells that express these transporters are found between neighboring
synapses and may prevent the released glutamate from activating receptors at
neighboring synapses (cross-talk). However a pathological increase in the density of
glutamate transporters can give rise to paradoxical effects. A high density of
transporters on glial cells can actually trap the glutamate and prevent it from leaving
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the cleft and allow glutamate the opportunity to re-enter the cleft upon unbinding
from these transporters. The transporters can also mediate release of glutamate via
reversed uptake (Danbolt, 2001). Reversed uptake is when dissipation of the ion
gradients that are driving force for the uptake causes the high intracellular
concentration of glutamate to drive the transporters backwards releasing glutamate.
This has been observed in ischemia (Danbolt, 2001). So though glutamate binding
to the transporter reduces the extracellular concentration of free glutamate, the
binding also slows down the diffusion of glutamate away from the release site.
Glutamate escaping from the synaptic cleft may then reach and activate
presynaptic receptors thus modulating its own release, this suggests an indirect
involvement of glutamate transporters because of they control the amount of
glutamate that can access the presynaptic receptors. Glutamate bound to GLAST
has a higher probability of unbinding than of being transported but it is the opposite
case for glutamate bound to GLT and EAAT4. Thus, the paradoxical effects may be
more important in those locations where GLAST rather than GLT-1 is the
predominant transporter (Danbolt, 2001).
Before being released into the synaptic cleft, cytosolic glutamate first need
cross the vesicular membrane via the activity of vesicular glutamate transporters
(VGLUTs). These transporters also belong to the family of glutamate transporters
and their expression is up-regulated in the DRG neurons after peripheral nerve
injury and evidence suggests that there is an increase in glutamate release by
VGLUT up-regulation that contributes to the elevated glutamatergic transmission
(Moechars, 2006).
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Figure 37: Glutamate transporters in astrocytes are responsible for synaptic
glutamate homeostasis.
Modified from (Y. P. Liu, Yang, & Tzeng, 2008)
4.8 The Role of Enzymes Involved in the Glutamate Cycle and Glutamate
Receptor Interacting Proteins in Diabetic Neuropathy
We found the mRNA expression of Grip1 to be significantly decreased in
TDRG1-4 of GK and also in the LDRG and TSG1-6 of both GK and GK Sucrose
animals in comparison to control.
Since a decrease in interactions of Grip1 with its respective AMPA receptors
could reduce sensitization, these findings suggest a compensatory mechanism is in
place to help reduce the increase in neuronal sensitivity and hyperexcitability that
manifests as some of the symptoms of diabetic neuropathy.
Glutamate is toxic in increased concentrations because of how important it
is. Since it is the main mediator of excitatory signals and also involved in nervous
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system plasticity, including cell elimination, it follows that glutamate should be
present at the correct concentrations in the right places and at the right time. Cells
should have the correct sensitivity to glutamate and be able to withstand normal
stimulation, and that glutamate should be removed with the right speed from the
right locations.
Glutamatergic neurotransmission is not an independent process. It regulates
other processes and is regulated by other systems including itself. Many, if not all,
structures that are important for glutamatergic neurotransmission such as cells,
synapses and dendritic spines are dynamic and subject to regulation. In pathological
situations, a change in one area of the nervous system often leads to changes at
other sites. In consequence of this, the primary cause of a disease may induce
several secondary changes. These changes can be part of adaptive responses that
affect the progression of the disease and the compensatory alterations try to
counteract the primary defect or changes. The secondary changes themselves can
aggravate the condition and thereby become problems in themselves.
Glutamine expression showed some minor changes which were statistically
significant. However, since these are not reproduced between the GK group and the
GK-Sucrose group and because these changes are generally very minor these are
probably of little biological importance. Glutamine is recycled form the glial cell back
to the presynaptic nerve terminal where the enzyme glutaminase converts it to
glutamate for packaging into secretory granules ready to be released at the synapse
(Bradford, 1978). The astrocytic export of glutamine implies a continuous loss of
alpha ketoglutarate from the astrocytic TCA cycle but this is not the case. The
intermediates of the TCA cycle have restricted access across the blood-brain barrier
and so the anaplerotic process of pyruvate carboxylation continually replenishes the
loss. Anaplerosis is the process of converting pyruvate, which is derived from
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glucose via glycolysis, to oxaloacetate or malate. Astrocytes express the enzymes
pyruvate carboxylase and cytosolic and mitochondrial malic enzyme (Kurz, 1993;
Salganicoff & Koeppe, 1968; A. C. Yu, 1983). Observations that neurons and
subpopulations of neurons have the ability to replenish their TCA cycle by
carboxylating pyruvate can explain why some glutamatergic pathways have a low
level of glutaminase, whereas others have high levels, and it explains how
transmitter glutamate can be formed from neuronal precursors (Hassel & Brathe,
2000a, 2000b). Neurons can thus carboxylate pyruvate and not completely depend
on glutamine as a precursor for transmitter glutamate.
The glutamine cycle, the 1:1 exchange between astrocytes and neurons of
glutamine for glutamate and GABA was conceptualized in the 1970s (van den Berg
& Garfinkel, 1971). In this cycle, astrocytes take up glutamate released from
neurons, convert it to glutamine in an energy dependent process and then supply
glutamine to the extracellular fluid to maintain a high concentration of glutamine
which is approximately 0.3mM. Neurons consume glutamine and convert it to
glutamate by glutaminase.
In dorsal root ganglia glutamine and glutamine related enzymes are enriched
in the satellite cells that surround the neurons. In the peripheral nervous system, the
glial tricarboxylic and glutamine cycles produces glutamine for neuronal cell uptake
and conversion to glutamate for synaptic transmission. These cycles may also
function in peripheral glia similar to central nervous system astrocytes in terms of
providing support for the energy demands of the neurons (Miller, Richards, &
Kriebel, 2002).
The glutamine cycle is often described occurring at the synaptic terminal but
evidence suggests that glutamine is also taken up and converted to glutamate for
synaptic use in the cell bodies and axons of DRG neurons. Glutamine and related
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enzymes in the satellite cells of the DRG may facilitate glutamate production in DRG
neurons for synaptic transmission in the spinal dorsal horn (Johnson, 1974).
There is a trend for reduction in expression of GAD2 in the DRG which
reaches statistical significant in TDRG 1-4, 9-12 of GK group and in TDRG 5-9 and
LDRG in the GK-Sucrose group. The decrease in mRNA expression may be due to
a reduced transcription/translation of GAD65. The consequence of this would be a
decrease in GABA concentrations and could contribute to neuropathic pain.
Glutamic acid decarboxylase (GAD) is an enzyme that catalyzes the
decarboxylation of glutamate to GABA and CO2. GAD exists in two isoforms
encoded by two different genes - GAD1 and GAD2. These isoforms are GAD67 and
GAD65 and have molecular weights of 67 and 65 kDa, respectively (Erlander,
Tillakaratne, Feldblum, Patel, & Tobin, 1991). GAD65 and GAD67 synthesize GABA
at different locations in the cell, at different times during development and for
functionally different reasons. This explains why GAD67 is spread evenly throughout
the cell while GAD65 is localized to nerve terminals. GAD67 synthesizes cytosolic
GABA for neuron activity that is not related to neurotransmission such as
synaptogenesis and protection from neural injury. GAD65, however, synthesizes a
synaptic GABA for vesicular release and neurotransmission and would be required
at nerve terminals and synapses. Post translation regulation of Gad65 involves
activation by phosphorylation and thus regulated by protein kinase C synapses(Pinal
& Tobin, 1998).
Gamma-aminobutyric

acid

(GABA),

the

product

by

glutamic

acid

decarboxylase (GAD), is a principal inhibitory neurotransmitter and plays a crucial
role in modulating synaptic circuits. The loss of GAD65-producing GABAergic
neurons in the dorsal horn of the spinal cord that results in GABA hypo-function has
been well documented in various pain models. The exogenous introduction of the
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GAD gene to the dorsal root ganglia (DRG) in genetic therapy has been shown to
increase GABA concentrations in the spinal dorsal horn and helped to reduce
symptoms of pain (J. Kim, Kim, Lee, & Chang, 2009; B. Lee, Kim, Kim, Lee, &
Chang, 2007).
Transfecting DRG neurons with vectors that express GAD65 and GAD67
have been found to reduce diabetes-induced mechanical allodynia more effectively
than gabapentin. Studies suggest that either GAD65 or GAD67 vectors are the most
effective in the treatment of diabetic pain (Y. Wang, 2013).
We observed an increase in the mRNA expression of Gclc in the TDRG1-4
and 5-8, LDRG and SDRG in both GK and GK Sucrose rats compared to controls.
This would be expected if there was an increase in production of this enzyme to
counteract the oxidative stress that is implicated in diabetic neuropathy.
Clinical

and

experimental

studies

have

documented

that

chronic

complications, including diabetic neuropathy, persist and progress even with good
glycaemic control. Hyperglycaemia induced oxidative stress has been implicated in
diabetic neuropathy (Andrea M Vincent ., 2004). Glutamate cysteine ligase
catalyzes the first and rate-limiting step in de novo glutathione synthesis and the
regulation

of

expression

homeostasis(Meister,

and

1983).

activity of

This

enzyme

Gclc
is

is

critical for

responsible

for

glutathione
maintaining

homeostasis of the intracellular antioxidant status. Mitochondria are vulnerable to
damage by reactive oxygen and nitrogen species. Reactive oxygen species are
produced by the mitochondria and usually removed by cellular agents such as
glutathione, catalase and superoxide dismutase. Hyperglycaemia accentuates ROS
production in the cell via mitochondrial activity (Friederich, 2009; Leinninger, 2006;
Andrea M Vincent, 2004).
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Figure 38: The gamma glutamyl cycle.
(γ-Glutamyl cycle, 1 Glutamate cysteine ligase (GCL), 2 Glutathione synthetase
(GS), 3 Glutathione peroxidase, 4 Glutathione reductase, 5 Glutathione-Stransferases (detoxification reactions), 6 γ-glutamyl-transferase (GGT), 7 γ-glutamyl
cyclotransferase (GCT), 8 5-Oxoprolinase, 9 Dipeptidase, R Protein, FAD, FADH2
Flavin-adenine dinucleotide, NAD, NAD+ Nicotinamide-adenoside dinucleotide,
NADP, NADPH+ Nicotinamide-adenoside dinucleotide phosphate, ADP, ATP
Adenosine diphosphate, Adenosine triphosphate(Main, Angley, O'Doherty, Thomas,
& Fenech, 2012).
Glutaminase (Gclc or GLS) is an enzyme that generates glutamate from
glutamine. The enzyme plays an important role in glial cells. The glutamate released
into the synapse for neurotransmission is rapidly taken up by nearby glial cells and
converted to glutamine. This glutamine is supplied to the presynaptic terminals of
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the neurons, where glutaminase converts it back to glutamate for loading into
synaptic vesicles. GLS is also expressed in the brain, spinal cord, and dorsal root
ganglia neurons.
We observed a decrease in mRNA levels of Gls in TDRG9-12 in GK and in
LDRG and TSG1-6 in the GK Sucrose animals compared to control rats. Decrease
levels of mRNA of Gls from the cell body can translate into decreased amounts of
Gls produced from the DRG cell bodies to axons. This could be a compensatory
mechanism to counteract the pathological levels of glutamate implicated in neuronal
hyperexcitability and central sensitization. We postulate that a decrease in the
amount of GLS during chronic diabetic neuropathy leads to decreased production
and release of glutamate. Decreased production and release of these substances
could adaptive mechanisms to ameliorate neuronal hypersensitivity that contributes
towards many of the symptoms of diabetic neuropathy. A decrease in GLS
production could affect the peripheral terminals as well because glutamate that is
released from the peripheral afferents that also have glutamate receptors. A
decrease in glutamate production and release could reduce the activation of these
terminals to compensate for the sensitization of primary afferents. A cycle of
decrease glutamate production and release, decrease in numbers of axons with
glutamate receptor expression on axons could lead to a decrease in sensitization of
peripheral nerve terminals and help to ameliorate the process of chronic pain and
hyperaglesia that is prevalent in diabetic neuropathy. Glutaminase inhibition has
been postulated to represent an ‘upstream’ mechanism of glutamate regulation that
could reduce transmission at all glutamatergic receptors and antagonists for this
enzyme have been been shown to provide analgesia which further supports the
theory that a reduction in glutamate production by inhibiting glutaminase enzyme
activity might provide pain relief in neuropathic pain (Hoffman & Miller, 2010).
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Glutamate carboxypeptidse II (N-acetylasparatylglutamate peptidase) is a
membrane bound metalloenyzme that cleaves the abundant neuropeptide NAAG to
N-acetylaspartate (NAA) and glutamate. GCP II is abundant in the spinal cord and
DRG. NAAG is one of the most common peptide transmitters in the brain and is also
a type 3 metabotropic glutamate receptor (mGluR3) agonist. GCP II inhibitors
increase extracellular NAAG, decrease glutamate and have been implicated in
reducing excess glutamate transmission in pathological conditions such as
ischemia/stroke, motoneuron disease, brain and spinal cord injury and peripheral
neuropathy.
It showed that daily oral intake of the drug protected against the sensory and
motor loss and neurodegeneration that plauges neuropathy. Administering GCP II
inhibitor improved the locomotor, sensory and thermal sensitivity deficits. GCP II
inhibition also protects against neurodegeneration. The mechanism could be by
reducing excitoxicity that is induced by excess glutamate concentrations. GCP II
inhibition also increases NAAG levels. NAAG partially antagonizes NMDA receptors
and could also provide neuroprotection. GCP II inhibition has also been protective in
diabetic and chemotherapy induced neuropathy. GCP II inhibitors have been well
tolerated in humans and appears to affect increased glutamate concentration levels
rather than baseline levels(Potter, Wozniak, Callizot, & Slusher, 2014).
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Figure 39: Glial cell metabolism is intricately related to neuronal metabolism.
This diagram illustrates that glutamine, glutamine synthetase, glutamate
dehydrogenase, and pyruvate carboxylase are located in the peripheral nervous
system in satellite cells of the DRG and Schwann cells of the peripheral nerve.
These enzymes have major roles in supporting peripheral neuronal metabolism and
neurotransmission. Glial cells take up glutamate from the extracellular milieu via
transporters (GLAST, GLT-1) and glutamate synthetase converts it to glutamine.
Glutamine can be shuttled out of glial cells by the SN1 glutamine transporter and
taken up by neurons via the SAT/ATA glutamine transporters for use by glutaminase
(GT) in the glutamine cycle. In addition, glutamine is an important branch point
substrate for purine synthesis via GPATase. Glutamate dehydrogenase is a
bidirectional enzyme that can either add glutamate for GS in the glutamine cycle or
convert glutamate to 2-oxoglutarate for the TCA cycle. 2-Oxoglutarate and other
TCA intermediates such as malate can be shuttled from glia for use in neurons.
Malate also can be converted to pyruvate via malic enzyme (ME). Pyruvate can be
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converted to lactate and used in neuronal metabolism. Pyruvate carboxylase is an
anaplerotic enzyme that refills the glial TCA cycle with carbon as TCA intermediates
are used for other purposes (Miller, 2002).
The Grip1 gene encodes for a member of the glutamate receptor interacting
protein family. This encoded scaffold protein binds to and mediates the trafficking
and membrane organization of several transmembrane proteins. Prototypical
scaffolding proteins such as the glutamate receptor interacting protein 1 (GRIP1)
contain several PSD-95/Discs-large/ZO-1 homology (PDZ) domains operate as
molecular adapters in neuronal synapses. The PDZ-containing scaffolds assemble
specific proteins into large molecular complexes at defined locations in the cell and
in the postsynaptic density of neuronal excitatory synapses organize glutamate
receptors and their associated signalling proteins. This helps to determine the size
and strength of synapses. The PDZ scaffolds also play a role in the dynamic
trafficking of synaptic proteins by assembling cargo complexes that are then
transported by molecular motors (E. Kim & Sheng, 2004).
GRIP1 has been implicated in playing a role in the synaptic clustering of
AMPA receptors and unmasking silent glutamatergic synapses in somatosensory
inputs (P. Li, 1999). Its role in neuropathic pain has been suggested by studies that
showed reducing interactions of the Grip1 protein with the product of Gria2 (GluR2
AMPA receptor) has inhibited the neuropathic reflex sensitization. This suggests an
involvement of Grip1, if expressed, in neuropathic pain (Garry, 2003).

165
Chapter 5: Conclusion

Diabetic neuropathy is the most common and debilitating complication of
diabetes. It manifests itself as pain, decreased motility, and often results in
amputation. Diabetic neuropathy encompasses a variety of forms whose impact
ranges from discomfort to death.
Amongst the myriad of therapeutic options available, glucose control remains
the single most important factor that can modify the disease (Leinninger, 2006).
Despite the wide reaching implication of diabetic neuropathy when considering the
number of people afflicted, the pathogenesis of diabetic neuropathy has many
theories that surround it. Despite extensive investigations and development of
multiple theories the mechanism involved in the development of diabetic neuropathy
are still not completely understood. When several theories orbit a condition, it
suggests that there is no unifying hypothesis.
The expression and regulation of genes gives the cell control over cellular
structure and function. It is the basis for cellular differentiation, morphogenesis and
is also crucial for the versatility and adaptability of any organism. The timing,
location and amount of gene expression can have a profound effect on the functions
of the gene. Analysing genomic and proteomic data from suitable animal models
and diabetic neuropathy patients can provide insight into disease pathogenesis and
possibly identify therapeutic targets for disease modifying treatments. Developing
symptomatic and disease-modifying therapeutic interventions depends on a
comprehensive

and

pertinent

understanding

of

the

pathogenesis

and

pathophysiology of diabetic neuropathy.
The genes that are involved in human pathology require study to improve the
outcome of disease processes and reveal therapeutic targets. Since genes and
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gene functions have been so highly conserved throughout evolution, the study of
less complex model organisms reveals critical information about similar genes and
processes in humans. The selection of appropriate animal models for gene
expression studies is of the utmost importance. Animal models allow control in vivo
the genetic and environmental factors that influence the development of diabetes
and its complications. Rodents are preferable due to advantages such as short
generation intervals, economic viability, ease of care and housing compared to
larger models. In our study we included the Goto-Kakizaki (GK) and Goto-Kakizaki
Sucrose (GK Sucrose) animal groups. The Goto-Kakizaki (GK) rat is a non-obese
Wistar substrain which develops Type 2 diabetes mellitus early in life. The GK rat is
one of the best characterized animal models of spontaneous T2DM and has proved
to be a valuable tool offering sufficient commonalities to study this aspect.
Comprehensive studies of gene expression provide a layer of information
that is useful for predicting gene function. Information about a gene’s function can
be deduced by identifying genes that share its expression pattern. Gene expression
studies that focus on sensory and sympathetic neurons from different animal models
of diabetic peripheral neuropathy and autonomic neuropathy will show differentially
regulated transcripts. These expression profiles will allow data to define categories
of genes that are functionally regulated in diabetic neuropathy such as genes
involved in metabolism or nerve regeneration.
On a broad level it can help to gain greater knowledge about how individual
mechanisms of the disease fit together as a whole and generate novel hypotheses
concerning the pathogenesis, diagnosis and progression of diabetic neuropathy.
This can also help pinpoint targets for disease regulation and therapeutic
intervention. Relevant pathways related to functional gene categories can be
pinpointed for new information of disease mechanisms and targets. Genes that are
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differentially expressed between healthy and diseased tissue can be put into the
context of cellular pathways and used to predict regulatory elements that control the
changes observed. Those regulatory elements that are identified can be utilized
later as drug targets and also used to predict the downstream effects of gene
expression. These can also pave the way for developing biomarkers.
For expression profiling, or high-throughput analysis of many genes within a
sample, quantitative PCR is a popular and reliable method to study hundreds of
genes simultaneously. In preliminary studies, low density arrays revealed many
interesting findings but it was not possible to follow all of these changes. Once a set
of genes involved in a particular biological process has been identified, the next
logical step is to further study the genes individually. Determining when a gene acts
can facilitate the reconstruction of entire genetic or biochemical pathways, and such
studies have been central to our understanding of pathological processes. The focus
was honed to the genes involved in the glutamate signalling pathway because of
there were several changes in the pathways of these genes. Genes for glutamate
receptor expression, glutamate processing enzymes and glutamate transporter
proteins showed significant changes in expression. This was also in light of the
literature that indicated the glutamate pathway was involved in neuropathic pain
including diabetic neuropathy.
The presence of excess glucose activates multiple biochemical pathways
that lead to damage. Amongst the myriad of therapeutic options available, glucose
control remains the single most important factor that can modify the disease
(Leinninger, 2006). However, no therapeutic agent aids in eliminating the root cause
of diabetic neuropathy. Understanding the root cause of neuropathy will illuminate
the path towards therapeutic intervention at a stage when complications have not
been fully established.
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Observing patterns of changes in gene expression using different animal
models of diabetes will help pave the way for further studies in individual gene
analysis, protein characterization and functional studies.
Using informatics to analyze genomic and proteomic data from suitable
animal models and DN patients can provide insight into disease pathogenesis and
possibly identify therapeutic targets for disease modifying treatments. Developing
symptomatic and disease-modifying therapeutic interventions depends on a
comprehensive

and

pertinent

understanding

of

the

pathogenesis

and

pathophysiology of diabetic neuropathy.
The low density arrays showed several interesting results of which the most
prominent changes were the genes that are involved in the glutamate pathway.
Changes in gene expression were confirmed by fast real-time RT-PCR. In GK rats,
these studies showed consistent changes in expression, particularly in the lumbar
and sacral dorsal root ganglia of the spinal cord and in the sympathetic ganglia. The
changes were consistent between the different groups of animals as well as
between adjacent groups of ganglia. The most prominent changes in both the GK
groups included marked upregulation of Gria4 (ionotropic AMPA receptor),
downregulation of Grik3 and Grik4 (both ionotropic, kainite receptors) and Grin1 and
Grin2A (both ionotropic, NMDA receptors), activation of all of which has been shown
to induce hyperalgesia; downregulation of Slc1a6 (excitatory amino acid transporter
4) and upregulation of Slc1a1 (excitatory amino acid transporter 3), both of which
mediate neural reuptake of glutamate from the synaptic cleft; and upregulation of
Gclc (glutathione synthase), which reflects a response to protect against oxidative
damage.
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The immense physical, psychological, and economic cost of diabetic
neuropathy underscore the need for better understanding of the pathogenesis at an
early interventional level.
The pathological signalling pathways associated with diabetic neuropathy
are complex and this influences the development of targeted therapies.
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Chapter 6: Future directions
The most prominent and interesting changes in these animal groups were
those involving; Gria4 (ionotropic AMPA receptor), Grik3 and Grik4 (both ionotropic,
kainite receptors) and Grin2A (both ionotropic, NMDA receptors). Future studies
could be focused in many directions such as incorporating more animal models,
further gene analysis and involving human studies. Obvious directions include
confirmation in other diabetic animal models for example Zucker fatty rats. Zucker
animals have been obtained and these studies are now underway. Earlier time
points of the GK model can also be investigated. Characterization of protein
expression needs to be investigated by western blot and/or immunohistochemistry.
In addition, it would be worthwhile to broaden the investigation of gene expression to
include genes that are colocalized with glutamate in the secretory granules. These
include those that code for genes such as CGRP, tachykinins (substance P,
neurokinin A etc) which are known to be involved in the pain pathways.
Analyzing gene expression patterns can provide clues about gene function
but further understanding require mutants that lack a particular gene may quickly
reveal the function of the protein that it encodes. Other directions include
manipulation of gene expression using knockout mice and also overexpression of
the respective genes and investigating the effects of that on diabetes in these
animal groups.
It may also be possible to undertake limited investigation using autopsy
tissues from patients with and without diabetic neuropathy.
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